

CURRICULUM VITAE

Vladimir P. Torchilin, Ph.D., D.Sc.

University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, School of Pharmacy, Bouve College of Health Sciences, Northeastern University

Address: Department of Pharmaceutical Sciences
School of Pharmacy
Bouve College of Health Sciences
Northeastern University
140 The Fenway, room 214
360 Huntington Avenue
Boston, MA 02129
Tel: (617) 373-3206; FAX: (617) 373-7509; e-mail: v.torchilin@neu.edu

Education:

M.S. in Polymer Chemistry from Moscow State University, Moscow, Russia, 1968
Ph.D. in Chemical Kinetics and Catalysis from Moscow State University, Moscow, Russia, 1971
D.Sc. in Bioorganic Chemistry from Moscow State University, Moscow, Russia, 1980
Since 1985 - Professor in Bioorganic Chemistry, Chemistry of Natural and Physiologically Active Compounds

Academic Appointments:

1971-1973 Junior Scientist, Moscow State University
1974-1980 Senior Scientist, Academy of Medical Sciences of the USSR
1985-1991 Professor of Biochemistry, Academy of Medical Sciences of the USSR
1989-1991 Professor in Biotechnology, Lomonosov Institute of Fine Chemical Technology, Moscow, USSR
1991 Visiting Professor of Biochemistry, University of Tennessee
1991 Visiting Professor, University of California, San Diego
1993-1999 Associate Professor of Radiology, Harvard Medical School
1998- Professor of Pharmaceutical Sciences, Northeastern University
1998-2008 Chair, Department of Pharmaceutical Sciences, Northeastern University
2004- Distinguished Professor of Pharmaceutical Sciences, Northeastern University
2005- Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University
2010- Director, Center for Translational Cancer Nanomedicine (NIH-funded CCNE)
2012- University Distinguished Professor

Hospital Appointments:

1974-1980 Senior Researcher, USSR Cardiology Research Center, Moscow
1981-1991 Head, Laboratory of Enzyme Engineering, USSR Cardiology Research Center, Moscow
1985-1991 Professor, Laboratory of Enzyme Engineering, USSR Cardiology Research Center, Moscow
1991-1993 Associate Chemist, Massachusetts General Hospital (MGH), Boston, MA
1993-1998 Head, Chemistry Program, Center for Imaging and Pharmaceutical Research (CIPR), MGH, Boston, MA
1998 Associate Director, CIPR, MGH, Boston, MA

Awards and Honors:

- 1982 Lenin Prize of the USSR in Science and Technology (the highest scientific award in the former USSR)
- 1978, 82, 85 Exchange Scientist, US/USSR Exchange Program in Cardiovascular
87,89, 90 Research - Myocardial Metabolism
- 1991 Full member (Academician), Russian Academy of Biotechnology
- 1994,1993 Outstanding Pharmaceutical Paper Award, Controlled Release Society
- 1994,1993 Outstanding Paper Award from the *Journal of Controlled Release*
- 1995-1998 Board of Governors, Controlled Release Society
- 1999 Co-Chair, 26th International Symposium on Controlled Release of Biologically Active Materials
- 2001,03,04,07 Creativity Awards from Northeastern University
- 2002 Co-Chair, Gordon Research Conference on Drug Carriers in Biology and Medicine
- 2002 Fellow, American Institute for Medical and Biological Engineering
- 2002 Innovation Award from Northeastern University
- 2002 Member, European Academy of Sciences
- 2003 Vice President, Controlled Release Society
- 2003 Fellow, American Association of Pharmaceutical Scientists (AAPS)
- 2003 ATOMS Research Excellence in Mentorship Award, National Institute of General Medical Sciences
- 2004 Distinguished Northeastern University Professor of Pharmaceutical Sciences
- 2004 Member, Board of Directors, International Liposome Society
- 2005 President, Controlled Release Society
- 2005 Research Achievements Award in Pharmaceutics and Drug Delivery, AAPS
- 2005 The Joy Goodwin Lecturer, Auburn University
- 2005 Member, Research and Graduate Affairs Committee, AACP
- 2006 2006 CRS-Baxter Healthcare Outstanding Parenteral Drug Delivery Award
- 2006 The Massachusetts Technology Transfer Center 2006 Investigation Award
- 2007 Research Achievements Award from the World Pharmaceutical Congress, Amsterdam
- 2007 Phi Beta Delta
- 2007 Chair, International Symposium on Nanomedicine and Drug Delivery Systems
- 2008 Prestige Lectureship, University of Montreal
- 2008 The Massachusetts Technology Transfer Center 2008 Investigation Award
- 2008 Co-Chair, 2008 NCI/NSTI Special Symposium on Nanotechnology for Cancer
- 2008 Horizons in Nanotechnology Lectureship, Emory University
- 2008 Key-note speaker, International Conference on NanoBio Technologies, St.Petersburg
- 2009 Key-note speaker, Indo-US Summit on Cancer Nanotechnology, New Delhi, India
- 2009 University of North Carolina-Eisai Distinguished Lectureship in Drug Delivery
- 2009 Key-note speaker, International Symposium on Microencapsulation, Japan
- 2009 The Meritorius Paper AAPS Journal 2008 Award
- 2009 Key-note speaker, American Society for Nanomedicine Conference, Potomac
- 2009 2009 International Journal of Nanomedicine Distinguished Scientist Award
- 2010 Key-note speaker, Nanomedicine: Visions for the Future, Amsterdam, The Netherlands
- 2010 Avis Distinguished Visiting Professor Lectureship, University of Tennessee, Memphis
- 2010 Key-note speaker, International Conference on Biological Barriers, Saarbrucken, Germany
- 2010 Founders Award, Controlled Release Society
- 2010 Key-note speaker, 3rd European Conference on Clinical Nanomedicine, Basel, Switzerland
- 2010 Fellow, Controlled Release Society
- 2010 Plenary speaker, Advances in Drug Delivery Conference, Aix-en-Provence, France

2011 Key-note Speaker, UKICRS Meeting, Belfast, UK
 2011 Excellence in Research and Creative Activity Award, Northeastern University
 2011 Chair, Nanotechnology Focus Group, AAPS
 2012 University Distinguished Professor, Northeastern University
 2012 Alec Bangham Life Achievement Award
 2012 Plenary speaker, European Conference and School on Nanomedicine and Nanotoxicology, Crete, Greece
 2012 Plenary speaker, Controlled Release Society Annual meeting, Quebec City, Canada
 2012 Plenary speaker, Israeli Controlled Release Society Meeting, Israel
 2012 Plenary speaker, International Pharmaceutical Technology Conference, Antalya, Turkey
 2012 Plenary speaker, Liposome Research Days, Hangzhou, China
 2012 Plenary speaker, International Pharmaceutical Technology Conference, Kuala Lumpur, Malaysia
 2013 Journal of Drug Targeting Life Time Achievement Award
 2013 Plenary speaker, World Pharma Congress, Philadelphia
 2013 Blaise Pascal Medal in Biomedicine from the European Academy of Sciences
 2013 Plenary speaker, 19th International Symposium on Microencapsulation, Pamplona, Spain
 2013 Plenary speaker, Pharmaceutical Congress, Cape Town, South Africa
 2013 Plenary speaker, International Conference on Nanotechnology for Health, Belo Horizonte, Brazil
 2014 Co-President and plenary speaker, International Congress on Biomaterials, Greece
 2014 Plenary speaker, Drug Discovery and Therapy World Congress, Boston
 2015 Co-President and plenary speaker, International Congress on Biomaterials, Greece
 2015 Plenary speaker, International Conference on Pharmaceutical Technology, Istanbul, Turkey
 2015 Chair, XX International Symposium on Microencapsulation, Boston
 2015 European Journal of Pharmaceutics and Biopharmaceutics best paper award for 2014
 2016 Co-President and plenary speaker, BIONANOTOX, Greece
 2016 International Chair of Therapeutic Innovation, LabEx LERMIT, France
 2016 Highly Cited Researcher from Thomson Reuters
 2017 Outstanding Excellence Award from Pharmaceutica 2017, London, UK
 2017 Key-note Speaker, Nanodelivery 2017, Osaka, Japan
 2017 Co-President and plenary speaker, BIONANOTOX, Greece
 2017 Co-Program Chair, Annual Controlled Release Society Meeting, Boston
 2017 Plenary Speaker, Drug Discovery and Therapy World Congress, Boston
 2017 Plenary Speaker, Drug Delivery and Formulation Summit, Boston
 2017 Plenary Speaker, YUCOMAT 2017, Montenegro
 2017 Plenary Speaker, 21st International Symposium on Microencapsulation, Faro, Portugal
 2017 Key-note Speaker, World Congress on Pharmacology and Chemistry of Natural Compounds, Tbilisi, Georgia
 2017 Key-note Speaker, 4th European Biopharma Congress, Vienna, Austria
 2017 Albert Nelson Marquis Lifetime Achievement Award
 2018 Plenary Speaker, 9th Global Drug Delivery and Formulation Summit, Berlin, Germany
 2018 Key-note Speaker, 16th International Conference on Pharmaceutics and Novel Drug Delivery Systems, Berlin, Germany
 2018 Key-note Speaker, AAPS-NERD Meeting, Farmington, CT
 2018 Co-President and plenary speaker, BIONANOTOX, Greece
 2018 Key-note speaker, Global Conference on Pharmaceutics and Drug Delivery Systems, Rome, Italy
 2018 Plenary speaker, Frontiers in Delivery of Therapeutics, Tartu, Estonia

2018 Plenary speaker, YUCOMAT 2018, Montenegro
2018 Conference Chair and Plenary speaker, Material Science-2018, Amsterdam, The Netherlands
2018 Key-note speaker, 21st European Biotechnology Congress, Moscow, Russia
2018 Key-note speaker, Pharmaceuticals and Novel Drug Delivery Systems, Moscow, Russia
2018 Key-note speaker, Applied Pharmaceutical Nanotechnology, Boston
2018 Co-Chair and Plenary speaker, 12th International Conference "Medical Applications of Advanced Biomaterials and Nano-biotechnology", Perugia, Italy
2019 Key-note speaker, 2nd International Conference on Pharmaceutical Nanotechnology and Nanomedicine, New York
2019 Plenary speaker, 6th World Summit on Cancer Research and Therapy, Dubai, UAE
2019 Honorary President and Plenary speaker, BIONANOTOX, Greece
2019 Sigma Xi
2019 Plenary speaker, YUCOMAT 2018, Montenegro
2019 Key-note speaker, 3rd Global Conference on Pharmaceuticals and Drug Delivery Systems, Paris, France
2019 Key-note speaker, International Cancer Conference, London, UK
2019 Highly Cited Researcher from Thomson Reuters
2022 Key-note speaker, INVITE Conference, Germany
2022 Plenary speaker, Global Summit on Pharmaceuticals and Drug Delivery Systems, Munich, Germany
2022 Plenary speaker, Global Summit and Expo on Materials Science and Engineering, Munich, Germany
2022 Invited speaker, Liposome Research Days, Vancouver, Canada
2022 Plenary speaker, CIMTEC, Perugia, Italy
2022 Plenary speaker, 2022 YUCOMAT, Montenegro
2022 Plenary speaker, ENDOCYTE conference, Berlin, Germany
2023 Plenary speaker, 2023 YUCOMAT, Montenegro
2023 2023 Citation Laureat by Clarivate

Major Committee Assignments:

1982-1991 The Highest Certifying Commission of the USSR (VAK)
1986-1991 International Commission on Pharmaceutical Enzymes.

Editorial Boards:

Editor-in-Chief *Drug Delivery*
Editor-in-Chief *Current Drug Discovery Technologies*
Co-Editor *Current Pharmaceutical Biotechnology*
Associate Editor *Biomedical Microdevices*
Review Editor *Journal of Controlled Release*
1979-1986 *Enzyme Microbial Technology*
1984-1995 *Journal of Controlled Release*
1987- *Advanced Drug Delivery Reviews*
1988-1996 *Hemostasis*
1989-1992 *Biokhimia* (Russian)
1989- *Journal of Microencapsulation*
1990- *Bioconjugate Chemistry*
1992- *Journal of Liposome Research*

1995-	<i>Journal of Drug Targeting</i>
1999-	<i>Journal of Controlled Release</i>
1999-	<i>European Journal of Pharmaceutics and Biopharmaceutics</i>
2002-	<i>Journal of Bioactive and Compatible Polymers</i>
2003-	<i>Molecular Pharmaceutics</i>
2003-	<i>Current Drug Delivery</i>
2003-	<i>Drug Discovery Today</i>
2004-	<i>Chinese Journal of Interventional Imaging and Therapy</i>
2004-	<i>Journal of Biomedical Nanotechnology</i>
2004-	<i>Expert Opinion on Drug Delivery</i>
2004-	<i>Current Protein and Peptide Science</i>
2005-	<i>International Journal of Nanomedicine</i>
2005-	<i>Journal of Biopharmaceutics and Biotechnology</i>
2005-	<i>Nanotechnology, Diagnostics, and Therapeutics</i> (web journal from BioMedCentral)
2007-	<i>Recent Patents on Drug Delivery and Formulation</i>
2011-	<i>Journal of Pharmaceutical Technology and Drug Research</i>
2011-	<i>Pharmacum Consequat</i>
2012-	<i>Biomedical Microdevices</i>
2014-	<i>Journal of Nanotechnology in Diagnosis and Treatment</i>
2014-	<i>NanoDrugs</i>

Referee for the Following Journals:

- *Proceedings of the National Academy of Sciences of the USA*
- *Nature Biotechnology*
- *Trends in Biotechnology*
- *Biochimica et Biophysica Acta*
- *Cancer Research*
- *Journal of Nuclear Medicine*
- *Bioconjugate Chemistry*
- *Biotechnology and Bioengineering*
- *Biophysical Journal*
- *Journal of Lipid Research*
- *Pharmaceutical Research*
- *Journal of Pharmaceutical Sciences*
- *Journal of Controlled Release*
- *International Journal of Pharmacology*
- *Hemostasis*
- *Biopolymers*
- *Journal of Drug Targeting*
- *Drug Delivery*
- *Gene Therapy*
- *Journal of Liposome Research*
- *Journal of Microencapsulation*
- *Journal of Molecular Recognition*
- *Designed Monomers and Polymers*
- *Colloids and Surfaces B: Biointerfaces*
- *Reactive and Functional Polymers*

- *European Journal of Pharmaceutics and Biopharmaceutics*
- *European Journal of Pharmaceutical Sciences*
- *Biotechnology Progress*
- *Journal of Bioactive and Compatible Polymers*
- *Langmuir*
- *Nanomedicine*
- *Expert Opinion in Drug Delivery*

Grant and Proposal Reviews for:

Academy of Sciences of the USSR
 Academy of Medical Sciences of the USSR
 Scientific Council on Medical Biotechnology (USSR)
 International Science Foundation
 United States Army Medical Research
 University of British Columbia, Canada
 North Carolina Biotechnology Center
 Natural Sciences and Engineering Research Council of Canada
 The Israel Science Foundation
 National Institutes of Health
 Fund for Scientific Research, Austria
 The Dutch Cancer Society
 The Canadian Institutes of Health Research
 Swiss National Science Foundation
 United States-Israel Binational Science Foundation
 Ireland Foundation Science
 Italian Scientific Council

Ph.D. and D.Sc. Thesis Committees:

The Highest Certifying Commission of the USSR
 Scientific Council of the USSR Cardiology Research Center, Academy of Medical Sciences of the USSR
 Scientific Council of the Institute of Experimental Cardiology, Academy of Medical Sciences of the USSR
 Scientific Council of the Institute of Petrochemical Synthesis, Academy of Sciences of the USSR
 Massachusetts Institute of Technology
 Northeastern University
 University of Massachusetts
 Harvard Medical School
 Massachusetts General Hospital

Own students – more than 50 PhDs and more than 100 MS are trained

Professional Societies:

1968-1992 USSR Mendeleev Chemical Society
 1975-1992 USSR Biochemical Society
 1991-1995 Society of Nuclear Medicine
 1991- Controlled Release Society (1995-1998 – Board of Governors; member of the following committees: Strategic Planning, Young Investigator Award, Best Pharmaceutical Paper

Award; 2003-2007 – Board Member as Vice President, President-Elect, President and Immediate Past President)
1992- American Chemical Society
2000- International Liposome Society
2001- American Association of Pharmaceutical Scientists
2010- American Association of Colleges of Pharmacy

Co-founder:

Oncologic Biopharmaceuticals
MitoVec Inc.
Encapsion Inc.
Nemucore Medical Innovations
Blue Ocean
Immix LLC
Mechanical Drugs

SAB member and/or Consultant for:

Labopharm Inc.
Genzyme Corp.
Procyon Biopharma Inc.
Boston Life Sciences Inc.
Endorex Inc.
Oncologic
MitoVec Inc.
PureTech
Nanopharma
CellGate Inc.
LigoCyte Inc.
Eurand
Oral Vaccine Institute
Encapsion
Solubest
Nemucore Medical Innovations
Blue Ocean

Organizing, Steering, Advisory, and Program Committees for:

- International Symposium “Advances in Enzyme Engineering”, Tbilisi 1978.
- Conference of CMEA countries, Warsaw, Poland 1980.
- I All-Union Symposium “Liposomes in Biology and Medicine”, Moscow 1980.
- VI All-Union Symposium on Synthetic Polymers of Medical Application, Alma-Ata 1983.
- VIII All-Union Symposium “Synthetic Polymers of Medical Application”, Kiev 1989.
- International Symposium “Liposomes in Biology and Medicine”, Tashkent 1990.
- International Liposome Conference, St. Petersburg, Russia 1993.
- 1st International Conference on Polymer Therapeutics, London, UK 1996.
- 10th International Symposium on Radiopharmacology, Rapallo, Italy 1997.
- Symposium on Targeting the Cardiovascular System, Boston 1997.
- 3rd Symposium on Polymer Therapeutics, London, UK, 1998.
- 26th International Symposium on Controlled Release of Bioactive Materials, Boston, 1999 (Co-Chairman, Program Committee).

- 3rd International Symposium on Frontiers in Biomedical Polymers, Shiga, Japan, 1999.
- 4th International Symposium on Polymer Therapeutics, London, UK, 2000.
- 4th International Symposium on Frontiers in Biomedical Polymers, Virginia Beach, 2001.
- 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, 2001.
- 5th International Symposium on Polymer Therapeutics, Cardiff, UK, 2002.
- Gordon Research Conference on Drug Carriers in Biology and Medicine, Ventura (2000 – Co-Vice-Chairman; 2002 – Co-Chairman).
- 7th International Symposium on Pharmaceutical Sciences, Ankara, Turkey, 2003.
- 3rd Symposium on Nanomedicine and Drug Delivery, Baltimore, 2005.
- Indo-Japanese Conference on Drug Delivery, Mumbai, India, 2005.
- 13th International Pharmaceutical Technology Symposium, Antalya, Turkey, 2006.
- 4th International Symposium on Nanomedicine and Drug Delivery, Omaha, Nebraska, 2006.
- Symposium on Nanomedicine, Brooklyn Polytechnic, 2006.
- Symposium on Cancer Nanomedicine, Santa Clara, 2007 (Co-Chairman).
- 5th International Symposium on Nanomedicine and Drug Delivery, Boston, 2007 (Chairman).
- 7th International Symposium on Polymer Therapeutics, Valencia, Spain, 2008.
- Symposium on Nanomedicine in Cancer, Boston, 2008.
- International Conference on Smart Materials, Aceriale, Italy, 2008.
- International Conference NanoBio'08, St. Petersburg, Russia, 2008.
- 17th International Conference on Microencapsulation, Japan, 2009.
- 19th International Microencapsulation Symposium, Pamplona, Spain, 2013.
- International Congress on Biomaterials, Greece, 2014.
- Liposome Research Days, Copenhagen, Denmark, 2014.
- 20th International Microencapsulation Symposium, Boston, USA, 2015 (Chairman).
- BIONANOTOX, Greece, 2016
- International Symposium on Controlled Release of Bioactive Materials, Boston, 2017 (Co-Chairman, Program Committee).
- BIONANOTOX, Greece, 2017.
- 4th European Biopharma Congress, Austria, 2017.
- 16th International Conference on Pharmaceutics and Novel Drug Delivery Systems, Germany, 2018
- BIONANOTOX, Greece, 2018
- Conference Chair, Material Science-2018, Amsterdam, The Netherlands

MAJOR RESEARCH INTERESTS:

1. Physiologically active polymers and their use as drug carriers. Polymeric drugs. Slow release systems. Pharmacokinetics and biodistribution of slow release drugs.
2. Engineering of various systems for controlled delivery of pharmaceuticals including macromolecular drugs, DNA, and imaging agents.
3. Targeted delivery of therapeutic and diagnostic agents. Tumor targeting and targeting within the cardiovascular system.
4. Physico-chemical aspects of enzyme stabilization and immobilization on polymeric carriers. Therapeutic enzymes. Experimental thrombolytic therapy.
5. Artificial phospholipid membranes. Liposomes, their physico-chemical and biological properties. Long-circulating and polymer-modified liposomes as drug carriers. Immunoliposomes. Protein binding with liposomes. Liposome-cell interactions. Pharmacokinetics of liposomes.
6. Micellar solubilization of poorly soluble drugs. Polymeric micelles. Targeted micelles. Immunomicelles. Micellar tumor targeting.

7. Experimental diagnostic imaging. Contrast agents for gamma-imaging, magnetic resonance imaging and computed tomography. Labeling of polymers, proteins (antibodies and their fragments), and microparticulates (liposomes, nanoparticles, micelles) with diagnostic metal isotopes via chelating groups. Chelating polymers for heavy loading antibodies with metal isotopes. Amphiphilic chelating polymers as key components of liposomal and micellar imaging agents. Iodine-containing long-circulating micelles for computed tomography.

8. Experimental tumor immunology and therapy. Intratumor delivery of drugs and imaging agents. Tumoricidal antibodies. Accumulation of long-circulating drugs in tumors.

Funding History (as PI unless noted):

1988-1989, from the USSR Academy of Medical Sciences: "Immobilized thrombolytic enzymes"	60, 000 rub.
1988-1989 from the USSR Academy of Medical Sciences: "Liposomes for drug targeting"	50, 000 rub.
1989-1990 from the USSR Scientific Council on Biotechnology: "Chelating polymers for antibody modification"	75, 000 rub.
1989-1990 from the USSR Academy of Medical Sciences: "Targeted visualization of thrombi"	45, 000 rub.
1992-1993 from Sterling Winthrop: "Chelating polymer-modified antibodies for the delivery of imaging agents"	\$ 70, 000
1992-1993 from Sterling Winthrop: "Micellar imaging agents for CT"	\$ 90, 000
1995 from Biogen: "Biodistribution of antibodies"	\$ 10, 000
1996-1997 from RSNA "Iodine-containing micellar carriers for CT"	\$ 20, 000
1996-1997 from Boston Life Sciences "Targeted drug delivery into tumors"	\$ 72, 500
1996-1997 from Boston Life Sciences "Delivery of PEGylated drugs into tumors"	\$ 205, 000
1997-2000 from NIH "Long-circulating polymer-modified liposomes" direct	\$ 370,000
1998 from Boston Life Sciences "Delivery of micellar drugs into tumors"	\$ 105,000
1998-1999 from Biostream "Polychelating polymers for imaging"	\$ 33,000
1999 from Procyon Biopharma "Experimental tumor therapy"	\$ 13,500
1999-2000 from Biogen "Antibody biodistribution"	\$ 22,000
1999-2003 from NIH: "Micellar carriers for sparingly soluble pharmaceuticals" direct	\$ 585,000
2000 from Procyon Biopharma "Experimental tumor therapy"	\$ 225,000
2000-2005 from NIH "Bioengineering of artificial blood" direct	\$ 740,000
2001 from Biogen "Antibody biodistribution"	\$ 19,000
2001-2005 from NIH: "Long-circulating polymer-modified liposomes" direct	\$600,000
2001-2002 from Procyon Biopharma "Imaging with anticancer antibodies"	\$ 94,000
2002-2003 from Center for Disease Control: "A liposome-based hepatitis-B vaccine" (sub-contract from Oral Vaccine Institute) direct	\$125,000
2003-2004 from The Medical Foundation: "Antibody-mediated drug delivery to astrocytic tumors" direct	\$100,000
2003-2007 from NIH "Antibody-targeted polymeric systems for tumor imaging" direct	\$765,000
2003-2008 from NIH "Micellar carriers for sparingly soluble drugs" direct	\$1,125,000

2005-2009 from NIH “Long-circulating polymer-modified liposomes”	direct \$700,000
2005 from Biogen “Protein biodistribution”	\$39,000
2006-2012 from NIH “Multifunctional pharmaceutical nanocarriers”	direct \$875,000
2007-2009 from Keck Foundation “Nanochip” (co-PI)	direct \$1,200,000
2007-2012 from NIH “Phage-protein modified nanopharmaceuticals for breast cancer therapy” (subcontract PI)	direct \$500,000
2008-2008 from DSM Corporation “liposomes from glycolipids”	\$90,000
2008-2013 from NIH “Nanocarriers for intracellular targeting”	direct \$1,000,000
2008-2009 from Samyang Corp. “siRNA delivery”	direct \$150,000
2009-2011 from NIH Supplement for Intracellular targeting grant	direct \$200,000
2010-2013 from NIH “Layer-by-layer technology for poorly soluble drugs”	direct \$1,000,000
2010-2015 from NIH “Center for Cancer Nanotechnology Excellence”	direct \$8,500,000
2011-2013 from US-Israel Binational Science Foundation	direct \$65,000
2010-2013 from Manganaro Fund	direct \$360,000
2012-2013 from Immix Co	direct \$45,000
2014-2015 from NIH “MMP-2-sensitive nanopreparations”	direct \$250,000
2015-2017 from NSF “Novel Nanoprinting for Oral Delivery of Poorly Soluble Drugs”	direct \$198,000
2015-2021 from NIH “Lipid-dendrimer conjugates for siRNA and drug delivery”	direct \$1,130,000
2015-2016 from Immix Co	direct \$35,000
2015-2016 from Tufts University	direct \$30,000
2016-2017 from Immix Co	direct \$25,000
2016-2021 from NIH “Mechanical Drugs”	direct \$440,000
2017-2018 TIER 1 grant from NEU	direct \$50,000
2020 Small COVID-19 grant from NEU	direct \$28,000

BIBLIOGRAPHY (Google Scholar gives >80,000 citations with H index of 130)

Original Papers:

1. Kirsh YE, Bessmertnaya LY, **Torchilin VP**, Papisov MI, Kabanov VA. Structural transformations of poly-4-vinylisamylpyridinium-bromide macromolecules. *DAN USSR* (Russ.) 1970; 191:603-606.
2. **Torchilin VP**, I'lina EV, Streltsova ZA, Smirnov VN, Chazov EI. Enzyme immobilization on heparin. *J Biomed Mater Res.* 1973; 12:685-690.
3. **Torchilin VP**, Litvak ZM, Esina GN, Makarova SB, Gryaznov GV. Immobilization of some enzymes on modified styrenedivinybenzene matrixes. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1975; 1:1231-1235.
4. **Torchilin VP**, Bobkova AS, Smirnov VN, Chazov EI. Immobilization of enzymes on biocompatible carriers. I. Immobilization of α -chymotrypsin on modified Sephadexes. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1976; 2:116-124.

5. **Torchilin VP**, Tischenko EG, Smirnov VN, Chazov EI. Immobilization of enzymes on biocompatible carriers. II. Immobilization of α -chymotrypsin on polyvinylpyrrolidone. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1976; 2:399-405.
6. **Torchilin VP**, Reyzer IL, Tischenko EG, Smirnov VN, Chazov EI. Immobilization of enzymes on biocompatible carriers. III. Immobilization of α -chymotrypsin on soluble dextrans. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1976; 2:1252-1253.
7. **Torchilin VP**, Reyzer TL, Tischenko EG, Il'ina EV, Smirnov VN, Chazov EI. Immobilization of enzymes on biocompatible carriers. IV. Modification of α -chymotrypsin with water soluble vinylic copolymers. The evaluation of immobilized chymotrypsin accessibility for protein inhibitor. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1976; 2:1687-1694.
8. Martinek K, Goldmacher VS, Klibanov AM, **Torchilin VP**, Smirnov VN, Chazov EI, Berezin IV. Main principles of enzyme stabilization. Increased thermostabilization of α -chymotrypsin upon covalent coupling to complimentary surface of polymer carrier. *DAN USSR* (Russ.) 1976; 228:1468-1471.
9. **Torchilin VP**, Tischenko EG, Smirnov VN, Chazov, EI. Immobilization of enzymes on slowly soluble carriers. *J Biomed Mater Res.* 1977; 11:223-235.
10. **Torchilin VP**, Tischenko EG, Smirnov VN. Covalent immobilization of enzymes on ionogenic carriers. Effect of electrostatic complex formation prior to immobilization. *J Solid-Phase Biochem.* 1977; 2:19-29.
11. **Torchilin VP**, Galka M, Ostrowski W. Comparative studies on immobilization of human prostatic acid phosphatase. *Biochim Biophys Acta.* 1977; 488:331-336.
12. Chazov EI, Mazaev AV, **Torchilin VP**, Lebedev BS, Il'ina EV, Smirnov VN. Experimental study of biosoluble drugs. Thrombus lysis with biosoluble immobilized fibrinolysin in experiment. *Thrombosis Res.* 1978; 12:809-816.
13. **Torchilin VP**, Il'ina EV, Mazaev AV, Lebedev BS, Smirnov VN, Chazov EI. Study of modified Sephadex-bound insulin in dog experiments. *J Solid-Phase Biochem.* 1978; 2:187-193.
14. **Torchilin VP**, Maksimenko AV, Smirnov VN, Martinek K, Klibanov AM, Berezin IV. Principles of enzyme stabilization. III. The effect of the length of intramolecular linkage on thermostability of enzymes. *Biochim Biophys Acta* 1978; 522:277-283.
15. Martinek K, **Torchilin VP**. Main principles of enzyme stabilization. *Biologicheskaya Khimia* (Russ.) (Biological Chemistry) 1978; 12:17-48.
16. **Torchilin VP**. Enzyme immobilization on biocompatible carriers. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1978; 4:566-568.
17. **Torchilin VP**, Goldmacher VS, Smirnov VN. Comparative study on covalent and noncovalent immobilization of enzymes on the surface of liposomes. *Biochem Biophys Res Commun.* 1978; 85:983-990.
18. **Torchilin VP**, Goldmacher VS, Smirnov VN. Binding of proteins with liposomes. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1978; 4:1560-1562.
19. Martinek K, **Torchilin VP**, Maksimenko AV, Smirnov VN, Berezin IV. Chemical modification of "key" functional groups in tertiary protein structure. *DAN USSR* (Russ.) 1979; 247:1505-1508.
20. **Torchilin VP**, Maksimenko AV, Smirnov VN, Klibanov AM, Berezin IV, Martinek K. Principles of enzyme stabilization. IV. The modification of "key" groups in the tertiary structure of proteins. *Biochim Biophys Acta.* 1979; 567:1-11.

21. **Torchilin VP**, Maksimenko AV, Smirnov VN, Berezin IV, Martinek K. Principles of enzyme stabilization. V. The possibility of enzyme self-stabilization under the action of potentially-reversible intramolecular cross-linkages of different length. *Biochim Biophys Acta* 1979; 568:1-10.
22. Varshavskaya MY, Klivanov AL, Goldmacher VS, **Torchilin VP**. Simple and accurate method for the determination of heparin content in Heparin-Sepharose. *Anal Biochem.* 1979; 95:449-451.
23. **Torchilin VP**, Maksimenko AV, Martinek K. Self stabilization of enzymes under the action of intra-molecular linkages of different length. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1979; 5:1243-1247.
24. Khoshtariya DA, Topolev VV, Krishtalik LI, Reyzer IL, **Torchilin VP**. The study on proton transition under enzyme hydrolysis by the method of temperature dependence of kinetic isotope effect. III. Hydrolysis of Ac-Tyr-OEt and Bz-Tyr-OEt with α -chymotrypsin immobilized on soluble dextran. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1979; 5:1243-1247.
25. Berdichevsky VR, Markosyan RA, Pozin EY, Smirnov VN, Suvorov AV, **Torchilin VP**, Chazov EI. Effect of liposomes on functional state of platelets. *Bull Exper Biol Med.* (Russ) 1979; 8:141-143.
26. **Torchilin VP**, Khaw BA, Locke E, Berdichevsky VR, Smirnov VN, Haber E, Chazov EI. Retention of specific binding activity by antibodies covalently bound to the surface of liposomes. *DAN USSR* (Russ.) 1979; 246:746-749.
27. **Torchilin VP**, Khaw BA, Smirnov VN, Haber E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. *Biochem Biophys Res Commun.* 1979; 89:1114-1119.
28. Martinek K, **Torchilin VP**, Maksimenko AV, Smirnov VN, Berezin IV. Effect of intra-molecular cross-linkages of different length to preserve catalytical activity of enzyme conformation. *DAN USSR* (Russ.) 1979; 248:244-246.
29. Bessolitsina LA, Mazaev AV, Markosyan RA, Suvorov AV, **Torchilin VP**, Chazov EI. Effect of biodegradable microspheres of immobilized fibrinolysin on fibrinolysis. *Bull Exper Biol Med.* (Russ) 1980; 89:16-18.
30. Gorshkova IN, Reyzer IL, Perova NV, **Torchilin VP**, Ruuge EK. Interaction of lipid spine label with apoproteins of high density lipoproteids modified with polyaldehydedextran. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1980; 6:1079-1086.
31. **Torchilin VP**, Klivanov AL. Preliminary "hydrophobization" of hydrophilic protein increases its binding with liposomes. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1980; 5:791-794.
32. **Torchilin VP**, Berdichevsky VR, Barsukov AA, Smirnov VN. Coating liposomes with protein decreases their capture by macrophages. *FEBS Lett.* 1980; 111:184-188.
33. Kinstler OB, Zhagat RY, **Torchilin VP**. Immobilization of enzymes on biocompatible carriers. Modification of tyrosin with water soluble CM-cellulose derivatives. *Bioorganicheskaya Khimia* (Russ.) (Bioorganic Chemistry) 1980; 6:1396-1403.
34. Martinek K, **Torchilin VP**, Shikshnis BA, Maksimenko AV, Smirnov VN, Berezin IV. Mechanism of salt stabilizing effect upon thermoinactivation of proteolytic enzymes. *DAN USSR* (Russ.) 1980; 251:1169-1172.
35. **Torchilin VP**, Omel'yanenko VG, Klivanov AL, Mikhailov AI, Goldanskyi VI, Smirnov VN. Incorporation of hydrophilic protein modified with hydrophobic agent into liposome membrane. *Biochim Biophys Acta.* 1981; 602:511-521.

36. Goldanskyi VI, Mikhailov AI, Omel'yanenko, Smirnov VN, **Torchilin VP**. Free-radical label: new approach to the study of super-slow molecular dynamics of lipid systems. *J Lip Res*. 1981; 22:131-137.
37. Martinek K, Shikshnis VA, Mozhaev VV, Smirnov VN, Berezin IV, **Torchilin VP**. Control of catalytic activity of enzymes immobilized on polyelectrolyte carrier, *DAN USSR (Russ.)* 1981; 259(3):746-749.
38. Koelsch R, Lasch J, Klivanov AL, **Torchilin VP**. Incorporation of chemically modified proteins into liposomes. *Acta Biol Med Germ* 1981; 40(3):331-335.
39. Chazov EI, Alexeev AV, Antonov AS, Koteliansky VE, Leytin VL, Ljubimova EV, Repin VS, Sviridov DD, **Torchilin VP**, Smirnov VN. Endothelial cell culture on fibrillar collagen: a model to study platelet adhesion and liposome targeting to intercellular collagen matrix. *Proc Natl Acad Sci USA* 1981; 78(N9):5603-5607.
40. Omel'yanenko VG, Mikhailov AI, **Torchilin VP**, Smirnov VN, Gol'danskii VI. Free-radical label – new approach to the study of dynamics of lipid systems. *Mol Biol (Molecular Biology, Russ)* 1981; 15(1):54-59.
41. **Torchilin VP**, Klivanov AL, Smirnov VN. Phosphatidylinositol may serve as the hydrophobic anchor for immobilization of proteins on liposome surface. *FEBS Lett* 1982; 138(N1):117-120.
42. Maksimenko AV, **Torchilin VP**, Smirnov VN. Kinetics of urokinase hydrolysis of low molecular weight substrate. *Biokhimiya (Biochemistry, Russ)* 1982; 47(3):405-408.
43. **Torchilin VP**, Trubetskly VS, Omelyanenko VG, Martinek K. Stabilization of subunit enzymes by intersubunit bifunctional reagents (studies with glyceraldehyde-3-phosphate dehydrogenase). *J Mol Catal* 1983; 19(N3):291-301.
44. Tchabanov SM, **Torchilin VP**, Berdichevsky VR, Loginov AS, Smirnov VN. Ultrastructure of myelin-like particles of mouse liver upon the administration of liposomes with different cholesterol and phosphatidyl choline contents. *Bull Exper Biol Med (Russ)* 1983; 45(N4):110-113.
45. Lasch J, Berdichevsky VR, **Torchilin VP**, Koelsch R, Kretschmer K. A method to measure critical detergent parameters. Preparation of liposomes. *Anal Biochem* 1983; 133:486-491.
46. Trubetskoy VS, **Torchilin VP**, Martinek K, Berezin IV, Smirnov VN. Stabilization of subunit enzymes by intersubunit cross-linking. *DAN USSR (Russ)* 1983; 270 (N3):748-750.
47. Dziembor-Gryszkiew E, Maksimenko AV, **Torchilin VP**, Ostrowski WS. Stabilization of human prostatic acid phosphatase by cross-linking with diamines. *Biochem Internatl* 1983; (N5):627-633.
48. Smirnov VN, **Torchilin VP**, Mazaev AV, Suvorova LA, Voronkov IuI. Clinico-experimental study of the possibility of the use of immobilized enzymes for local thrombolysis and thromboformation. *Ukr Biokhim Zh (Ukrainian Biochemical Journal, Russ)* 1983; 55(3):311-317.
49. Mozhaev VV, Shikshnis VA, **Torchilin VP**, Martinek K. Operational stability of copolymerized enzymes at elevated temperatures. *Biotechnol Bioeng* 1984; 25:1937-1945.
50. Korshak VV, **Torchilin VP**, Shtilman MI, Il'ina EV, Brudz SP. On the relative reactive activity of some water-soluble epoxy-containing polymers with alpha-chymotrypsin. *DAN USSR (Russ)* 1984; 273(N3):626-628.
51. Papisov MI, Samokhin GP, Smirnov MD, **Torchilin VP**, Smirnov VN. Possible use of ferromagnetic materials for drug targeting. *Bull Exper Biol Med (Russ)* 1984; N48:372-374.
52. **Torchilin VP**, Klivanov AL, Ivanov NN, Papisov IM, Chebanov SM. On the mechanism of liposome internalization by macrophages. *J Cell Biol* 1984; 99(N4):1404.

53. **Torchilin VP**, Maksimenko AV, Tischenko EG, Ignashenkova GV, Ermolin GA. Immobilized thrombolytic enzymes possessing increased affinity toward substrate. *Ann NY Acad Sci* 1984; 434:289-291.
54. **Torchilin VP**, Trubetsky VS. Stabilization of subunit enzymes by intramolecular crosslinking with bifunctional reagents. *Ann NY Acad Sci* 1984; 434:27-30.
55. Bogdanov AA, Klibanov AL, **Torchilin VP**. Immobilization of chymotrypsin on sucrose stearate-palmitate containing liposomes. *FEBS Lett* 1984; 175(N1):178-182.
56. Palubinskas VJ, Yankevich NB, Yanulaiteva KK, Vesa VS, Bendikene VG, Maksimenko AV, **Torchilin VP**, Il'ina EV, Smirnov VN, Kresyanova IN, Bortoshevich YE, Zabirowa RC. Trypsine-like enzyme from *Streptomyces* 771. Purification and properties of native and immobilized enzyme. *Appl Biochem Biotechnol* 1984; 9(N3):231-241.
57. **Torchilin VP**, Papisov MI, Smirnov VN. Magnetic Sephadex as a carrier for enzyme immobilization and drug targeting. *J Biomed Mater Res* 1985; 19(N4):461-466.
58. Ivanov NN, Rykov SV, Isakova OL, Ruuge EK, **Torchilin VP**. Estimation of liposome integrity by $^1\text{H-NMR}$ -spectroscopy. *Anal Biochem* 1985; 147(N2):280-284.
59. Trubetsky VS, **Torchilin VP**. Natural and artificial stabilization of subunit enzymes. Do they have similar mechanisms? *Int J Biochem* 1985; 17(N5):661-663.
60. Papisov IM, Maksimenko AV, **Torchilin VP**. The optimization of reaction conditions during enzyme immobilization on soluble carboxyl-containing carriers. *Enz Microb Technol* 1985; 7(N1):11-16.
61. **Torchilin VP**, Maksimenko AV, Ignashenkova GP, Tischenko EG, Ermolin GA, Smirnov VN. Fibrinolytic action of enzyme conjugated with specific antibodies. *Bull Exper Biol Med (Russ)* 1985; 48(N11):556-559.
62. Printseva OY, Faerman AI, Maksimenko AV, Tonevitsky AG, Ilynsky OB, **Torchilin VP**. Selective killing of smooth muscle in culture by the ricin A-chain conjugated with monoclonal antibodies to cell surface via dextran bridge. *Experientia* 1985; 41(N10), 13342-1344.
63. **Torchilin VP**, Klibanov AL, Ivanov NN, Glukhova MA, Koteliansky VE, Martin G, Kleinman H. Targeted liposome transport to the components of extracellular matrix. *J Cell Biochem* 1985; 28:23-29.
64. Burkhanov SA, Dormeneva EV, Kosykh VA, Berdichevsky VR, **Torchilin VP**, Saatov TS, Repin VS. Interaction of liposomes of different lipid composition with hepatocytes cells *in vitro*. *Bull Exper Biol Med (Russ)* 1985; 49(N6):679-681.
65. Maksimenko AV, **Torchilin VP**. Water-soluble urokinase derivatives of combined action. *Thromb Res* 1985; 38:277-288.
66. Maksimenko AV, **Torchilin VP**. Water-soluble urokinase derivatives with increased affinity to the fibrin clot. *Thromb Res* 1985; 38:289-295.
67. Arens AK, Berezin IV, Julis YY, Martinek K, Mozhaev VV, Poltorak OM, **Torchilin VP**, Tschukhrai ES. Stabilization of enzymes by suppressing primary reversible stages of dissociation and denaturation of native structures. *DAN USSR (Russ)* 1985; 283(N5):1212-1216.
68. Klibanov AL, Muzykantov VR, Ivanov NN, **Torchilin VP**. Evaluation of quantitative parameters of the interaction of antibody-bearing liposomes with target antigens. *Anal Biochem* 1985; 150:251-257.
69. Khaw BA, **Torchilin VP**, Strauss HW, Haber E. Rapid detection of acute myocardial necrosis with antimyosin antibody modified with DTPA-polylysine. *Circulation* 1985; 72(Suppl III):1203.

70. Khaw BA, **Torchilin VP**, Klibanov AL, Gold MK, Yasuda T, Smirnov VN, Haber E. Modification of monoclonal antibody with DTPA-linked synthetic polymers; possible application in magnetic resonance imaging. *Circulation* 1985; 72(Suppl III):1205.
71. Glushakova SE, Naroditskii BS, Tikhonenko TI, Klibanov AL, **Torchilin VP**. The use of the cationic detergent dodecyltrimethylammonium bromide for the isolation of influenza virus glycoproteins with subsequent integration of the protein into liposome membrane. *Mol Gen Microbiol Virusol (Molecular Genetics, Microbiology and Virusology, Russ.)* 1985; 4:39-44.
72. Blinov VA, Mirzaiv BS, **Torchilin VP**, Smirnov VN. Streptokinase and streptodectase – new inhibitors of glucogenesis. *Kardiologia (Cardiology, Russ)* 1985; 25(8):75-78.
73. Khaw BA, **Torchilin VP**, Strauss HW, Klibanov AL, Gold HK, Smirnov VN, Haber E. DTPA-Polylysine linked monoclonal antimyosine localization in acute experimental myocardial infarction. *J Nucl Med* 1986; 27(N6), 909.
74. Weissig V, Lasch J, Klibanov AL, **Torchilin VP**. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. *FEBS Lett* 1986; 202(N1):86-90.
75. Maksimenko AV, Konovalova OY, Berdichevsky VR, Arkhipova OG, **Torchilin VP**. Study on the functions of native and dextran-modified hyaluronidase in *in vitro* and *in vivo* systems. *Bull Exper Biol Med (Russ)* 1986; 11:567-569.
76. Lasch J, Niedermann G, Bogdanov AA, **Torchilin VP**. Thiolation of preformed liposomes with iminothiolane. *FEBS Lett* 1986; 214(N1), 13-16.
77. Smirnov VN, Domogatsky SP, Dolgov VV, Hvatov VB, Klibanov AL, Koteliansky VE, Myzykantov VR, Repin VS, Samokhin GP, Shekhonin BV, Smirnov MD, Sviridov DD, **Torchilin VP**, Chazov EI. Carrier-directed targeting of liposomes and erythrocytes to denuded areas of vessel wall. *Proc Natl Acad Sci USA* 1986; 83:6603-6607.
78. Trubetskoi VS, Berdichevskii VR, Efremov EE, **Torchilin VP**, Smirnov VN. Possibility of the unification of directed drug transport as illustrated by liposome transport to target antigens. *Bull Exper Biol Med (Russ)* 1986; 102(9):305-307.
79. Maksimenko AV, Rusetsky AN, **Torchilin VP**. Fibrinolytic action of enzyme preparation covalently bound to modified thrombin. *Bull Exper Biol Med (Russ)* 1987; 1:35-38.
80. Trubetskoy VS, Berdichevsky VR, Efremov EE, **Torchilin VP**. On the possibility of the unification of drug targeting systems. Studies with liposome transport to the mixtures of target antigens. *Biochem Pharm* 1987; 36:839-842.
81. Tertov VV, Orekhov AN, Kudryashov SA, Klibanov AL, Ivanov NN, **Torchilin VP**, Smirnov VN. Cyclic nucleotides and atherosclerosis: studies in primary culture of human aortic cells. *Exper Molec Pathol* 1987; 47(N3):337-390.
82. **Torchilin VP**, Klibanov AL, Nossiff ND, Slinkin MA, Strauss HW, Haber E, Smirnov VN, Khaw BA. Monoclonal antibody modification with chelate-linked high-molecular weight polymers: major increases in polyvalent cation binding without loss of antigen binding. *Hybridoma* 1987; 6(N3):229-240.
83. **Torchilin VP**, Klibanov AL, Ivanov NN. Polymerization of liposome-encapsulated hydrophilic monomers. *Macrom Chem Rapid Commun* 1987; 8:457-460.
84. Wasylewska E, Dulinska I, Trubetskoy VS, **Torchilin VP**, Ostrowski WS. Stabilization of human prostate acid phosphatase by cross-linking with diimidoesters. *Acta Biochimica Polonica* 1987; 34(N2):145-156.

85. Papisov MI, Savelyev VY, Sergienko VB, **Torchilin VP**. Magnetic drug targeting. I. *In vivo* kinetic of radio-labelled magnetic drug carriers. *Int J Pharm* 1987; 40:201-206.
86. Papisov MI, Savel'ev Vlu, Sergienko VB, **Torchilin VP**. Biokinetics of magnetic carriers for directed transport of drugs. *Antibiot Khimioter* (Antibiotics and Chemotherapy, Russ) 1988; 33:744-751.
87. Papisov MI, **Torchilin VP**. Prediction of the biological effect of magnetically egulated drugs. *Antibiot Khimioter* (Antibiotics and Chemotherapy, Russ) 1988; 33:751-757.
88. Papisov MI, **Torchilin VP**. Magnetic drug targeting. II. Targeted drug transport by magnetic microparticles: factors influencing therapeutic effect. *Int J Pharm* 1987; 40:207-214.
89. **Torchilin VP**, Papisov MI, Orekhova NM, Belyaev AA, Petrov AD, Ragimov SE. Magnetically driven thrombolytic preparation containing immobilized streptokinase: targeted transport and action. *Haemostasis* 1988; 18(N2):113-116.
90. Trubetskaya OV, Trubetskoy VS, Domogatsky SP, Rudin AV, Popov NV, Danilov SM, Nikolayeva MN, Klibanov AL, **Torchilin VP**. Monoclonal antibody to human endothelial cell surface: internalization and liposome delivery in cell culture. *FEBS Lett* 1988; 228(N1):131-134.
91. Maksimenko AV, Konovalova OY, Petrov AD, Arkhipova OG, **Torchilin VP**. Comparative study on the properties of native and modified collagenase. *Bull Exper Biol Med* (Russ) 1988; 105(N3):294-297.
92. Bogdanov AA Jr, Klibanov AL, **Torchilin VP**. Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydroxysulfosuccinimide. *FEBS Lett* 1988; 231(N2):381-384.
93. Danilov S, Martynov A, Klibanov A, Slinkin M, Sakharov I, Muzykantov V, Malov A, Sergienko V, **Torchilin VP**. Imaging of lung vessels using ¹¹¹In-labelled monoclonal antibody to angiotensin-converting enzyme. *Eur J Nucl Med* 1988; 14(N5/6), 230.
94. Trubetskoy VS, Dormeneva EV, Tsibulsky VP, Repin VS, **Torchilin VP**. Use of enzyme label for quantitative evaluation of liposome adhesion on cell surface: studies with J774 macrophage monolayers. *Anal Biochem* 1988; 172:185-189.
95. Burkhanov SA, Kosykh VA, Repin VS, Saatov TS, **Torchilin VP**. Interaction of liposomes of different phospholipid and ganglioside composition with rat hepatocytes. *Int J Pharm* 1988; 43:31-34.
96. Maksimenko AV, Tischenko EG, Petrov AD, Orekhova NM, Ragimov SE, Belyaev AA, **Torchilin VP**. Thrombolytic action of urokinase covalently bound to modified thrombin. *Bull Exper Biol Med* (Russ) 1988; 9:322-324.
97. Ivanov AA, Kalinin NL, Gromakovskaya ET, Levin AD, Podrez EA, **Torchilin VP**. Immunochemical properties of immunoglobulin G conjugated with dextran. *Bull Exper Biol Med* (Russ) 1988; 7:78-80.
98. Gordeeva LV, Bogdanov AA Jr, Baibakov BA, **Torchilin VP**, Margolis LB. Adhesion defect of ascites cells corrected with membrane-bound attachment molecules. *FEBS Lett* 1988; 241(N1/2):185-187.
99. Klibanov AL, Martynov AV, Slinkin AL, Sakharov IY, Smirnov MD, Muzykantov VR, Danilov SM, **Torchilin VP**. Blood clearance of radiolabeled antibody: enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies. *J Nucl Med* 1988; 29:1956-1988.

100. Khaw BA, **Torchilin VP**, Klibanov AL, Nossiff ND, Powers JB, Strauss HW, Haber E. Modification of monoclonal antimyosin antibody: enhanced specificity of localization and scintigraphic visualization in acute experimental myocardial infarction. *J Mol Cell Cardiol* 1989; 21(Suppl):31-35.
101. Maksimenko AV, Nadirashvili LA, Romaschenko AD, Erkomaishvili GS, Abramova VV, **Torchilin VP**. The modification of soluble complex of papaya proteinases with synthetic polymers. *J Contr Release* 1989; 10(N1):131-145.
102. Klibanov AL, Bogdanov AA Jr, **Torchilin VP**, Huang L. Biotin-bearing pH-sensitive liposomes: high-affinity binding to avidin layer. *J Liposome Res* 1989; 1(N2):233-244.
103. Bogdanov AA, Gordeeva LV, **Torchilin VP**, Margolis LB. Lectin-bearing liposomes: differential binding to normal and to transformed mouse fibroblasts. *Exper Cell Res* 1989; 181:362-374.
104. Khaw BA, Klibanov AL, O'Donnell S, Saito T, Nossiff N, Strauss HW, **Torchilin VP**. Charge modification of monoclonal antibodies for enhanced target localization. *J Nucl Med* 1989; 30(N5):762.
105. Danilov SM, Martynov AV, Klibanov AL, Slinkin MA, Sakharov IY, Malov AG, Sergienko VB, Vedernikov AY, Muzykantov VR, **Torchilin VP**. Radioimmunoaging of lung vessels: an approach using indium-111-labelled monoclonal antibody to angiotensin-converting enzyme. *J Nucl Med* 1989; 30:1686-1692.
106. **Torchilin VP**, Klibanov AL, Slinkin MA, Danilov SM, Levitsky DO, Khaw BA. Antibody-linked chelating polymers for immunoimaging *in vivo*. *J Contr Release* 1989; 11:297-303.
107. Trubetskoy VS, Trubetskaya OV, Domogatsky SP, **Torchilin VP**. Immunoliposome complexes: preparation, characterization and directed delivery to the human endothelial cell culture. *Bioorganicheskaya Khimia* (Russ) (Bioorg Chem) 1989; 6(N2):143-148.
108. Mukhamedova NM, Obukhov SK, Slinkin MA, Klibanov AL, **Torchilin VP**. Chemical modification of immunoglobulins to accelerate their blood clearance during radioimmunodiagnostics. *Bull Exp Biol Med* (Russ) 1989; 12:705-707.
109. Lasch J, Hoffman J, Omelyanenko WG, Klibanov AL, **Torchilin VP**, Binder H, Gawrisch K. Interaction of Triton X-100 and octyl glucoside with liposomal membranes at sublytic and lytic concentrations. Spectroscopic studies. *Biochim Biophys Acta* 1990; 1022:171-180.
110. Holmberg E, Maruyama K, Kennel S, Klibanov AL, **Torchilin VP**, Ryan U, Huang L. Target-specific binding of immunoliposomes *in vivo*. *J Liposome Res* 1990; 1(N4):393-406.
111. Greidziak M, Ehrke R, Baust G, **Torchilin V**, Lasch J. Interactions of liposomes with human erythrocyte ghosts. *Biomed Biochim Acta* 1990; 49(N4):189-200.
112. Slinkin M, Klibanov A, Khaw B, **Torchilin VP**. Succinylated polylysine as a possible link between an antibody molecule and deferoxamine. *Bioconj Chem* 1990; 1:291-295.
113. Klibanov AL, Maruyama K, **Torchilin VP**, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett* 1990; 268:235-237.
114. Trubetskoy VS, Koshkina NV, Omelyanenko VG, L'vov VL, Dmitriev BA, Petrov AB, **Torchilin VP**. FITC-labeled lipopolysaccharide: use as a probe for liposomal membrane incorporation studies. *FEBS Lett* 1990; 269:79-82.
115. Maruyama K, Holmberg E, Kennel S, Klibanov A, **Torchilin VP**, Huang L. Characterization of *in vivo* immunoliposome targeting to pulmonary endothelium. *J Pharm Sci* 1990; 79(N11):978-984.

116. **Torchilin VP**, Omelyanenko VG, Slinkin MA, Lukyanov AN, Dulinska I, Ostrovsky W. Effect of the lipid bilayer on the enzymatic activity and conformation of acid phosphates from human prostate. *Biol Membr* (Russ) 1990; 7:1125-1130.
117. **Klibanov AL**, Maruyama K, Beckerleg AM, **Torchilin VP**, Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. *Biochim Biophys Acta* 1991;1062:142-148.
118. Mori A, Klibanov AL, **Torchilin VP**, Huang L. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes *in vivo*. *FEBS Lett* 1991; 284(N2); 263-266.
119. Khaw BA, Klibanov AL, O'Donnel SM, Saito T, Nossiff N, Slinkin MA, Newell JB, Strauss HW, **Torchilin VP**. Gamma-imaging with negatively charge-modified monoclonal antibody: modification with synthetic polymers. *J Nucl Med* 1991; 32:1742-1751.
120. Glushakova SE, Omelyanenko VG, Lukashevich IS, Bogdanov AA Jr, Moshnicova AV, Kozhich AT, **Torchilin VP**. Fusion of artificial lipid membranes induced by a synthetic "fusion peptide" of arenaviruses. *Biokhimiya* (Russ) 1991; 56:579-588.
121. Bogdanov AA Jr, Gordeeva LV, Baibakov BA, Margolis LB, **Torchilin VP**. Restoration of adhesive potentials of Ehrlich ascites carcinoma cells by modification of plasma membrane. *J Cell Physiol* 1991; 147(N1):182-190.
122. Slinkin MA, Klibanov AL, **Torchilin VP**. Terminal-modified polylysine-based chelating polymers: highly efficient coupling to antibody with minimal loss in immunoreactivity. *Bioconj Chem* 1991;2(N5); 342-348.
123. Klibanov AL, Khaw BA, Nossiff N, O'Donnel SM, Huang L, Slinkin MA, **Torchilin VP**. Targeting of macromolecular carriers and liposomes by antibodies to myosin heavy chain. *Am J Physiol* 1991; 261(Suppl)(N4); 60-65.
124. Gorlova AV, **Torchilin VP**. Use of liposomes to associate foreign genetic material with spermatazoa. *Bull Exper Biol Med* (Engl Trans) 1991; 112(9):1309-1311.
125. Luchter-Wasilewska E, Dulinska J, Ostrowski WS, **Torchilin VP**, Trubetskoy VS. Stabilization of human prostatic acid phosphatase by coupling with chondroitin sulfate. *Biotechnol Appl Biochem* 1991; 13(1):36-47.
126. Timofeev BA, Bolotin IM, Stepanova LP, Bogdanov AA Jr, Georgiu KH, Malyshev SN, Petrovsky VV, Klibanov AL, **Torchilin VP**. Liposomal form of diamidine: decrease of toxicity. *Antibiotiki i Khimioterapiya* (Antibiotics and Chemotherapy, Russ.) 1991; 36:34-36.
127. Maksimenko AV, Grigor'eva EL, Morozkin AD, Tischenko EG, Minkovskii EB, **Torchilin VP**. Assessment of the composition and structure of covalent complexes of superoxide dismutase with aldehyde dextran by analytical ultracentrifugation. *Biokhimiya (Biochemistry, Russ)* 1991; 56:1330-1336.
128. Maksimenko AV, Grigor'eva EL, Bezrukavnikova LM, Petrov AD, Tischenko EG, Arkhipova OG, **Torchilin VP**. Antifibrotic effects of aldehyde dextran modified superoxide dismutase in experimental silicosis. *Biull Eksp Biol Med* (Bulletin of Experimental Biology and Medicine, Russ) 1991; 112:265-267.
129. Maksimenko AV, Bezrukavnikova LM, Grigor'eva EL, Tischenko EG, Arkhipova OG, Iaglov VV, **Torchilin VP**. Antifibrotic effect of modified forms of catalase and superoxide dismutase in experimental silicosis. *Vopr Med Khim* (Problems of Medicinal Chemistry, Russ.) 1992; 38:4-8.

130. Maksimenko AV, Bezrukavnikova LM, Grigoreva EL, Iaglov VV, **Torchilin VP**. Effect of native and modified forms of superoxide dismutase and catalase on experimental silicosis in rats. *Ann NY Acad Sci* 1992; 672:118-125.
131. **Torchilin VP**, Klibanov AL, Huang L, O'Donnell S, Nossif ND, Khaw BA. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. *FASEB J* 1992; 6:2716-2719.
132. Trubetskoy VS, **Torchilin VP**, Kennel SJ, Huang L. Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells. *Bioconj Chem* 1992; 3(4):323-327.
133. Trubetskoy VS, **Torchilin VP**, Kennel SJ, Huang L. Cationic liposomes enhance targeted delivery and expression of exogenous DNA mediated by N-terminal modified poly(L-lysine)-antibody conjugate in mouse lung endothelial cells. *Biochim Biophys Acta* 1992; 1131:311-313.
134. **Torchilin VP**, Lukyanov AN, Klibanov AL, Omelyanenko VG. Interaction between oleic acid-containing pH-sensitive and plain liposomes: fluorescent spectroscopy studies. *FEBS Lett* 1992; 305(3):185-188.
135. Glushakova SE, Omelyanenko VG, Lukashevitch IS, Bogdanov AA Jr, Moshnikova AB, Kozytch AT, **Torchilin VP**. The fusion of artificial lipid membranes induced by the synthetic arenavirus "fusion peptide". *Biochim Biophys Acta* 1992; 1110:202-208.
136. Petrov AB, Semenov BF, Vartanyan YP, Zakirov MM, **Torchilin VP**, Trubetskoy VS, Koshkina NV, Lvov VL, Verner IK, Lopyrev IL, Dmitriev BA. Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes. *Infection and Immunity* 1992; 60(9):3897-3903.
137. Romanova EV, Gelashvili DB, Koshkina NV, **Torchilin VP**. Toxicity and immunogenic properties of liposomal form of *Vipera libetina* venom. *J Liposome Res* 1992; 2(2):205-216.
138. **Torchilin VP**, Omelyanenko VG, Lukyanov AN. Temperature-dependent aggregation of pH-sensitive, phosphatidyl ethanolamine-oleic acid-cholesterol liposomes as measured by fluorescent spectroscopy. *Anal Biochem* 1992; 207:109-113.
139. Greidziak M, Bogdanov AA, **Torchilin VP**, Lasch J. Destabilization of pH-sensitive liposomes in the presence of human erythrocyte ghosts. *J Contr Release* 1992; 20:219-230.
140. Slinkin MA, Curtet C, Sai-Maurel C, Gestin JF, **Torchilin VP**, Chatal JF. Site-specific conjugation of chain-terminal chelating polymers to Fab^γ fragments of anti-CEA mAb: effect of linkage type and polymer size on conjugate biodistribution in nude mice bearing human colorectal carcinoma. *Bioconj Chem* 1992; 3(6):477-483.
141. **Torchilin VP**. Targeting of thrombolytic agents: current state of knowledge and perspectives. *Ann NY Acad Sci* 1992; 667:404-416.
142. **Torchilin VP**, Mukhamedova NM, Ilyina AI, Iakoubov LZ, Tshitkov KG. Selective accumulation of monoclonal antibodies in the lung after cyclophosphamide administration into rats. *Bull Exper Biol Med (Russ)* 1992; 10:400-401.
143. **Torchilin VP**, Trubetskoy VS, Narula J, Khaw BA. Monoclonal antibody-chelating polymer conjugates specifically labeled with heavy metal radioisotopes. Possible use for tumor imaging and therapy. *Antibody Immunoconj Radiopharm* 1993; 6(1):83.

144. Slinkin MA, Curet C, Faivre-Chauvet A, Sai-Maurel C, Gestin JF, **Torchilin VP**, Chatal JF. Biodistribution of anti-CEA F(ab')₂ fragments conjugated with chelating polymers: influence of conjugated electron charge on tumor uptake and blood clearance, *Nucl Med Biol* 1993; 20:443-452.
145. **Torchilin VP**. Interactions of immunoliposomes with targets *in vivo*. *J Liposome Res* 1993; 3:138-139.
146. Trubetskoy VS, Cannillo JA, Milshteyn A, **Torchilin VP**, Wolf GL. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. *Proceed Intern Symp Control Rel Bioact Mater* 1993; 20:123-124.
147. **Torchilin VP**, Trubetskoy VS, Narula J, Khaw BA, Klivanov AL, Slinkin MA. Chelating polymer modified monoclonal antibodies for radioimmunodiagnosics and radioimmunotherapy. *J Contr Release* 1993; 24:111-118.
148. Trubetskoy VS, Narula J, Khaw BA, **Torchilin VP**. Chemically optimized antimyosin Fab conjugates with chelating polymers: importance of the nature of the protein-polymer single site covalent bond for biodistribution and infarct localization. *Bioconj Chem* 1993; 4:251-255.
149. Hiemisch H, Gavriyuk V, Atochina E, Slinkin M, **Torchilin V**, Muzykantov V, Danilov S. Purification of radiolabeled monoclonal antibodies to angiotensin-converting enzyme significantly improves specificity and efficacy of its targeting into the lung. *Nucl Med Biol* 1993; 20:435-441.
150. Zolin VV, Luk'ianov AN, Nesterov AE, Kolokol'tsov AA, **Torchilin VP**, Popov VF, Vardanian NV, Antonov NA. Methodological approaches to creating a liposomal form of human recombinant alpha 2-interferon. *Vestn Ross Acad Med Nauk (Russ)* 1993; 2:29-31.
151. **Torchilin VP**, Trubetskoy VS, Milshteyn AM, Cannillo J, Wolf GL, Papisov MI, Bogdanov AA Jr, Narula J, Khaw BA, Omelyanenko VG. Targeted delivery of diagnostic agents by surface-modified liposomes. *J Contr Release* 1994; 26:45-58.
152. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, **Torchilin VP**, Langer R. Biodegradable long-circulating polymeric nanospheres. *Science* 1994; 263:1600-1603.
153. **Torchilin VP**, Papisov MI. Why do polyethylene glycol-coated liposomes circulate so long? *J Liposome Res* 1994; 4:725-739.
154. **Torchilin VP**. Chelating polymer-based immunoconjugates: new agents for diagnostic imaging. *Polymer Sci (Russ)* 1994; 36:228-243.
155. Trubetskoy VS, **Torchilin VP**. New approaches in the chemical design of Gd-containing liposomes for use in magnetic resonance imaging of lymph nodes. *J Liposome Res* 1994; 4(2):961-980.
156. **Torchilin VP**, Omelyanenko VG, Papisov MI, Bogdanov AA Jr, Trubetskoy VS, Herron JN, Gentry CA. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. *Biochim Biophys Acta* 1994; 1195(1):11-20.
157. **Torchilin VP**, Shtilman MI, Trubetskoy VS, Whiteman K, Milstein AM. Amphiphilic vinyl polymers effectively prolong liposome circulation time *in vivo*. *Biochim Biophys Acta* 1994; 1195(1):181-184.
158. Timofeev BA, Bolotin IM, Stepanova LP, Bogdanov AA Jr, Georgiu KH, Malyshev SN, Petrovsky VV, Klivanov AL, **Torchilin VP**. Liposomal diamidine (imidocarb): preparation and animal studies. *J Microencapsulation* 1994; 11(6):627-632.
159. Lukyanov AN, **Torchilin VP**. Autoclaving of liposomes. *J Microencapsulation* 1994; 11(6):669-672.

160. Trubetskoy VS, Cannillo JA, Milshteyn A, Wolf GL, **Torchilin VP**. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. *Magn Res Imaging* 1995; 13(1):31-37.
161. Narula J, **Torchilin VP**, Petrov A, Khaw S, Trubetskoy VS, O'Donnell SM, Nossiff ND, Khaw BA. In vivo targeting of acute myocardial infarction with negative-charge, polymer-modified antimyosin antibody: use of different cross-linkers. *J Nucl Cardiol* 1995; 2:26-34.
162. Narula J, Petrov A, Bianchi C, Ditlow CC, Lister BC, Dilley J, Pieslak I, Chen FW, **Torchilin VP**, Khaw BA. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')₂ specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments. *Circulation* 1995; 92:474-484.
163. Zakirov MM, Petrov AB, Burkhanov SA, Vartanian IuP, **Torchilin VP**, Trubetskoy VS, Koshkina NV, Dmitriev BA, L'vov VL. The immunological activity of Neisseria meningitidis lipo-oligosaccharide incorporated into liposomes. *Zh Mikrobiol Epidemiol Immunobiol (J Microbiology, Epidemiology and Immunobiology, Russ)* 1995; 1:49-53.
164. Trubetskoy VS, **Torchilin VP**. Fast and specific labeling of antibody fragments with multiple atoms of heavy metal radioisotopes. *Anal Biochem* 1995; 229:345-347.
165. Iakoubov L, Rokhlin O, **Torchilin V**. Anti-nuclear autoantibodies of the aged reactive against the surface of tumor but not normal cells. *Immunol Lett* 1995; 47:147-149.
166. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, **Torchilin VP**, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. *Cancer Res* 1995; 55:3752-3756.
167. **Torchilin VP**, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P, Veronese FM. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. *J Pharm Sci* 1995; 84:1049-1053.
168. Khaw BA, **Torchilin VP**, Vural I, Narula J. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. *Nature Medicine* 1995; 1:1195-1198.
169. Iakoubov L, Mongait D, **Torchilin V**. Monoclonal anti-nuclear autoantibody from the aged effectively suppresses tumor development in vivo. *Cancer Biother Radiopharm (formerly Antibody, Immunoconj Radiopharm)* 1995; 8:299-310.
170. **Torchilin VP**, Narula J, Halpern E, Khaw BA. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: Factors influencing targeted accumulation in the infarcted myocardium. *Biochim Biophys Acta* 1996; 1279:75-83.
171. Trubetskoy VS, Frank-Kamenetsky MD, Whiteman KR, Wolf GL, **Torchilin VP**. Stable polymeric micelles: Lymphangiographic contrast media for gamma-scintigraphnd magnetic resonance imaging. *Acad Radiol* 1996; 3:232-238.
172. Trubetskoy VS, **Torchilin VP**. Polyethylene glycol based micelles as carriers of therapeutic and diagnostic agents. *STP Pharma Sci* 1996; 6:79-86.
173. Chen H, **Torchilin VP**, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers, *Pharm Res* 1996; 13:1378-1383.
174. Chen H, **Torchilin VP**, Langer R. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability, *J Contr Release* 1996; 42:263-272.

175. Trubetskoy VS, Gazelle GS, Wolf GL, **Torchilin VP**. Block-copolymers of polyethylene glycol and polylysine as a carrier of organic iodine: Design of long-circulating particulate contrast medium for X-ray computed tomography, *J Drug Targ* 1997; 6:381-388.
176. Gref R, Minamitake Y, Peracchia MT, Domb A, Trubetskoy V, **Torchilin V**, Langer R. Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. *Pharm Biotechnol* 1997; 10:167-198.
177. Iakoubov LZ, **Torchilin VP**. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice, *Oncol Res* 1997; 9:439-446.
178. Trubetskoy VS, Whiteman KR, **Torchilin VP**, Wolf GL. Massage-induced release of subcutaneously injected liposome-encapsulated drugs in the blood, *J Contr Release* 1998; 50:13-19.
179. Hobbs SK, Monsky WL, Fan Yuan, Roberts WG, Griffith L, **Torchilin VP**, Jain RK. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment, *Proc Natl Acad Sci USA* 1998; 95:4607-4612.
180. Khaw BA, Narula J, Vural I, **Torchilin VP**. Cytoskeleton-specific immunoliposomes: sealing of hypoxic cells and intracellular delivery of DNA, *Intl J Pharm* 1998; 162:71-76.
181. Iakoubov LZ, **Torchilin VP**. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies, *Cancer Detect Prevent* 1998; 22:470-475.
182. Weissig V, Lizano C, **Torchilin VP**. Micellar delivery system for dequalinium – a lipophilic cationic drug with anticarcinoma activity, *J Liposome Res* 1998; 8:391-400.
183. Weissig V, Whiteman KR, **Torchilin VP**. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice, *Pharm Res* 1998; 15:1552-1556.
184. Dalkara S, Petrov A, Trubetskoy VS, Khaw BA, **Torchilin VP**. Disulfide cross-linked Fab-aggregates: preparation and biodistribution, *J Drug Targ* 1998; 6:45-52.
185. **Torchilin VP**. Biotin-conjugated polychelating agent, *Bioconj Chem* 1999; 10:146-149.
186. **Torchilin VP**, Frank-Kamenetsky MD, Wolf GL. CT visualization of blood pool in rats by using long-circulating, iodine-containing micelles, *Acad Radiol* 1999; 6:61-65.
187. **Torchilin VP**, Weissig V. Polymeric micelles for delivery of poorly soluble drugs, *Polym Prepr* 1999; 40:320-321.
188. Monsky WL, Fukumura D, Gohongi T, Ancukiewicz M, Weich HA, **Torchilin VP**, Yuan F, Jain RK. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. *Cancer Res* 1999; 59: 429-4135.
189. Savva M, **Torchilin VP**, Huang L. Effect of polyvinyl pyrrolidone on the thermal phase transition of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine bilayer. *J Coll Interf Sci* 1999; 217:160-165.
190. Savva M, **Torchilin VP**, Huang L. Effect of grafted amphiphilic PVP-palmityl polymers on the thermotropic phase behavior of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine bilayer. *J Coll Interf Sci* 1999; 217:166-171.
191. **Torchilin VP**. Novel polymers in microparticulate diagnostic agents, *CHEMTECH* 1999; 29(11):27-34.
192. Weissig V, Lizano C, **Torchilin VP**. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes, *Drug Deliv* 2000; 7:1-5.

193. Dellian M, Yuan F, Trubetskiy VS, **Torchilin VP**, Jain RK, Vascular permeability in a human tumor xenograft: molecular charge dependence, *Br J Cancer* 2000; 82:1513-1518.
194. Weissig V, Babich J, **Torchilin VP**. Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool, *Colloids Surf B: Biointerfaces*, 2000; 18:293-299.
195. Khaw BA, Vural I, DaSilva J, **Torchilin VP**. Use of cytoskeleton-specific immunoliposomes for preservation of cell viability and gene delivery, *STP Pharma Sci* 2000; 10:279-283.
196. **Torchilin VP**, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, Rammohan R, Samokhin GP, Whiteman KR. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups, *Biochim Biophys Acta – Biomembranes* 2001; 1511:397-411.
197. Weissig V, Lizano C, Ganellin CR, **Torchilin VP**. DNA binding cationic liposomes with delocalized charge center: A structure-activity relationship study, *STP Pharma Sci* 2001; 11:91-96.
198. Samokhin GP, Mongayt DA, Iakoubov LZ, Levchenko TS, **Torchilin VP**. Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents, *Anal Biochem* 2001; 292:245-249.
199. Weissig V, D'Souza GGM, **Torchilin VP**. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria, *J Contr Release* 2001; 75: 401-408.
200. **Torchilin VP**, Levchenko TS, Whiteman KR, Yaroslavov AA, Tsatsakis AM, Rizos AK, Michailova EV, Shtilman MI. Amphiphilic poly-N-vinylpyrrolidones: synthesis, Properties and liposome surface modification, *Biomaterials* 2001; 22:3035-3044.
201. Khaw BA, daSilva J, Vural I, Narula J, **Torchilin VP**. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes, *J Contr Release* 2001; 75:199-210.
202. **Torchilin VP**, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors, *Proc Natl Acad Sci USA* 2001; 98:8786-8791.
203. Whiteman KR, Subr V, Ulbrich K, **Torchilin VP**. Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice, *J Liposome Res* 2001; 11:153-164.
204. Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, **Torchilin VP**, Halpern EF, Kruskal LB, Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model, *Radiology* 2002; 222:797-804.
205. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, **Torchilin VP**. Liposome clearance in mice: the effect of a separate and combined presence of Surface charge and polymer coating, *Int J Pharm* 2002; 240:95-102.
206. **Torchilin VP**, Lukyanov AN, Gao Z, Mazzola L. Polymer-lipid micelles as non-targeted and targeted pharmaceutical carriers, *Polym Prepr* 2002; 43(2):677-678.
207. Monsky WL, Kruskal LB, Lukyanov AN, Girnan GD, Ahmed M, Gazelle GS, Huertas JC, Stuart KE, **Torchilin VP**, Goldberg SN. Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model, *Radiology* 2002; 224:823-829.
208. Gao Z, Lukyanov AN, Singhal A, **Torchilin VP**, Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs, *Nano Lett* 2002; 2:979-982.

209. Lukyanov AN, Gao Z, Mazzola L, **Torchilin VP**, Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice, *Pharm Res* 2002; 19:1424-1429.
210. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, **Torchilin VP**, Munn LL, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors, *Cancer Res* 2002; 62:6831-6836.
211. **Torchilin VP**, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Sternberg B, D'Souza GGM, Cell transfection in vitro and in vivo with non-toxic TAT peptide-liposome-DNA complexes, *Proc Natl Acad Sci USA* 2003; 100:1972-1977.
212. **Torchilin VP**, Levchenko TS, TAT-liposomes: A novel intracellular drug carrier, *Curr Protein Pept Sci* 2003; 4:133-140.
213. **Torchilin VP**, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B, Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs, *Proc Natl Acad Sci USA* 2003; 100:6039-6044.
214. Gao Z, Lukyanov AN, Chakilam AR, **Torchilin VP**, PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing, *J Drug Targ* 2003; 11:87-92.
215. Asahi M, Rammohan R, Sumii T, Wang X, Pauw RJ, Weissig V, **Torchilin VP**, Lo EH, Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator- induced hemorrhage after focal embolic stroke, *J Cerebral Blood Flow Metab* 2003; 23:895-899.
216. Lukyanov AN, Gao Z, **Torchilin VP**, Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery, *J Contr Release* 2003; 91:97-102.
217. Lizano C, Weissig V, **Torchilin VP**, Sancho P, Isabel Garcia-Perez A, Pinilla M, In vivo biodistribution of erythrocytes and polyethyleneglycol-phosphatidyl ethanolamine micelles carrying the antitumor agent dequalinium, *Eur J Pharm Biopharm* 2003; 56:153-157.
218. D'Souza GGM, Rammohan R, Cheng S-M, **Torchilin VP**, Weissig V, DQAsome-mediated delivery of plasmid DNA toward mitochondria of living cells, *J Contr Release* 2003; 92:189-197.
219. Ahmed M, Monsky WE, Girnun G, Lukyanov A, D'Ippolito G, Kruskal JB, Stuart KE, **Torchilin VP**, Goldberg SN, Radiofrequency thermal ablation sharply increases intratumoral liposomal Doxorubicin accumulation and tumor coagulation, *Cancer Res* 2003; 63:6327-6333.
220. Levchenko TS, Rammohan R, Volodina N, **Torchilin VP**, Tat peptide-mediated intracellular delivery of liposomes, *Meth Enzymol* 2003; 372:339-349.
221. Lukyanov AN, Hartner WC, **Torchilin VP**, Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits, *J Contr Release* 2004; 94:187-193.
222. Liang W, Levchenko T, Khaw B-A, **Torchilin VP**, ATP-containing immunoliposomes specific for cardiac myosin, *Curr Drug Delivery* 2004; 1:1-7.
223. Wettstein R, Tsai AG, Erni D, Lukyanov AN, **Torchilin VP**, M.Intaglietta, Improved microcirculation is more effective than substitution of red blood cells to correct metabolic disorder in experimental hemorrhagic shock, *Shock* 2004; 21:235-240.
224. Wang J, Mongayt DA, Lukyanov AN, Levchenko TS, **Torchilin VP**, Preparation and in vitro synergistic anticancer effect of Vitamin K₂ and 1,8-diazabicyclo[5,4,0]undec-7-ene in poly(ethylene glycol)-diacyllipid micelles, *Int J Pharm* 2004; 272:129-135.
225. Liang W, Levchenko TS, **Torchilin VP**, Encapsulation of ATP into liposomes by different methods: optimization of the procedure, *J Microencapsul* 2004; 21:251-261.

226. Lukyanov AN, Sawant RM, Hartner WC, **Torchilin VP**, PEGylated dextran as long-circulating pharmaceutical carrier, *J Biomater Sci Polymer Edn* 2004; 15:621-630.
227. Lukyanov AN, Elbayoumi TA, Chakilam AR, **Torchilin VP**, Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody, *J Control Release* 2004; 100:135-144.
228. Chakilam AR, Pabba S, Mongayt D, Iakoubov LZ, **Torchilin VP**, A single monoclonal antinuclear autoantibody with nucleosome-restricted specificity inhibits growth of diverse human tumors in nude mice, *Cancer Ther* 2004; 2:353-364.
229. Cheng SM, Pabba S, **Torchilin VP**, Fowle W, Kimpfler A, Schubert R, Weissig V, Towards mitochondria-specific delivery of apoptosis-inducing agents: DQAsomal incorporated paclitaxel, *J Drug Del Sci Tech* 2005; 15:81-86.
230. Wang J, Mongayt D, **Torchilin VP**, Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids, *J Drug Target* 2005; 13:73-80.
231. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, **Torchilin VP**, Goldberg SN, Combination radiofrequency ablation with intratumoral liposomal Doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals, *Radiology* 2005; 235:469-477.
232. Boddapati SV, Tongcharoensirikul P, Hanson RN, D'Souza GGM, **Torchilin VP**, Weissig V, Mitochondriotropic liposomes, *J Liposome Res* 2005; 15:49-58.
233. **Torchilin VP**, Verma DD, Levchenko NS, Hartner WC, Bernstein EA, ATP-loaded liposomes and immunoliposomes protect ischemic myocardium in isolated rat hearts and in rabbits with experimental myocardial infarction, *Cell Molec Biol Lett* 2005; 10:53-54.
234. Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, **Torchilin VP**, Bawendi MG, Fukumura D, Jain RK, Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo, *Nat Med* 2005; 11:678-682.
235. Leevy WM, Gammon ST, Levchenko T, Daranciang DD, Murillo O, **Torchilin V**, Piwnica-Worms D, Huettner JE, Gokel GW, Structure-activity relationships, kinetics, selectivity, and mechanistic studies of synthetic hydrophilic channels in bacterial and mammalian cells, *Org Biomol Chem* 2005; 3:3544-3550.
236. Mu L, Chrastina A, Levchenko T, **Torchilin VP**, Micelles from poly(ethylene glycol)-phosphatidyl ethanolamine conjugate (PEG-PE) as pharmaceutical nanocarriers for poorly soluble drug camptothecin, *J Biomed Nanotechnol* 2005; 1:190-196.
237. Ahmed M, Lukyanov AN, **Torchilin V**, Tournier H, Schneider AN, Goldberg SN, Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time, *J Vasc Interv Radiol* 2005; 16:1365-1371.
238. Verma DD, Levchenko TS, Bernstein EA, **Torchilin VP**, ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model, *J Control Release* 2005; 108:460-471.
239. Gupta B, Levchenko TS, Mongayt DA, **Torchilin VP**, Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo, *J Drug Target* 2005; 13:337-343.

240. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, **Torchilin VP**, ATP-loaded liposomes effectively protect the myocardium in rabbits with a acute experimental myocardial infarction, *Pharm Res* 2005.
241. Mu L, Elbayoumi TA, **Torchilin VP**, Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and D- α -tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin, *Int J Pharm* 2005; 306:142-149.
242. Tolcheva EV, Barishnikov AYu, Oborotova NA, Kortava MA, Barishnikov KA, Mongayt D, Levchenko TS, **Torchilin VP**, Anti-CD5-immunoliposomes as a transport system for targeted drug delivery to CD5+ cells, *Russ Biotherapeutic J (Russ)* 2005; 4; #4:38-43.
243. Erdogan S, Roby A, Sawant S, Hurley J, **Torchilin VP**, Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes, *J Liposome Res* 2006; 16:45-55.
244. Roby A, Erdogan S, **Torchilin VP**, Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro, *Eur J Pharm Biopharm* 2006; 62:235-240.
245. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, **Torchilin VP**, Polyethyleneglycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux, *Int J Pharm* 2006; 315:148-157.
246. Zhang C, Tang N, Liu X, Liang W, Xu W, **Torchilin VP**, siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene, *J Control Release* 2006; 112:229-239.
247. Erdogan S, Roby A, **Torchilin VP**, Enhanced tumor visualization by gamma-scintigraphy with (111)In-labeled polychelating polymer-containing immunoliposomes, *Mol Pharm* 2006; 3:525-530.
248. Elbayoumi TA, **Torchilin VP**, Tumor-targeted immunoliposomes for delivery of therapeutics and diagnostics, *Pharm. Eng* 2006; 26,#5:96-104.
249. Elbayoumi T, **Torchilin VP**, Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies, *Eur J Nucl Med Mol Imaging* 2006; 33:1196-1205.
250. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, **Torchilin VP**, "Smart" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers, *Bioconj Chem* 2006; 17:943-949.
251. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, **Torchilin VP**, ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model, *J Drug Target* 2006; 14:273-280.
252. Kale A, **Torchilin VP**, Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the pH-stability of PEG-PE conjugates, *Bioconj Chem* 2007; 18:363-370.
253. Elbayoumi TA, Pabba S, Roby A, **Torchilin VP**, Antinucleosome antibody- modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents, *J Liposome Res* 2007; 17:1-14.
254. Gupta B, **Torchilin VP**, Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U087 tumor xenografts in nude mice, *Cancer Immunol Immunother* 2007; 56:1215-1223.

255. Roby A, Erdogan S, **Torchilin VP**, Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles, *Cancer Biol Ther* 2007; 6:1136-1142.
256. Elbayoumi TA, **Torchilin VP**, Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines, *Eur J Pharm Sci* 32; 159-168:2007.
257. Gupta B, **Torchilin VP**, TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice, *Oncol Res* 2007; 16:351-359.
258. **Torchilin VP**, TATp-mediated intracellular delivery of pharmaceutical nanocarriers. *Biochem Soc Trans* 2007; 35:816-8120.
259. Verma DD, Hartner WC, Thakkar V, Levchenko TS, **Torchilin VP**, Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. *Pharm Res* 2007; 24:2131-2137.
260. Kale AA, **Torchilin VP**, Enhanced transfection of tumor cells in vivo using "smart" pH-sensitive TAT-modified pegylated liposomes, *J Drug Target* 2007; 15: 538-545.
261. Kale AA, **Torchilin VP**, "Smart" drug carriers: PEGylated TATp-modified pH- sensitive liposomes, *J Liposome Res* 2007; 17:197-203.
262. Matthaus C, Kale A, Chernenko T, **Torchilin V**, Diem M, New ways of imaging uptake and intracellular fate of liposomal drug carrier systems inside individual cells, based on Raman microscopy, *Mol Pharm* 2008; 5:287-293.
263. Erdogan S, Medarova ZO, Roby A, Moore A, **Torchilin VP**, Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes, *J Magn Reson Imaging* 2008; 27:574-580.
264. Elbayoumi T, **Torchilin VP**, Tumor-specific antibody-mediated targeted delivery of Doxil® reduces the manifestation of auricular erythema side effect in mice, *Int J Pharm* 2008; 357:272-279.
265. D'Souza GGM, Wang T, Rockwell K, **Torchilin VP**, Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro, *Pharm Res* 2008; 25:2567-2572.
266. Boddapati SV, D'Souza GGM, Erdogan S, **Torchilin VP**, Weissig V, Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo, *Nano Lett* 2008; 8:2559-2563.
267. Skidan I, Dholakia P, **Torchilin VP**, Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles, *J Drug Target* 2008; 16:486-493.
268. Sawant RR, Sawant RM, **Torchilin VP**, Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity, *Eur J Pharm Biopharm* 2008; 70:51-57.
269. Sawant RR, Sawant RM, Kale AA, **Torchilin VP**, The architecture of ligand attachment to nanocarriers controls their specific interaction with cells, *J Drug Target* 2008; 16:596-600.
270. Sawant RM, Cohen MB, **Torchilin VP**, Rokhlin OW, Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro, *J Drug Target* 2008; 16:601-604.

271. Ko YT, Hartner WC, Kale A, **Torchilin VT**, Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide, *Gene Therapy* 2009; 16:52-59.
272. Pappalardo JS, Quattrocchi V, Langellotti C, Di Giacomo S, Gnazzo V, Olivera V, Calamante G, Zamorano PI, Levchenko TS, **Torchilin VP**, Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes, *J Control Release* 2009; 134:41-46.
273. Elbayoumi TA, **Torchilin VP**, Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice, *Mol Pharm* 2009; 6:246-254.
274. Ko YT, Kale A, Hartner WC, Papahadjopoulos-Sternberg B, **Torchilin VP**, Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery, *J Control Release* 2009; 133:132-138.
275. Jayanna PK, **Torchilin VP**, Petrenko VA, Liposomes targeted by fusion phage proteins, *Nanomedicine* 2009; 5:83-89.
276. Musacchio T, Laquintana V, Latrofa A, Trapani G, **Torchilin VP**, PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: Synergistic anticancer effect, *Mol Pharm* 2009.
277. Papagiannaros A, Levchenko T, Hartner W, Mongayt D, **Torchilin VP**, Quantumdots encapsulated in phospholipid micelles for imaging and quantification of tumors in the near-infrared region, *Nanomedicine* 2009.
278. Salmaso S, Pappalardo JS, Sawant RR, Musacchio T, Rockwell K, Caliceti P, **Torchilin VP**, Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers, *Bioconjug Chem* 2009; 12:2348-2355.
279. Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, **Torchilin VP**, Weissig V, D'Souza GG, Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol, *J Liposome Res* 2010; 20:244-249.
280. Musacchio T, Toniutti M, Kautz R, **Torchilin VP**, ¹H NMR detection of mobile lipids as a marker for apoptosis: the case of anticancer drug-loaded liposomes and polymeric micelles, *Mol Pharm* 2009; 6:1876-1882.
281. LaBeaume P, Wager K, Falcone D, Li J, **Torchilin V**, Castro C, Holewa C, Kallmerten AE, Jones GB, Synthesis, functionalization and photo-Bergman chemistry of enediyne bioconjugates, *Bioorg Med Chem* 2009; 17:6292-6300.
282. Grunwald J, Rejtar T, Sawant R, Wang Z, **Torchilin VP**, TAT peptide and its conjugates: proteolytic stability, *Bioconjug Chem* 2009; 20:1531-1537.
283. Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, **Torchilin V**, In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL, *Drug Deliv* 2009; 16:45-51.
284. Papagiannaros A, Kale A, Levchenko TS, Mongayt D, Hartner WC, **Torchilin VP**, Near infrared planar tumor imaging and quantification using nanosized Alexa 750- labeled phospholipid micelles, *Int J Nanomedicine* 2009; 4:123-131.
285. Sawant RR, **Torchilin VP**, Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo, *Int J Pharm* 2009; 374:114-118.

286. Ko YT, Falcao C, **Torchilin VP**, Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy, *Mol Pharm* 2009; 6:971-977.
287. ElBayoumi TA, **Torchilin VP**, Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody, *Clin Cancer Res* 2009; 15:1973-1980.
288. Veerabadrnan NG, Mongayt D, **Torchilin VP**, Price RR, Lvov YM, Organized shells on clay nanotubes for controlled release of macromolecules, *Macromol Rapid Commun* 2009; 30:99-103.
289. Solazzo SA, Ahmed M, Schor-Bardach R, Yang W, Girnun GD, Rahmanuddin S, Levchenko T, Signoretti S, Spitz DR, **Torchilin VP**, Goldberg SN, Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways, *Radiology* 2010; 255:62-74.
290. Jayanna PK, Bedi D, Gillespie JW, Deinnocentes P, Wang T, **Torchilin VP**, Bird RC, Petrenko VA, Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency, *Nanomedicine* 2010; 6:538-546.
291. Wang T, Yang S, Petrenko VA, **Torchilin V**, Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein, *MolPharm* 2010; 7:1149-1158.
292. Sawant RR, Vaze O, Rockwell K, **Torchilin VP**, Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery, *Eur J Pharm Biopharm* 2010; 75:321-326.
293. Papagiannaros A, Upponi J, Hartner W, Mongayt W, Levchenko T, **Torchilin V**, Quantum dot-loaded immunomicelles for tumor imaging, *BMC Med Imaging* 2010; 10:22.
294. Wang T, Petrenko VA, **Torchilin VP**, Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: Enhanced binding to target cancer cells and increased cytotoxicity, *Mol Pharm* 2010; 7:1007-1014.
295. Miao B, Skidan I, Yang J, Lugovskoy A, Reibarkh M, Long K, Brazell T, Durugkar KA, Maki J, Ramana CV, Schaffhausen B, Wagner G, **Torchilin V**, Yuan J, Degterev A, Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. *Proc Natl Acad Sci U S A*, 2010; 107:20126-31.
296. Musacchio T, Vase O, D'Souza G, **Torchilin VP**, Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles, *Bioconj Chem* 2010; 21:1530-1536.
297. Yang W, Ahmed M, Elian M, Hady ES, Levchenko TS, Sawant RR, Signoretti S, Collins M, **Torchilin VP**, Goldberg SN, Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in rat tumor model? *Radiology* 2010; 257:685-696.
298. Wang T, D'Souza GG, Bedi D, Fagbohun OA, Potturi LP, Papahadjopoulos-Sternberg B, Petrenko VA, **Torchilin VP**, Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein, *Nanomedicine (Lond)* 2010; 5:563-574.
299. Bedi D, Musacchio T, Fagbohun OA, Gillespie JW, Deinnocentes P, Bird RC, Bookbinder L, **Torchilin VP**, Petrenko VA, Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. *Nanomedicine*, 2011; 7:315-323.

300. Tirabassi RS, Ace CI, Levchenko T, **Torchilin VP**, Selin LK, Nie S, Guberski DL, Yang K, A mucosal vaccination approach for herpes simplex virus type 2, *Vaccine* 2011; 29:1090-1098.
301. Lvov YM, Pattekari P, Zhang X, **Torchilin VP**, Converting poorly soluble materials into stable aqueous nanocolloids, *Langmuir* 2011; 27:1212-1217.
302. Sawant RR, Vaze O, D'Souza G, Rockwell K, **Torchilin VP**, Palmitoyl ascorbate- loaded polymeric micelles: cancer cell targeting and cytotoxicity, *Pharm Res* 2011; 28:301-308.
303. Pattekari P, Zheng Z, Zhang X, Levchenko T, **Torchilin V**, Lvov Y, Top-down and bottom-up approaches in production of aqueous nanocolloids of low solubility drug paclitaxel, *Phys Chem Chem Phys* 2011; 13:9014-9019.
304. Koren E, Apte A, Sawant RR, Grunwald J, **Torchilin VP**, Cell-penetrating TAT peptide in drug delivery systems: Proteolytic stability requirements, *Drug Deliv*, 2011; 18:377-384.
305. Biswas S, Dodwadkar NS, Sawant RR, Koshkaryev A, **Torchilin VP**, Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting, *J Drug Target*, 2011; 19:552-561.
306. Serda RE, Blanco E, Mack A, Stafford SJ, Amra S, Li Q, van de Ven A, Tanaka T, **Torchilin VP**, Wiktorowicz JE, Ferrari M, Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles, *Mol Imaging*, 2011; 10:43-55.
307. Koshkaryev A, Thekkedath R, Pagano C, Meerovich I, **Torchilin VP**, Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B, *J Drug Target*, 2011; 19:606-614.
308. Wang T, Kulkarni N, Bedi D, D'Souza GG, Papahadjopoulos-Sternberg B, Petrenko VA, **Torchilin VP**, In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein, *J Drug Target*, 2011; 19:597-605.
309. Wang T, Kulkarni N, D'Souza GG, Petrenko VA, **Torchilin VP**, On the mechanism of targeting of phage-fusion protein-modified nanocarriers: only the binding peptide matters, *Mol Pharm*, 2011; 8:1720-1728.
310. Siavoshi S, Yilmaz C, Somu S, Musacchio T, Upponi JR, **Torchilin VP**, Busnaina A, Size-effective template-assisted electrophoretic assembly of nanoparticulates for biosensing applications, *Langmuir*, 2011; 27:7301-7306.
311. Skidan I, Grunwald J, Thekkedath R, Degterev A, **Torchilin VP**, A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamine in biological samples, *J Chromatogr B Analyt Technol Biomed Life Sci*, 2011; 879:1610-1616.
312. Patel N, Rathi A, Mongayt D, **Torchilin VP**, Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes, *Int J Pharm*, 2011; 416:296-299.
313. Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant R, Collins M, Signoretti S, **Torchilin V**, Goldberg SN, Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model, *Int J Hyperthermia*, 2011; 27:527-538.
314. Sawant RR, Vaze OS, Wang T, D'Souza GG, Rockwell K, Gada K, Khaw BA, **Torchilin**, Palmitoyl ascorbate liposomes and free ascorbic acid: Comparison of anticancer therapeutic effects upon parenteral administration, *Pharm Res*, 2011; 29:375-383.
315. Meerovich I, Koshkaryev A, Thekkedath R, **Torchilin V**, Screening and optimization of ligand conjugates for lysosomal targeting, *Bioconj Chem*, 2011; 22:2271-2282.

316. Biswas S, Dodwadkar NS, Sawant RR, **Torchilin VP**, Development of novel PEG- PE-based polymer for the reversible attachment of specific ligands to liposomes: Synthesis and in vitro characterization, *Bioconj Chem*, 2011; 22:2005-2013.
317. Koren E, Apte A, Jani A, **Torchilin VP**, Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity, *J Control Release*, 2011. 10;160(2):264-73.
318. Miao B, Skidan I, Yang J, Zou Z, Fu X, Famulok M, **Torchilin V**, Yuan J, Degtrev A, Inhibition of cell migration by PITENINs: the role of ARF6, *Oncogene*, 2011. Sep 27;31(39):4317-32.
319. Buyens K, De Smedt SC, Braeckmans K, Demeester J, Peeters L, van Grunssynen LA, de Mollerat du Jeu X, Sawant R, **Torchilin V**, Farkasova K, Ogris M, Sanders NN, Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design, *J Control Release*, 2011; 158:362-370.
320. Movassaghian S, Moghimi HR, Shirazi FH, **Torchilin VP**, Dendrosome – dendriplex inside liposomes – as a gene delivery system, *J Drug Target*, 2011; 19:925-32.
321. Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, **Torchilin VP**, Goldberg SN, Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: Reduced tumor growth and increased animal endpoint survival in a small animal tumor model, *J Control Release*, 2012. 12 Jun 10;160(2):239-44.
322. Musacchio T, Navarro G, **Torchilin VP**, Molecular assemblies for siRNA delivery, *J Drug Del Sci Tech*, 2012; 22:5-16.
323. Biswas S, Dodwadkar NS, Deshpande PP, **Torchilin VP**, Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo, *J Control Release*, 2012; 159:393-402.
324. Etzerodt A, Maniecki MB, Graversen JH, Moller HJ, **Torchilin VP**, Moestrup SK, Efficient intracellular drug targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163, *J Control Release*, 2012; 160:72-80.
325. Chernenko T, Sawant RR, Miljkovic M, Quintero L, Diem M, **Torchilin VP**, Raman microscopy for non-invasive imaging of pharmaceutical nanocarriers: Intracellular distribution of cationic liposomes of different composition, *Mol Pharm*, 2012; 9:930-936.
326. Sawant RR, Sriraman SK, Navarro G, Biswas S, Dalvi RA, **Torchilin VP**, Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery *Biomaterials*, 2012; 33(15):3942-3951.
327. Koshkaryev A, Piroyan A, **Torchilin VP**, Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes, *Cancer Biol Ther*, 2012; 13:50-60.
328. Sawant RR, Vaze OS, Wang T, D'Souza GG, Rockwell K, Gada K, Khaw BA, **Torchilin VP**, Palmitoyl ascorbate liposomes and free ascorbic acid: Comparison of anticancer therapeutic effects upon parenteral administration, *Pharm Res*, 2012; 29:375-383.
329. Zhu L, Kate P, **Torchilin VP**, Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting, *ACS Nano*, 2012; 6:3491-3498.
330. Dao KL, Sawant R, Hendricks JA, Ronga V, **Torchilin VP**, Hanson RN, Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin hybrid for targeting estrogen receptor-positive breast cancer cells, *Bioconj Chem*, 2012; 23:785-795.

331. Biswas S, Dodwadkar NS, Piroyan A, **Torchilin VP**, Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria, *Biomaterials*, 2012; 33:4773-4782.
332. Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C, **Torchilin VP**, P-Glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells, *Nanomedicine (Lond)*, 2012; 7:65-78.
333. Xing C, Levchenko T, Guo S, Stins M, **Torchilin VP**, Lo EH. Delivering minocycline into brain endothelial cells with liposome-based technology. *J Cereb Blood Flow Metab*, 2012 Jun;32(6):983-8.
334. Sarisozen C, Vural I, Levchenko T, Hincal AA, **Torchilin VP**. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. *Drug Deliv*, 2012; 19(4):169-76.
335. Zamboni WC, **Torchilin V**, Patri AK, Hrkach J, Stern S, Lee R, Nel A, Panaro NJ, Grodzinski P. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. *Clin Cancer Res*, 2012; 18(12):3229-41.
336. Perche F, **Torchilin VP**. Cancer cell spheroids as a model to evaluate chemotherapy protocols. *Cancer Biol Ther*, 2012 Oct 1;13(12):1205-13.
337. Perche F, Patel NR, **Torchilin VP**. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. *J Control Release*, 2012; 164(1):95-102.
338. Malima A, Siavoshi S, Musacchio T, Upponi J, Yilmaz C, Somu S, Hartner W, **Torchilin V**, Busnaina A. Highly sensitive microscale in vivo sensor enabled by electrophoretic assembly of nanoparticles for multiple biomarker detection. *Lab Chip*, 2012; 12(22):4748-54.
339. Sarisozen C, Vural I, Levchenko T, Hincal AA, **Torchilin VP**. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. *Drug Deliv*, 2012; 19(8):363-70.
340. Lau Convener YS, Blouin R, Brixner D, Crismon L, Cutler S, Ho R, Jusko W, Nahata M, Sorkness C, **Torchilin VP**, Wu-Pong S. Report of the 2011-2012 AACP Special Advisory Committee on Research and Graduate Education. *Am J Pharm Educ*, 2012; 76(8):S14.
341. Shutava TG, Pattekari PP, Arapov KA, **Torchilin VP**, Lvov YM. Architectural layer-by-layer assembly of drug nanocapsules with PEGylated polyelectrolytes. *Soft Matter*, 2012; 8(36):9418-9427.
342. Koshkaryev A, Piroyan A, **Torchilin VP**. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. *Cancer Lett*, 2013; 334:293-301.
343. Nedosekin DA, Sarimollaoglu M, Galanzha EI, Sawant R, **Torchilin VP**, Verkhusha VV, Ma J, Frank MH, Biris AS, Zharov VP. Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts. *J Biophotonics*, 2013; 6:425-434.
344. Silindir M, Erdoğan S, Ozer AY, Doğan AL, Tuncel M, Uğur O, **Torchilin VP**. Nanosized multifunctional liposomes for tumor diagnosis and molecular imaging by SPECT/CT. *J Liposome Res*, 2013; 23:20-27.
345. Wu H, Zhu L, **Torchilin VP**. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. *Biomaterials*, 2013; 34:1213-1222.
346. Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, **Torchilin VP**. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. *Biomaterials*, 2013; 34:1289-1301.

347. Biswas S, Dodwadkar NS, Deshpande PP, Parab S, **Torchilin VP**. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity, *Eur J Pharm Biopharm*, 2013; 84:517-525.
348. Biswas S, Deshpande PP, Perche F, Dodwadkar NS, Sane SD, **Torchilin VP**. Octa-arginine-modified PEGylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer, *Cancer Lett*, 2013; 335:191-200.
349. Movassaghian S, Moghimi HR, Shirazi FH, Koshkaryev A, Trivedi MS, **Torchilin VP**. Efficient down-regulation of PKC- α gene expression in A549 lung cancer cells mediated by antisense oligodeoxynucleotides in dendrosomes, *Int J Pharm*, 2013; 441:82-91.
350. Sawant RR, Jhaveri AM, Koshkaryev A, Qureshi F, **Torchilin VP**. The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy, *J Drug Target*, 2013.
351. Koshkaryev A, Piroyan A, **Torchilin VP**. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition, *Cancer Lett*, 2013; 334:293-301.
352. Moussa M, Goldberg SN, Tasawwar B, Sawant RR, Levchenko T, Kumar G, **Torchilin VP**, Ahmed M. Adjuvant liposomal doxorubicin markedly affects radiofrequency ablation-induced effects on periablational microvasculature, *J Vasc Interv Radiol*, 2013; 24:1021-1033.
353. Riehle RD, Cornea S, Degtarev A, **Torchilin VP**. Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRIAL in vitro and in vivo, *Drug Deliv*, 2013; 20:78-85.
354. Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, **Torchilin VP**. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer, *Cancer Lett*, 2013.
355. Abouzeid AH, Patel NR, Rachman IM, Senn S, **Torchilin VP**. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin, *J Drug Target*, 2013.
356. Zhu L, Wang T, Perche F, Taigind A, **Torchilin VP**. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety, *Proc Natl Acad Sci USA*, 2013; 100:17047-17052.
357. Navarro G, Essex S, Sawant RR, Biswas S, Nagesha D, Sridar S, de Ilardua CI, **Torchilin VP**. Phospholipid-modified polyethyleneimine-based nanopreparations for siRNA-mediated gene silencing: implications for transfection and the role of lipid component, *Nanomedicine*, 2014;10:411-419.
358. Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, **Torchilin VP**. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein, *Nanomedicine*, 2014;10:421-430.
359. Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, **Torchilin VP**. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: A promising strategy to overcome drug resistance in cancer, *Cancer Lett*, 2014;343:224-231.
360. A.Apte, E.Koren, A.Koshkaryev, **V.P.Torchilin**, Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models, *Cancer Biol Ther*, 2014; 15:69-80.
361. A.H.Abouzeid, N.R.Patel, **V.P.Torchilin**, Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/Vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer, *Int J Pharm*, 2014; 464(1-2):178-184.

362. G.Parekh, P.Pattekari, C.Joshi, T.Shutava, M/Decoster, T.Levchenko, **V.Torchilin**, Y.Lvov, Layer-by-layer nanoencapsulation of camptothecin with improved activity, *Int J Pharm*, 465, 218-227, 2014.
363. L.Zhu, F.Perche, T.Wang, **V.P.Torchilin**, Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs, *Biomaterials*, 2014; 35:4213-4222.
364. A.H.Abouzeid, N.R.Patel, C.Sarisozen, **V.P.Torchilin**, Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: Efficient killing of paclitaxel-resistant cancer cells, *Pharm Res*, 2014.
365. S.V.Mussi, R.Sawant, F.Perche, M.C.Oliveira, R.B.Azevedo, L.A.Ferreira, **V.P.Torchilin**, Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexanoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells, *Pharm Res*, 2014.
366. F.Perche, S.Biswas, T.Wang, L.Zhu, **V.P.Torchilin**, Hypoxia-targeted siRNA delivery, *Angew Chemie*, 2014; 53:3363-3366.
367. J.S.Pappalardo, C.A.Langellotti, S.Di Giacomo, V.Olivera, V.Quattrocchi, P.I.Zamorano, W.C.Hartner, T.S.Levchenko, **V.P.Torchilin**, In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes, *Int J Nanomed*, 2014; 9:963-973.
368. Sawant RR, Jhaveri AM, Koshkaryev A, Zhu L, Qureshi F, **Torchilin VP**. Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma. *Mol Pharm*. 2014; 11(2):375-81.
369. D'Arrigo G, Navarro G, Di Meo C, Matricardi P, **Torchilin V**. Gellan gum nanohydrogel containing anti-inflammatory and anti-cancer drugs: a multi-drug delivery system for a combination therapy in cancer treatment. *Eur J Pharm Biopharm*, 2014;87(1):208-16.
370. Lukianova-Hleb EY, Ren X, Sawant RR, Wu X, **Torchilin VP**, Lapotko DO, On demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles, *Nat Med*, 2014; 20:78-84.
371. Sydow K, **Torchilin VP**, Dathe M, Lipopeptide-modified PEG-PE-based pharmaceutical nanocarriers for enhanced uptake in blood-brain barrier cells and improved cytotoxicity against glioma cells, *Eur J Lipid Sci Technol*, 2014.
372. Memanashvili T, Zavrashvili N, Kupatadze N, Gverdsiteli M, **Torchilin VP**, Wandrey C, Baldi L, Manoli SS, Katsarava R, Agrinine-based biodegradable ether-ester polymers with low cytotoxicity as potential gene carriers, *Biomacromolecules*, 2014; 15:2839-2848.
373. Kommagalla Y, Cornea S, Riehle R, **Torchilin VP**, Degterev A, Ramana CV, Optimization of the anti-cancer activity of phosphoinositol-3 kinase pathway inhibitor PITENIN-1: switching a thiourea with 1,2,3-triazol, *Med Chem Commun*, 2014; 5:1359-1363.
374. Sarisozen C, Abouzeid AH, **Torchilin VP**, The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors, *Eur J Pharm Biopharm*, 2014; 88:539-550.
375. Moussa M, Goldberg SN, Kumar G, Sawant RR, Levchenko T, **Torchilin VP**, Ahmed M, Nanodrug-enhanced radiofrequency tumor ablation: Effect of micellar or liposomal carrier on drug delivery and treatment efficacy, *PLOS One*, 2014; 9(8):1-11.
376. Moussa M, Goldberg SN, Kumar G, Sawant RR, Levchenko T, **Torchilin VP**, Ahmed M, Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1 α can be suppressed with adjuvant bortezomib or liposomal chemotherapy, *J Vasc Interv Radiol*, 2014; 25:1972-1982.

377. Wang T, Yang S, Mei LA, Parmar CK, Gillespie JW, Praveen KP, Petrenko VA, Torchilin VP, Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and effectively reduce tumors, *Mol Cancer Ther*, 2014; 13:2864-2875.
378. Essex S, Navarro G, Sabhachandani P, Chordia A, Trivedi M, Movassaghian S, **Torchilin VP**, Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors, *Gene Ther*, 2015; 22:257-266.
379. Salzano G, Navarro G, Trivedi MS, De Rosa G, **Torchilin VP**, Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer, *Mol Cancer Ther*, 2015; 14:1075-1084.
380. Ahmed M, Kumar G, Navarro G, Wang Y, Gourevitch S, Moussa MH, Rozenblum N, Levchenko T, Galun E, Torchilin VP, Goldberg SN, Systemic siRNA nanoparticle-based drugs combined with radiofrequency ablation for cancer therapy, *PLoS One*, 2015
381. Mussi SV, Parekh G, Pattekari P, Levchenko T, Lvov Y, Ferreira LA, **Torchilin VP**, Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating, *Int J Pharm*, 2015; 496:186-193.
382. Sriraman SK, Geraldo V, Luther E, Degtrev A, **Torchilin VP**, Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. *J Control Release*, 2015; 220(A):160-168.
383. Lukianova-Hleb EY, Kim YS, Aryasomayajula B, Boulikas T, Phan J, Hung MC, **Torchilin VP**, O'Neill BE, Lapotko DO, Safety and efficacy of quadruplets versus chemoradiation in head and neck carcinoma xenograft model, *Am J Cancer Res*, 2015;5:3534-3547.
384. Sabhachandani P, Motwani V, Cohen N, Sarkar S, **Torchilin V**, Konry T, Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform. *Lab Chip*, 2016;16:497-505.
385. Kitatani K, Usui T, Sriraman SK, Toyoshima M, Ishibashi M, Shigeta S, Nagase S, Sakamoto M, Ogiso H, Okazaki T, Hannun YA, **Torchilin VP**, Yaegashi N, Ceramide limits phosphatidylinositol-3-kinase C2 β -controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid, *Oncogene*, 2016;35:2801-2812.
386. Riehle R, Pattni B, Jhaveri A, Kulkarni A, Thakur G, Degtrev A, **Torchilin V**, Combination nanopreparations of a novel proapoptotic drug - NCL-240, TRAIL and siRNA, *Pharm Res*, 2016;33:1587-1601.
387. Klauber TC, Søndergaard RV, Sawant RR, **Torchilin VP**, Andresen TL, Elucidating the role of free polycations in gene knockdown by siRNA polyplexes, *Acta Biomater*, 2016;35:248-259.
388. Sriraman SK, Pan J, Sarisozen C, Luther E, **Torchilin V**, Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR and H69-AR Cells. *Mol Pharm*, 2016;13:428-437.
389. Wang T, Narayanaswamy B, Ren H, **Torchilin VP**, Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment. *Cancer Biol Ther*, 2016;17:698-707.
390. Sriraman SK, Salzano G, Sarisozen C, **Torchilin V**, Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid. *Eur J Pharm Biopharm*, 2016;105:40-49.

391. Salzano G, Costa DF, Sarisozen C, Luther E, Mattheolabakis G, Dhargalkar PP, **Torchilin VP**. Mixed nanosized polymeric micelles as promoter of doxorubicin and miRNA-34a co-delivery triggered by dual stimuli in tumor tissue. *Small*, 2016;12:4837-4848.
392. Pattni BS, Nagelli SG, Aryasomayajula B, Deshpande PP, Kulkarni A, Hartner WC, Thakur G, Degterev A, **Torchilin VP**, Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-res cells in a 3d spheroid model. *Pharm Res*, 2016;33:2540-2551.
393. Moussa M, Goldberg SN, Kumar G, Levchenko T, **Torchilin V**, Ahmed M. Effect of thermal dose on heat shock protein expression after radiofrequency ablation with and without adjuvant nanoparticle chemotherapy. *Int J Hyperthermia*, 2016;32:829-841.
394. Sarisozen C, Dhokai S, Tsikudo EG, Luther E, Rachman IM, **Torchilin VP**, Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: in vitro evaluation on 2D and 3D tumor models. *Eur J Pharm Biopharm*, 2016; 16:30464-30467.
395. Oliveira MS, Aryasomayajula B, Pattni B, Mussi SV, Ferreira LA, **Torchilin VP**, Solid lipid nanoparticles co-loaded with doxorubicin and tocopherol succinate are affective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell model. *Int J Pharm*, 2016;512:292-300.
396. Sanchez-Pura M, Ramos V, Petrenko VA, **Torchilin VP**, Borros S, Double-targeted polyerosomes and liposomes for multiple barrier crossing. *Int J Pharm*; 2016;511:946-956.
397. Zhang Y, Sriraman SK, Kenny HA, Luther E, **Torchilin V**, Lengyel E, Reversal of chemoresistance in ovarian cancer by co-delivery of a P-glycoprotein inhibitor and paclitaxel in a liposomal platform. *Mol Cancer Ther*, 2016;15:2282-2293.
398. C.Yilmaz, C.Sarisozen, V.Torchilin, A.Busnaina, Novel nanoprinting for oral delivery of poorly soluble drugs, *Methodist Debaque Cardiovasc J.*, 2016;12:157-162.
399. Erdogan S, **Torchilin VP**, Gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. *Methods Mol Biol*, 2017; 1522:179-182.
400. Zou W, Sarisozen C, **Torchilin VP**, The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles. *J Drug Target*, 2017;25:225-234.
401. Muddineti OS, Kumari P, Ghosh B, **Torchilin VP**, Biswas S, d- α -Tocopheryl succinate/phosphatidyl ethanolamine conjugated amphiphilic polymer-based nanomicellar system for the efficient delivery of curcumin and to overcome multiple drug resistance in cancer. *ACS Appl Mater Interfaces*, 2017;9:16778-16792.
402. Vladimirov YA, Sarisozen C, Vladimirov GK, Filipczak N, Polimova AM, **Torchilin VP**, The cytotoxic action of cytochrome C/cardiophilin nanocomplex (CytC-CL) on cancer cells in culture, *Pharm Res*, 2017;34:1264-1275.
403. Luther E, Mendes LP, Pan J, Costa DF, **Torchilin VP**, Applications of label-free, quantitative phase holographic imaging cytometry to the development of multi-specific nanoscale pharmaceutical formulations, *Cytometry*, 2017;91:412-243.
404. Kohay H, Sarisozen C, Sawant R, Jhaveri A, **Torchilin VP**, Y.G.Mishael, PEG-PE/Clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity, *Acta Biomater*, 2017;55:443-454.
405. Pattni BS, Jhaveri A, Dutta I, Baleja JD, Degterev A, **Torchilin VP**, Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. *Int J Pharm*, 2017;532:149-156.

406. Palmerston Mendes L, Pan J, **Torchilin VP**, Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. *Molecules*, 2017;22.
407. Wang T, Narayanaswamy R, Ren H, Gillespie JW, Petrenko VA, **Torchilin VP**, Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer. *J Drug Target*, 2018;26:505-515.
408. Kumar G, Goldberg SN, Gourevitch S, Levchenko T, **Torchilin V**, Galun E, Ahmed M, Targeting STAT3 to suppress systemic pro-oncogenic effects from hepatic radiofrequency ablation, *Radiology*, 2018;286:524-536.
409. Sherif MS, Rehab TA, Hamida ZA, **Torchilin VP**, Cytotoxicity of propolis nanopreparations in cancer cell monolayers: Multimode of action including apoptosis and nitric oxide production, *Gen Physiol Biophys*, 2018;37:101-119.
410. Deshpande P, Javeri A, Pattni B, Biswas S, **Torchilin VP**, Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer, *Drug Deliv*, 2018;25:517-532.
411. Jhaveri A, Deshpande P, Pattni B, **Torchilin V**, Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. *J Control Release*, 2018;277:89-101.
412. Joanitti GA, Sawant RS, **Torchilin VP**, Freitas SM, Azevedo RB, Optimizing liposomes for delivery of Bowman-Birk protease inhibitors. Platform for multiple biomedical applications. *Colloids Surf B Biointerfaces*, 2018;167:474-482.
413. Upponi JR, Jerajani K, Nagesha DK, Kulkarni P, Sridhar S, Ferris C, **Torchilin VP**, Polymeric micelles: Theranostic co-delivery system for poorly-soluble drugs and contrast agents. *Biomaterials*, 2018;170:26-36.
414. Ahmed M, Kumar G, Gourevitch S, Levchenko T, Galun E, **Torchilin V**, Goldberg SN, Radiofrequency ablation (RFA) induced systemic tumor growth can be reduced by suppression of resultant heat-shock proteins. *Int J Hyperthermia*, 2018;9:1-25.
415. Mutlu Agardan NB, Sarisozen C, **Torchilin VP**, Redox-triggered intracellular siRNA delivery. *Chem Commun (Camb)*, 2018;54:6368-6371.
416. Zavrashvili N, Sarisozen C, Titvinidze G, Otinashvili G, Kantaria T, Tugushi, D, Puiggali J, **Torchilin VP**, Katsarava R, Library of cationic polymers composed of polyamines and arginine as gene transfection agents, *ACS Omega*, 2019;4:2090-2101.
417. Pan J, Mendes LP, Yao M, Filipczak N, Garai S, Thakur GA, Sarisozen C, **Torchilin VP**, Polyamidoamine dendrimer-based Nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance, *Eur J Pharm Biopharm*, 2019;136:18-28.
418. Sarisozen C, Tan Y, Liu J, Bilir C, Shen L, Filipczak N, Porter TM, **Torchilin VP**, MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation, *J Drug Target*, 2019;27:624-633.
419. Mendes LP, Sarisozen C, Luther E, Pan J, **Torchilin VP**. Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers, *Drug Deliv*, 2019;26:443-458.
420. Costa DF, Sarisozen C, **Torchilin VP**, Synthesis of doxorubicin and miRNA stimuli-sensitive conjugates for combination therapy. *Methods Mol Biol*, 2019;1974:99-109.

421. Jhaveri A, Luther E, **Torchilin V**, The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: implications for targeting tumour-initiating cells. *J Drug Target*, 2019;27:601-613.
422. Bhatt H, Kiran Rompicharla SV, Ghosh B, **Torchilin V**, Biswas S. Transferrin/ α -tocopherol modified poly(amidoamine) dendrimers for improved tumor targeting and anticancer activity of paclitaxel. *Nanomedicine (Lond)*. 2019;14(24):3159-3176
423. Filipczak N, Jaromin A, Piwoni A, Mahmud M, Sarisozen C, **Torchilin V**, Gubernator J. A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells. *Cancers (Basel)*. 2019 Dec 9;11(12)
424. Mensah SA, Harding IC, Zhang M, Jaeggli MP, **Torchilin VP**, Niedre MJ, Ebong EE. Metastatic cancer cell attachment to endothelium is promoted by endothelial glycocalyx sialic acid degradation. *AICHE J*. 2019; 65(8).
425. Khan MM, Madni A, **Torchilin V**, Filipczak N, Pan J, Tahir N, Shah H. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin. *Drug Deliv*. 2019; 26(1):765-772.
426. Hussein WM, Cheong YS, Liu C, Liu G, Begum AA, Attallah MA, Moyle PM, **Torchilin VP**, Smith R, Toth I. Peptide-based targeted polymeric nanoparticles for siRNA delivery. *Nanotechnology*. 2019; 30(41):415604.
427. Campos PM, Praça FG, Mussi SV, Figueiredo SA, Fantini MCA, Fonseca MJV, **Torchilin VP**, Bentley MVLB, Liquid crystalline nanodispersion functionalized with cell-penetrating peptides improves skin penetration and anti-inflammatory effect of lipoic acid after in vivo skin exposure to UVB radiation. *Drug Deliv. Transl. Res*. 2020; 10:1810-1828.
428. Zhang X, Pan J, Yao M, Palmerston Mendes L, Sarisozen C, Mao S, **Torchilin VP**, Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery. *Eur. J. Pharm. Biopharm*. 154, 43-49, 2020.
429. Kornuta CA, Bidart JE, Soria I, Gammella M, Quattrocchi V, Pappalardo JS, Salmaso S, **Torchilin VP**, Cheuquepán Valenzuela F, Hecker YP, Moore DP, Zamorano PI, Langellotti CA, MAN α 1-2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV-1. *Transbound Emerg. Dis*. 10, 1810-1828, 2020..
430. Khan MM, Madni A, Filipczak N, Pan J, Rehman M, Rai N, Attia SA, **Torchilin VP**, Folate targeted lipid chitosan hybrid nanoparticles for enhanced anti-tumor efficacy. *Nanomedicine*. 2020; 28:102228.
431. Pan J, Attia SA, Subhan MA, Filipczak N, Mendes LP, Li X, Kishan Yalamarty SS, **Torchilin VP**, Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA. *Mol. Pharm*. 2020; 17:1638-1647.
432. Mensah SA, Nersesyan AA, Harding IC, Lee CI, Tan X, Banerjee S, Niedre M, **Torchilin VP**, Ebong EE, Flow-regulated endothelial glycocalyx determines metastatic cancer cell activity. *FASEB J*. 2020; 34:6166-6184.
433. Mutlu-Agardan NB, Sarisozen C, **Torchilin VP**, Cytotoxicity of Novel Redox Sensitive PEG₂₀₀₀-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells. *Pharm. Res*. 2020; 37:65.

434. Joshi U, Filipczak N, Khan MM, Attia SA, **Torchilin V**, Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. *Int J Pharm.* 2020; 590:119915.
435. Mendes LP, Rostamizadeh K, Gollomp K, Myerson JW, Marcos-Contreras OA, Zamora M, Luther E, Brenner JS, Filipczak N, Li X, **Torchilin VP**, Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps. *MAbs.* 2020; 12(1):1850394
436. Narayanaswamy R, **Torchilin VP**, Targeted delivery of combination therapeutics using monoclonal antibody 2C5-modified immunoliposomes for cancer therapy. *Pharm Res.* 2021; 38:429-450
437. Pappalardo JS, Salmaso S, Levchenko TS, Mastrotto F, Bersani S, Langellotti CA, Vermeulen M, Ghersa F, Quattrocchi V, Zamorano PI, Hartner WC, Toniutti M, Musacchio T, **Torchilin VP**, Characterization of a Nanovaccine Platform Based on an α 1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells, *Mol Pharm.* 2021; 18:2540-2555.
438. Attia SA, Li X, Filipczak N, Costa DF, **Torchilin VP**, Modification of Nanoparticles with Transferrin for Targeting Brain Tissues. *Methods Mol Biol.* 2021; 2355:49-56.
439. Filipczak N, Joshi U, Attia SA, Berger Fridman I, Cohen S, Konry T, **Torchilin V**, Hypoxia-sensitive drug delivery to tumors. *J Control Release.* 2022;341:431-442.
440. Parveen F, Madni A, **Torchilin VP**, Rehman M, Jamshaid T, Filipczak N, Rai N, Khan MM, Khan MI, Investigation of Eutectic Mixtures of Fatty Acids as a Novel Construct for Temperature-Responsive Drug Delivery. *Int J Nanomedicine.* 2022 May;17:2413-2434.
441. Li X, Zhou X, Liu J, Zhang J, Feng Y, Wang F, He Y, Wan A, Filipczak N, Yalamarty SSK, Jin Y, **Torchilin VP**, Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect. *ACS Appl Mater Interfaces.* 2022;14(25):28439-28454.
442. Yalamarty SSK, Filipczak N, Li X, Pathrikar TV, Cotter C, **Torchilin VP**, Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers. *Pharmaceutics.* 2022;14(7):1470.
443. Davatgaran Taghipour Y, Salehi R, Zarebkohan A, Zakeri Z, Khordadmehr M, Saeedi Honar Y, **Torchilin VP**. Dual targeting salinomycin-loaded smart nanomicelles for enhanced accumulation and therapeutic outcome in breast cancer. *Int J Pharm.* 2023;642:123095.
444. Filipczak N, Li X, Saawant GR, Yalamarty SSK, Luther E, **Torchilin VP**. Antibody-modified DNase I micelles specifically recognize the neutrophil extracellular traps (NETs) and promote their degradation. *J Control Release.* 2023;354:109-119.

Reviews, Chapters and Editorials:

1. **Torchilin VP**, Smirnov VN, Chazov EI. Immobilization and stabilization of enzymes for use in therapy. In: Bungay HR, ed. *Advances in Enzyme Engineering*. National Science Foundation, 1978:130-151.
2. **Torchilin VP**, Martinek K. Enzyme stabilization without carriers. *Enz Microb Technol* 1979; 1:74-82.
3. **Torchilin VP**, Mazaev AV, Il'ina EV, Goldmacher VS, Smirnov VN, Chazov EI. Chemical aspects of enzyme modification and stabilization for the use in therapy. In: Wingard LB, Berezin IV, Klyosov AA, eds. *Future Directions for Enzyme Engineering*. New York: Plenum Press, 1980:219-240.
4. **Torchilin VP**, Berdichevsky VR, Klibanov AL, Smirnov VN, Chazov EI. Principles of immobilization and directed transport of drugs in the organism. In: Weetall HH, Bungay HR, eds. *Microbial Enzymes*. National Science Foundation, 1980:317-334.
5. **Torchilin VP**, Berdichevsky VR, Khaw BA, Zemskov VM, Haber E, Smirnov VN, Chazov EI. Possibility of using liposomes for targeting of drugs in the treatment of cardiovascular diseases. In: *Energy Transport, Protein Synthesis and Hormonal Control of Heart Metabolism*. NIH Publication, 1980: 80:2017.
6. Chazov EI, Smirnov VN, **Torchilin VP**, Tereshin IM, Moskvichev BV. Immobilized enzymes for medical application. In: Weetall HH, Royer GP, eds. *Enzyme Engineering*. New York: Plenum Publishing Corporation, 1980:209-211.
7. Larionova NI, **Torchilin VP**. Recent advances and prospects of medical application of immobilized proteins as physiologically active agents. *Khimico-Pharmatsevtichesky J* (Russ.) (Chemical Pharmaceutical J) 1980; 4:21-36.
8. **Torchilin VP**, Klibanov AL, Smirnov VN. Problems and perspectives of liposome application for drug targeting. In: *Liposomes and their Interaction with Tissues and Cells*. Moscow: Nauka Publishers, 1981:10-17.
9. **Torchilin VP**, Klibanov AL. Immobilization of proteins on liposome surface. *Enz Microb Technol*. 1981; 3:297-304.
10. Smirnov VN, Berdichevsky VR, Alexeev AV, Sviridov DD, **Torchilin VP**. Targeted liposome transport to the reconstituted vessel wall. In: Chazov EI and Smirnov VN, eds. *Vessel Walls in Thrombosis and Atherosclerosis*. Berlin-Heidelberg-New York: Springer Verlag, 1982:195-201.
11. **Torchilin VP**, Klibanov AL, Berdichevsky VR, Omel'yanenko VG, Smirnov VN. The use of immobilization principles for the construction of drug targeting systems. In: Chibata I, Fukui S, Wingard LB, eds. *Enzyme Engineering*, vol. 6. New York: Plenum Publishing Corporation, 1982:461-463.
12. **Torchilin VP**, Smirnov VN, Chazov EI. Problems and perspectives of liposome application in drug targeting. *Voprosy Meditsynskoy Khimii* (Russ.) (Problems of Medical Chemistry) 1982; 1:3-14.
13. **Torchilin VP**. Immobilized enzymes and the use of immobilization principles for drug targeting. In: Goldberg EP, ed. *Targeted Drugs*. New York: John Wiley & Sons, 1983:127-152.
14. **Torchilin VP**, Smirnov VN. Liposomes for drug targeting. *Ukrainsky Biokhimichesky J* (Russ.) (Ukrainian Biochemical J) 1984; 56:339-345.
15. **Torchilin VP**. Immobilization of specific proteins on liposome surface: systems for drug targeting. In: Gregoriadis G, ed. *Liposome Technology*, Vol. 3. CRC Press, 1984:Chapter 6.
16. **Torchilin VP**. Liposomes as targetable drug carriers. *CRC Critical Reviews in Therapeutic Drug Carrier Systems*, 1985; 1:65-115.

17. Chazov EI, Smirnov VN, Mazaev AV, **Torchilin VP**. Macromolecular drug preparations in cardiology. *D.I. Mendeleev USSR Chemical Society J* (Russ.). 1985; 30:365-372.
18. Smirnov VN, Voronkov YN, **Torchilin VP**, Mazaev AV. Development of biocompatible preparations of immobilized enzymes and clinical results with immobilized streptokinase (Streptodekaze). In: Chazov EI, Smirnov VN, eds. *Thrombosis and Thrombolysis*. New York: Plenum Publishing Corporation, 1986:113-162.
19. **Torchilin VP**, Maksimenko AV, Mazaev AV. Immobilized enzymes for thrombolytic therapy. In: Mosbach K, ed. *Methods in Enzymology*, Vol. 137, *Immobilized Enzymes and Cells*, Part D. New York: Academic Press, Inc., 1988:552-566.
20. Maksimenko AV, Arkhipova OG, Yaglov VV, **Torchilin VP**. Aldehyde dextran modified enzymes for medical application. In: Blazej A, Zemek J, eds. *Progress in Biotechnology*, Vol. 4, Interbiotech '87, Enzyme Technologies. Amsterdam: Elsevier Science Publishers, 1988:509-522.
21. **Torchilin VP**, Ivanov NN, Klivanov AL, Papisov MI, Chebanov SM. On the mechanism of electron-dense liposome internalization by macrophages *in vitro*. In: Gregoriadis G, ed. *Liposomes as Drug Carriers: Recent Trends and Progress*. London: John Wiley & Sons, 1988:63-74.
22. **Torchilin VP**, Burkhanov SA, Mazhul LA, Ageeva ON. Liposomal vaccine against influenza virus. In: Gregoriadis G, ed. *Liposomes as Drug Carriers: Recent Trends and Progress*. London: John Wiley & Sons, 1988:229-234.
23. Margolis LB, Bodgdanov AA, Jr, Gordeeva LV, **Torchilin VP**. Interaction of Con A-liposomes with cells: binding to normal and transformed mouse fibroblasts. In: Gregoriadis G, ed. *Liposomes as Drug Carriers: Recent Trends and Progress*. London: John Wiley & Sons, 1988:727-736.
24. Burkhanov SA, **Torchilin VP**. Liposome-hepatocyte interaction: targeted liposome transport to liver cells by varying phospholipid and ganglioside composition of the liposomal membrane. In: Gregoriadis G, ed. *Liposomes as Drug Carriers: Recent Trends and Progress*. London: John Wiley & Sons, 1988:737-748.
25. Martinek K, **Torchilin VP**. Stabilization of enzymes by intramolecular crosslinking using bifunctional reagents. In: Mosbach K, ed. *Methods in Enzymology*, Vol. 137, *Immobilized Enzymes and Cells*, Part D. New York: Academic Press, Inc., 1988:615-626.
26. **Torchilin VP**. Interaction of modified liposomes with cells and intercellular fate of liposomes. In: Archakov AI, Gundermann KJ, eds. *Phosphatidylcholine (Polyenephosphatidylcholine/PPC): Effects on Cell Membranes and Transport of Cholesterol*. Bingen-Rhein: WBU-Verlag, 1989:111-127.
27. **Torchilin VP**, Klivanov AL. The antibody-linked chelating polymers for nuclear therapy and diagnostics. *CRC Critical Reviews in Therapeutic Drug Carrier Systems* 1991; 7:275-308.
28. Semenov BF, Petrov AB, Chulok TA, **Torchilin VP**, Trubetskoy VS, Koshkina NV, Ivanov VT, Andronova TM, Ivanov BB. Immunomodulating complex of oligopeptide antigen and liposomal form of *Neisseria meningitidis* lipooligosaccharide. In: Achtman M et al, eds. *Neisseriae 1990*. Berlin-New York: Walter de Gruyter, 1991:277-281.
29. Petrov AB, Semenov BF, Vartanyan YuP, **Torchilin VP**, Trubetskoy VS, Koshkina NV, Dmitriev BA, Lvov VL, Lopyrev IV. Development of liposomal vaccine on the basis of *Neisseria meningitidis* lipooligosaccharide. In: Achtman M et al, eds. *Neisseriae 1990*. Berlin-New York: Walter de Gruyter, 1991; 259-263.

30. **Torchilin VP.** Targeting of thrombolytic agents: current state of the knowledge and perspectives. In: Brakman P, Kluft C, eds. *Plasminogen Activation in Fibrinolysis, in Tissue Remodeling, and in Development*. New York: NY Acad Sci, 1992; 667:404-416.
31. **Torchilin VP, Klivanov AL.** Coupling of ligands with liposome membrane. In: Gregoriadis G et al, eds. *Liposomes in Drug Delivery*. Switzerland: Harwood Academic Publishers, 1993:227-238.
32. **Torchilin VP, Fan Zhou, Leaf Huang.** pH-sensitive liposomes. *J Liposome Res* 1993; 3:201-255.
33. **Torchilin VP, Klivanov AL.** Coupling and labeling of phospholipids. In: Cevc G, ed. *Phospholipid Handbook*. New York: Marcel Dekker, 1993:293-321.
34. **Torchilin VP.** Immunoliposomes as targeted carriers of pharmaceuticals in the cardiovascular system. In: Strauss HW and Khaw BA, eds. *Monoclonal Antibodies in Cardiovascular Diseases*. Malvern, PA:Lea & Febiger, 1994:257-267.
35. **Torchilin VP.** Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. *Immunomethods* 1994; 4:244-258.
36. **Torchilin VP, Trubetskoy VS.** Polymers on the surface of nanocarriers: modulation of carrier properties and biodistribution. *Polymer Sci (Russ.)* 1994; 36:1585-1598.
37. **Torchilin VP, Papisov MI, Bogdanov AA, Trubetskoy VS, Omelyanenko VG.** Molecular mechanism of liposome and immunoliposome steric protection with poly(ethylene glycol): theoretical and experimental proofs of the role of polymer chain flexibility. In: Martin F and Lasic D, eds. *Stealth® Liposomes*. Boca Raton, FL: CRC Press, 1995:57-68.
38. **Torchilin VP, Trubetskoy VS, Narula J, Khaw BA.** PEG-modified liposomes for gamma- and magnetic resonance imaging. In: Martin F and Lasic D, eds. *Stealth® Liposomes*. Boca Raton, FL: CRC Press, 1995:225-237.
39. **Torchilin VP.** Chelating polymer-based immunoconjugates for targeted diagnostic imaging. In: Torchilin VP, ed. *Handbook of Targeted Delivery of Imaging Agents*. Boca Raton, FL: CRC Press, 1995:117-130.
40. **Torchilin VP, Trubetskoy VS, Wolf GL.** Magnetic Resonance Imaging of lymph nodes with Gd-containing liposomes. In: Torchilin VP, ed. *Handbook of Targeted Delivery of Imaging Agents*. Boca Raton, FL: CRC Press, 1995: 401-411.
41. **Torchilin VP, Trubetskoy VS.** Which polymers can make nanoparticulate drug carriers long-circulating? *Adv Drug Delivery Rev* 1995; 16:141-155.
42. Trubetskoy VS, **Torchilin VP.** Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. *Adv Drug Delivery Rev* 1995; 16:311-320.
43. **Torchilin VP, Trubetskoy VS.** In vivo visualizing of organs and tissues with liposomes. *J Liposome Res* 1995; 5:795-812.
44. **Torchilin VP.** Targeting of drugs and drug carriers within the cardiovascular system. *Adv Drug Delivery Rev* 1995; 17:75-101.
45. **Torchilin VP.** Effect of polymers attached to lipid headgroups on properties of liposomes, In: Lasic DD, and Barenholz Y, eds., *Handbook of Nonmedical Applications of Liposomes*. Boca Raton, FL : CRC Press, 1995: Volume 1, Chapter 13, 263-284.
46. **Torchilin VP.** How do polymers prolong circulation time of liposomes? *J Liposome Res* 1996; 6:99-116.

47. **Torchilin VP.** Liposomes as delivery agents for medical imaging. *Molec Med Today* 1996; June:242-249.
48. **Torchilin VP,** Trubetskoy VS. Biodistribution of surface-modified liposomes and particles, In: Cohen S, and Bernstein H, eds. *Microparticulate Systems for the Delivery of Proteins and Vaccines.* New York, NY: Marcel Dekker, Inc., 1996: Chapter 8, 243-277.
49. **Torchilin VP.** Affinity liposomes in vivo: factors influencing target accumulation. *J Molec Recogn* 1996; 9: 335-346.
50. **Torchilin VP.** Drug targeting by functional polymers: Targeting of polymer-coated liposomes, In: Arshady R, ed. *Desk Reference of Functional Polymers.* Washington, DC: American Chemical Society, 1997: Chapter 5.7, 769-788.
51. **Torchilin VP.** Surface-modified liposomes in gamma and MR-imaging. *Adv Drug Delivery Rev* 1997; 24:301-313.
52. **Torchilin VP.** Pharmacokinetic considerations in the development of labeled liposomes and micelles for diagnostic imaging. *Quat J Nucl Med* 1997; 41: 141-153.
53. **Torchilin VP,** Modification of molecules and particles with polyethylene glycol (PEG): long-circulating pharmaceuticals, In: Winslow RM, Vandegriff KD, and Intaglietta M, eds. *Advances in Blood Substitutes.* Boston, MA: Birkhauser, 1997: Chapter 13, 251-293.
54. **Torchilin VP.** Targeting of liposomes within cardiovascular system. *J Liposome Res* 1997; 7: 433-454.
55. **Torchilin VP.** Polymer-coated long-circulating microparticulate pharmaceuticals. *J Microencapsulation* 1998; 15:1-19.
56. Trubetskoy VS, **Torchilin VP.** Long circulating liposomes for diagnostic imaging, In: Woodle MC, and Storm G, eds. *Long Circulating Liposomes.* Berlin, Germany: Springer, 1998: Chapter 17, 241-255.
57. **Torchilin VP.** *In vivo* and *in vitro* availability of liposomes, In: Kabanov AV, Felgner PL, and Seymour LW, eds. *Self-Assembling Complexes for Gene Delivery.* Chichester, England: Wiley, 1998: Chapter 14, 277-293.
58. **Torchilin VP.** Liposomes as carriers of contrast agents for in vivo diagnostics, In: Lasic DD, and Papahajopoulos D, eds. *Medical Application of Liposomes,* Amsterdam, The Netherlands: Elsevier, 1998: Chapter 6.6, 515-543.
59. **Torchilin VP,** Trubetskoy VS. Optimization of lymphatic delivery of polylysine-based imaging agents, In: Hincal AA, and Oner F, eds. *Recent Advances in Peptide and Protein Delivery,* Paris, France: Editions de Sante, 1998, 58-75.
60. **Torchilin VP.** Polymeric micelles in diagnostic imaging, *Colloids and Surfaces. B: Biointerfaces* 1999; 16:305-319.
61. Ban An Khaw, **Torchilin VP.** Targeting in myocardial infarction, In: Methods in Molecular Medicine, Vol. 25; Francis GE, and Delgado C, eds. *Drug Targeting: Strategies, Principles and Applications,* Totowa, NJ, Humana Press, 2000: Chapter 10, 159-191.
62. **Torchilin VP,** Weissig V. Polymeric Micelles for the delivery of poorly soluble drugs, In: ACS Symposium Series, Vol. 752; Park K, and Mersny RJ, eds. *Controlled Drug Delivery. Designing Technologies for the Future,* Washington, DC, American Chemical Society, 2000: Chapter 29, 297-313.

63. Weissig V, Lizano C, **Torchilin VP**. DQAsomes: A strategy for mitochondrial gene therapy, In: Gregoriadis G, and McCormack B, eds. *Targeting of Drugs. Strategies for Gene Constructs and Delivery*, Amsterdam, The Netherlands: IOS Press, 2000: 200-209.
64. **Torchilin VP**, Polymers as carriers of imaging agents, In: Park KD, Kwon IC, Yui N, Jeong SY, and Park K, eds. *Biomaterials and Drug Delivery toward New Millennium*, Seoul, Korea: Han Rim Won Publishing Co., 2000: 593-612.
65. Weissig V, **Torchilin VP**, Mitochondriale Genterapie. In: Kayser O, and Muller RH, eds. *Pharmazeutische Biotechnologie*, Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH, 2000: 341-356.
66. **Torchilin VP**. Polymeric contrast agents for medical imaging. *Current Pharm Biotech* 2000; 1:183-215.
67. **Torchilin VP**. Drug targeting. *Eur J Pharm Sci* 2000; 11, Suppl 2:S81-S91.
68. **Torchilin VP**, Babich J, Weissig V. Liposomes and micelles to target the blood pool for imaging purposes. *J Liposome Res* 2000; 10:329-345.
69. Weissig V, **Torchilin VP**. Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy. *Curentr Pharm Biotech* 2000; 1:325-346.
70. Weissig V, **Torchilin VP**. Towards mitochondrial gene therapy: DQAsomes as a strategy, *J Drug Targ* 2001; 9:1-13.
71. Weissig V, **Torchilin VP**. Cationic bolosomes with delocalized charge centers as mitochondria-specific DNA delivery systems, *Adv Drug Deliv Rev* 2001; 49:127-149.
72. **Torchilin VP**, Structure and design of polymeric surfactant-based drug delivery systems, *J Contr Release* 2001; 73:137-172.
73. **Torchilin VP**, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents, *Trends Immunol* 2001; 22:424-427.
74. **Torchilin VP**, The use of polychelating and amphiphilic polymers in gamma, MR and CT imaging, In: Chiellini E, Sunamoto J, Migliaresi C, Ottenbrite R, and Cohn D, eds. *Biomedical Polymers and Polymer Therapeutics*, New York, Kluwer Academic/Plenum Publishers, 2001, 269-284.
75. Lo EH, Singhal AB, **Torchilin VP**, Abbott NJ, Drug delivery to damaged brain, *Brain Res Rev* 2001; 38:140-148.
76. **Torchilin VP**, PEG-based micelles as carriers of contrast agents for different imaging modalities, *Adv Drug Deliv Rev* 2002; 54:235-251.
77. **Torchilin VP**, Strategies and means for drug targeting: An overview, In Muzykantov VR, Torchilin VP, eds. *Biomedical Aspects of Drug Targeting*, Boston/Dordrecht/London, Kluwer Academic Publishers, 2002, 3-26.
78. Weissig V, D'Souza G, **Torchilin VP**, Targeting mitochondria, In Muzykantov VR, Torchilin VP, eds. *Biomedical Aspects of Drug Targeting*, Boston/Dordrecht/London, Kluwer Academic Publishers, 2002, 473-495.
79. **Torchilin VP**, Khaw B-A, Weissig V, Intracellular targets for DNA delivery: nuclei and mitochondria, *Somat Cell Mol Genet* 2002; 27:49-64.
80. **Torchilin VP**, Lukyanov AN, Peptide and protein drug delivery to and into tumors: challenges and solutions, *Drug Discov Today* 2003; 8:259-266.

81. **Torchilin VP**, Weissig V, Martin FJ, Heath TD, New RRC, Surface modification of liposomes, In Torchilin VP, V.Weissig, eds. *Liposomes: Practical Approach*, Oxford, UK, Oxford University Press, 2003, 193-229.
82. Klibanov AL, **Torchilin VP**, Zalipsky S, Long-circulating sterically protected liposomes, In Torchilin VP, V.Weissig, eds. *Liposomes: Practical Approach*, Oxford, UK, Oxford University Press, 2003, 231-265.
83. **Torchilin VP**, Targeted drug delivery: current status and future challenges, *Ann Eur Acad Sci*, EAS Publishing House 2003; 5-21.
84. **Torchilin VP**, Khaw B-A, Weissig V, Intracellular targets for DNA delivery: nuclei and mitochondria, In Luo D, Saltzman WM, eds. *Synthetic DNA Delivery Systems*, Kluwer Academic/Plenum Publishers, 2003, 45-60.
85. **Torchilin VP**, Iakoubov LZ, Estrov Z, Therapeutic potential of antinuclear autoantibodies in cancer, *Cancer Therapy* 2003; 1:179-190.
86. **Torchilin VP**, Intracellular drug delivery: Current status and challenges for the future, In *Challenge in Drug Delivery for the New Millenium*, Bulletin Technique Gattefosse, N96, vol.1, 2003, 61-75.
87. **Torchilin VP**, Polymeric immunomicelles: Carriers of choice for targeted delivery of water-insoluble pharmaceuticals, *Drug Deliv Technol* 2004; 4,N2:63-68.
88. Lukyanov AN, **Torchilin VP**, Tumor delivery of peptide and protein drugs, *AmerPharm Rev* 2004; 7, N1:77-81.
89. Lukyanov AN, **Torchilin VP**, Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs, *Adv Drug Deliv Rev* 2004; 56:1273-1289.
90. **Torchilin VP**, Lukyanov AN, Gao Z, Wang J, Levchenko TS, Polymeric micelles as targetable pharmaceutical carriers, In Svenson S, ed. *Carrier-Based Drug Delivery*, ACS Symposium Series 879, Washington, DC, American Chemical Society, 2004, Chapter 9, 120-129.
91. **Torchilin VP**, Targeted polymeric micelles for delivery of poorly soluble drugs, *Cell Molec Life Sci* 2004; 61:2549-2559.
92. **Torchilin VP**, Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate, *Adv Drug Deliv Rev* 2005; 57:95-109.
93. **Torchilin VP**, Liposomal delivery of protein and peptide drugs, In Mahato RI, ed. *Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids*, Boca Raton, FL, CRC Press, 2005, Chapter 14, 433-459.
94. **Torchilin VP**, Block copolymer micelles as a solution for drug delivery problems, *Expert Opin Ther Patents* 2005; 15:63-75.
95. **Torchilin VP**, Recent advances with liposomes as pharmaceutical carriers, *Nature Rev Drug Discov* 2005; 4:145-160.
96. Gupta B, Levchenko T, **Torchilin VP**, Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides, *Adv Drug Deliv Rev* 2005; 57:637-651.
97. **Torchilin VP**, Lipid-core micelles for targeted drug delivery, *Curr Drug Deliv* 2005; 2:319-327.
98. Gupta B, **Torchilin VP**, Transactivating transcriptional activator-mediated drug delivery, *Expert Opin Drug Deliv* 2006; 3:177-190.

99. **Torchilin VP**, Recent approaches to intracellular delivery of drugs and DNA and organelle targeting, *Ann Rev Biomed Eng* 2006; 8:343-375.
100. **Torchilin VP**, Lipid-based parenteral drug delivery systems: Biological implications, In Wasan KM, ed. *Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery*, Hoboken, NJ, Wiley, 2006, Chapter 3, 48-87.
101. **Torchilin VP**, Multifunctional nanocarriers, *Adv Drug Deliv Rev* 2006; 58:1532-1555.
102. **Torchilin VP**, Tumor-targeted delivery of sparingly-soluble anti-cancer drugs with polymeric lipid-core micelles, In Amiji M, ed. *Nanotechnology for Cancer Therapy*, Boca Raton, FL, CRC Press, 2007, Chapter 20, 409-420.
103. **Torchilin VP**, Cell penetrating peptide (CPP)-modified liposomal nanocarriers for intracellular drug and gene delivery, In Amiji M, ed. *Nanotechnology for Cancer Therapy*, Boca Raton, FL, CRC Press, 2007, Chapter 31, 629-641.
104. Gupta B, **Torchilin VP**, Intracellular delivery of nanoparticles by CPPs, In Langel U, ed. *Handbook of Cell-Penetrating Peptides*, Boca Raton, FL, CRC Press, 2007, Chapter 25, 439-454.
105. Weissig V, Boddapati SV, Cheng S-M, D'Souza GGM, **Torchilin VP**, Phospholipid-and nonphospholipid-based vesicles for drug and DNA delivery to mitochondria in living mammalian cells, In Gregoriadis G, ed. *Liposome Technology*, 3rd edition, New York, NY Informa Healthcare USA, 2007, vol. 2, Chapter 18, 317-339.
106. Verma DD, Levchenko TS, Hartner WC, Bernstein EA, **Torchilin VP**, Adenosine triphosphate-loaded liposomes for myocardium preservation under ischemic conditions, In Gregoriadis G, ed. *Liposome Technology*, 3rd edition, New York, NY Informa Healthcare USA, 2007, vol. 3, Chapter 6, 95-112.
107. **Torchilin VP**, Targeted pharmaceutical nanocarriers for cancer therapy and imaging, *AAPS J* 2007; 9:E128-E147.
108. **Torchilin VP**, Micellar nanocarriers: pharmaceutical perspectives, *Pharm Res* 2007; 24:1-16.
109. **Torchilin VP**, Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers, *Adv Drug Deliv Rev* 2007; 60:548-558.
110. Elbayoumi T, **Torchilin VT**, Use of radiolabeled liposomes for tumor imaging, In Bulte JMW, Modo MMJ, eds. *Nanoparticles in Biomedical Imaging*, New York, NY Springer USA, 2008, Chapter 11, 211-236.
111. **Torchilin VP**, Antibody-modified liposomes for cancer chemotherapy, *Expert Opin Drug Deliv* 2008; 5:1003-1025.
112. **Torchilin VP**, Nanotechnology for intracellular delivery and targeting, In de Villiers MM, Aramwit P, Kwon GS, eds. *Nanotechnology in Drug Delivery*, New York, NY, Springer, 2008, Chapter 11, 313-346.
113. Elbayoumi TA, **Torchilin VP**, Liposomes for targeted delivery of antithrombotic drugs, *Expert Opin Drug Deliv* 2008; 5:1185-1198.
114. **Torchilin V**, Intracellular delivery of protein and peptide therapeutics, *Drug Discovery Today: Technologies* 2008; e95-e103.
115. **Torchilin VP**, Multifunctional and stimuli-sensitive pharmaceutical nanocarriers, *Eur J Pharm Biopharm* 2009; 71:431-444.

116. Kale AA, **Torchilin VP**, Environmentally responsive multifunctional liposomes, In Rege K, Mednitz IL, eds. *Nanoscale Bioengineering and Nanomedicine*, Boston/London, Artech House, 2009, Chapter 11, 169-195.
117. Sawant R, **Torchilin VP**, Intracellular transduction using cell-penetrating peptides, *Molec Biosyst* 2009;1-13.
118. **Torchilin VP**, Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example, In Schafer-Korting M, ed. *Handbook of Experimental Pharmacology*, Berlin/Heidelberg, Springer-Verlag, 2010, Chapter 1.
119. Hartner WC, Verma DD, Levchenko TS, Bernstein EA, Torchilin VP, ATP-loaded liposomes for treatment of myocardial ischemia, *Wiley Interdiscip Rev Nanomed Nanotechnol* 2009; 1:530-539.
120. Sawant RR, **Torchilin VP**, Polymeric micelles: Polyethylene glycol-phosphatidyl Ethanolamine (PEG-PE)-based micelles as an example, In Grobmyer SR, Moudgil BM, eds. *Cancer Nanotechnology*, Berlin/Heidelberg, Humana Press-Springer Science, 2010, 131-149.
121. Sawant RR, **Torchilin VP**, Engineering of cell-penetrating peptide-conjugated intracellular delivery systems, In Jabbari E, ed. *Biologically-Responsive Hybrid Biomaterials: A reference for Material Scientist and Bioengineers*, Singapore, World Scientific Publishing Co, 2010, Chapter 9.
122. ElBayoumi T, **Torchilin VP**, Current trends in liposome research, In Weissig V, ed. *Liposomes, Methods in Molecular Biology*, vol. 605, Humana Press, 2010, Chapter 1, 1-27.
123. Kale AA, **Torchilin VP**, Environment-responsive multifunctional liposomes, In Weissig V, ed. *Liposomes, Methods in Molecular Biology*, vol. 605, Humana Press, 2010, Chapter 15, 213-242.
124. Levchenko TS, Hartner WC, Verma DD, Berstein EA, **Torchilin VP**, ATP-loaded liposomes for targeted treatment myocardial ischemia, In Weissig V, ed. *Liposomes, Methods in Molecular Biology*, vol. 605, Humana Press, 2010, 361-375.
125. Erdogan S, **Torchilin VP**, Gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes, In Weissig V, ed. *Liposomes, Methods in Molecular Biology*, vol. 605, Humana Press, 2010, 321-324.
126. **Torchilin VP**, Polymeric micelles for therapeutic application in medicine, In Broz P, ed. *Polymer-Based Nanostructures. Medical Applications*, RSC Publishing, Cambridge, UK, 2010, Chapter 8, 261-299.
127. Musacchio T, **Torchilin VP**, Lipid-based delivery systems: Liposomes and lipid-core micelles – properties and application, In Morishita M and Park K, eds. *Biodrug Delivery Systems*, Informa, New York, 2010, Chapter 17, 260-292.
128. Sawant R, **Torchilin VP**, Intracellular transduction using cell-penetrating peptides, *Mol Biosyst* 2010; 6:628-640.
129. **Torchilin VP**, Tumor delivery of macromolecular drugs based on the EPR effect, *Adv Drug Deliv Rev* 2010; 63:131-135.
130. Sawant RR, **Torchilin VP**, Multifunctionality of lipid-core micelles for drug delivery and tumor targeting, *Mol Membr Biol* 2010; 27:232-246.
131. Sawant R, **Torchilin VP**, Intracellular delivery of nanoparticles with CPPs, In Langel U, ed. *Cell-Penetrating Peptides*, Springer/Humana Press, New York, 2011, Ch.31, 431-451.
132. **Torchilin VP**, Multifunctional Pharmaceutical Nanocarriers, In Satter KD, ed. *Handbook of Nanophysics. Nanomedicine and Nanorobotics*. CRC Pres, Boca Raton, FL, 2011, Ch. 26, 26-1 – 26-26.

133. Musacchio T, **Torchilin VP**, Recent developments in lipid-based pharmaceutical Nanocarriers, *Front Biosci* 2011; 16:1388-412.
134. Sawant R, **Torchilin V**, Intracellular delivery of nanoparticles with CPPs, *Methods Mol Biol*, 2011; 683:431-51.
135. Sawant RR, **Torchilin VP**, Design and synthesis of novel functional lipid-based bioconjugates for drug delivery and other applications, *Methods Mol. Biol. (Bioconjugation protocols*, Editor, S.S.Mark, Humana Press), 2011, 751, 357-378.
136. Sawant RR, **Torchilin VP**, Intracellular Delivery: A multifunctional and modular approach, In Prokop A, ed. *Intracellular Delivery. Fundamentals and Applications*, Springer, 2011, 199-223.
137. Elbayoumi T, **Torchilin VP**, Antibody-targeted liposomes and micelles for imaging applications, In Goins BA, Phillips WT, eds. *Nanoimaging*. Pan Stanford, Singapore, 2011, Ch. 5, 109-128.
138. **Torchilin V**, Nanocarriers for the delivery of drugs, genes, and diagnostics, In Alexiou C, ed. *Nanomedicine – Basic and Clinical Applications in Diagnostics and Therapy*. Karger, Basel, 2011, 15-34.
139. Koren E, **Torchilin VP**, Drug carriers for vascular drug delivery, *IUBMB Life*, 2011; 63:586-595.
140. Meerovich I, Koshkarev A, **Torchilin VP**, Kinetic and thermodynamic approaches to the drug targeting phenomena (A Review), *Curr Drug Discov Technol*, 2011; 8:287-300.
141. **Torchilin VP**, Immunoliposomes, In Kratz F, Senter P, Steinhagen H, eds. *Drug Delivery in Oncology*. Wiley-VCH, Weinheim, 2011, vol. 2, 951-987.
142. Elbayoumi T, **Torchilin V**, Antibody-targeted liposomes and micelles for imaging applications, In Goins BA, Phillips WT, eds. *Nanoimaging*. Pan Stanford, Singapore, 2011, Ch. 5, 109-128.
143. Wang T, Upponi JR, **Torchilin VP**, Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies, *Int J Pharm*, 2012; 427:3-20.
144. **Torchilin VP**, PEGylated pharmaceutical nanocarriers, In Wright JC, Burgess DJ, eds. *Long Acting Injections and Implants*, CRS/Springer, New York, 2012, Chapter 14, 263-293.
145. **Torchilin VP**, Liposomes in drug delivery, In: Siepmann J, Sigel RA, Rathbone MJ eds. *Fundamentals and Applications of Controlled Release Drug Delivery*, CRS/Springer, New York, 2012, Chapter 11, 289-328.
146. Levchenko T, Hartner W, **Torchilin VP**, Immunoliposomes for cardiovascular targeting, In: Pathak Y, Benita S, eds. *Antibody-Mediated Drug Delivery Systems*, Wiley, Hoboken, NJ, USA, 2012, Chapter 2, 13-33.
147. Sawant RR, **Torchilin VP**. Challenges in development of targeted liposomal therapeutics. *AAPS J* 2012; 14(2):303-15.
148. Levchenko TS, Hartner WC, **Torchilin VP**. Liposomes for cardiovascular targeting. *Ther Deliv* 2012; (4):501-14.
149. Levchenko TS, Hartner WC, **Torchilin VP**. Liposomes in diagnosis and treatment of cardiovascular disorders. *Methodist Debaque Cardiovasc J* 2012; 8(1):36-41.
150. Sawant RR, Jhaveri AM, **Torchilin VP**. Immunomicelles for advancing personalized therapy. *Adv Drug Deliv Rev* 2012; 64(13):1436-46.
151. Koren E, **Torchilin VP**. Cell-penetrating peptides: breaking through to the other side. *Trends Mol Med* 2012; 18(7):385-93.

152. Zhu L, **Torchilin VP**. Stimulus-responsive nanopreparations for tumor targeting. *Integr Biol (Camb)* 2012;5: 96-107.
153. Musacchio T, **Torchilin VP**. siRNA delivery: from basics to therapeutic applications, *Front Biosci* 2013; 18:58-79.
154. Koshkaryev A, Sawant R, Deshpande M, **Torchilin VP**, Immunoconjugates and long-circulating systems: Origins, current state of the art and future directions, *Adv Drug Deliv Rev* 2013; 65:24-35.
155. Biswas S, Vaze O, Movassaghian S, **Torchilin VP**, Polymeric micelles for the delivery of poorly soluble drugs In: Douroumis D, Fahr A, eds. *Drug Delivery Strategies for Poorly Water-Soluble Drugs*, Wiley, Chichester, UK, 2013, Ch 14, 411-476.
156. Abouzeid AH, **Torchilin VP**, The role of cell cycle in the efficiency and activity of cancer nanomedicines, *Expert Opin Drug Deliv* 2013; 10:775-786.
157. Perche F, **Torchilin VP**, Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting, *J Drug Deliv* 2013.
158. Essex S, **Torchilin VP**, Liposomal formulations for focal and targeted drug delivery in cancer and other diseases, In: Domb AJ, Khan W, eds. *Focal Controlled Drug Delivery*, CRS/Springer, New York, 2014, Chapter 4, 93-116.
159. Biswas S, **Torchilin VP**, Nanopreparations for organelle-specific delivery in cancer, *Adv Drug Deliv Rev* 2014; 66:26-4.
160. **Torchilin VP**, Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery, *Nat Rev Drug Discov* 2014; 13:813-827.
161. A.Jhaveri, P.Deshpande, **V.P.Torchilin**, Stimuli-sensitive preparations for combination cancer therapy, *J Control Release* 2014; 190:352-370.
162. A.Jhaveri, **V.P.Torchilin**, Multifunctional polymeric micelles for delivery of drugs and siRNA, *Front Pharmacol* 2014; 5:77.
163. Sriraman SK, **Torchilin VP**, Recent advances with liposomes as drug carriers, In: Tiwari A, Nordin N, eds. *Advanced Biomaterials and Biodevices*, Wiley, 2014, Chapter 3, 79-120.
164. Sriraman SK, Aryasomayajula B, **Torchilin VP**, Barriers to drug delivery in solid tumors, *Tissue Barriers*, 2014.
165. Upponi JR, **Torchilin VP**, Passive vs. active targeting: An update of the EPR role in drug delivery in tumors, In: Alonso AJ, Garcia-Fuentes M, eds., CRS-Springer, 2014, Chapter 1, 3-45. *Nano-Oncologicals. New Targeting and Delivery Approaches*
166. Elbayoumi T, **Torchilin VP**, Lipid-based pharmaceutical nanocarriers for imaging applications, In: Berezin MY, ed. *Nanotechnology for Biomedical Imaging and Diagnosis*, Wiley, 2015, Chapter 3, 49-81.
167. Navarro G, Movassaghian S, **Torchilin VP**, Multifunctional nanocarriers for tumor drug delivery and imaging, In: Mitra AK, Kwatra D, Vadlapudi AD, eds. *Drug Delivery*, Jones & Bartlett Learning, 2015, Chapter 8, 157-187.
168. Navarro G, Pan J, **Torchilin VP**, Micelle-like nanoparticles as carriers for DNA and siRNA, *Mol Pharm* 2015; 12:301-313.
169. Pattni B, **Torchilin VP**, Targeted drug delivery systems: Strategies and Challenges, In: Devarajan P, Jain S, eds. *Targeted Drug Delivery: Concepts and Design*, Springer, 2015, Chapter 1, 3-38.

170. Movassaghian S, **Torchilin VP**, Long-circulating therapies for cancer treatment, In: Singh M, Salnikova M, eds. *Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies*, Academic Press, 2015, Chapter 18, 433-462.
171. Movassaghian S, Merkel OM, **Torchilin VP**, Applications of polymer micelles for imaging and drug delivery. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.*, 2015; 7:691-707.
172. Salzano G, **Torchilin VP**, Intracellular delivery of nanoparticles with cell-penetrating peptides, In: Langel U, ed. *Cell-Penetrating Peptides*, Humana Press, 2015, Chapter 24, 357-368.
173. Perche F, Biswas S, **Torchilin VP**, Stimuli-sensitive polymeric nanomedicines for cancer, In: Thakur VK, Thakur MK, eds. *Handbook of Polymers for Pharmaceutical Technologies*, Wiley, 2015, vol. 2, Chapter 11, 311-344.
174. Salzano G, **Torchilin VP**, Intracellular Delivery of Nanoparticles with Cell Penetrating Peptides, *Methods Mol Biol* 2015; 1324:357-368.
175. Al-Abd AM, Al-Abbasi FA, **Torchilin VP**, Intratumoral pharmacokinetics: Challenges to nanobiomaterials, *Curr Pharm Des* 2015; 21:3208-3214.
176. Pattni BS, Chupin VV, **Torchilin VP**, New developments in liposomal drug delivery, *Chem Rev* 2015
177. Patel NR, Aryasomayajula B, Abouzeid AH, **Torchilin VP**, Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems, *Ther Deliv* 2015; 6:509-520.
178. Jhaveri A, **Torchilin VP**, Intracellular delivery of nanocarriers and targeting to subcellular organelles, *Exp Opin Drug Deliv* 2015.
179. Al-Abd AM, Aljehani ZK, Gazzaz RW, Fakhri SH, Jabbad AH, Alahdal AM, **Torchilin VP**, Pharmacokinetic strategies to improve drug penetration and entrapment in solid tumors, *J Control Rel* 2015.
180. Narayanaswamy R, Wang T, **Torchilin VP**, Improving peptide application using nanotechnology, *Curr Top Med Chem* 2015.
181. Salzano F, Costa DF, **Torchilin VP**, siRNA delivery by stimuli-sensitive nanocarriers, *Curr Pharm Des* 2015; 12:4566-4573.
182. Al-Abd AM, Aljehani ZK, Gazzaz RW, Fakhri SH, Jabbad AH, Alahdal AM, **Torchilin VP**, Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. *J Control Release* 2015; 219:269-277.
183. Jhaveri A, **Torchilin VP**, Intracellular delivery of nanocarriers and targeting to subcellular organelles. *Expert Opin Drug Deliv* 2015; 11:1-22.
184. Sarisozen C, Salzano G, **Torchilin VP**, Recent advances in siRNA delivery. *Biomol Concepts* 2015; 6:321-341.
185. Jhaveri A, Tao Wang, **Torchilin V**, Stimuli-reactive nanoparticles for drug targeting, In: Van Herk A, Forcada J, Pastorin G, eds. *Controlled Release Systems: Advances in Nanobottles and Active Nanoparticles*, Pan Stanford Publishing, Singapore, 2016, Chapter 14, 287-350.
186. Perche F, Biswas S, Patel NR, **Torchilin VP**, Hypoxia-responsive copolymer for siRNA delivery. *Methods Mol Biol* 2016; 1372:139-162.
187. Narayanaswamy R, Wang T, **Torchilin VP**, Improving peptide applications using nanotechnology. *Curr Top Med Chem* 2016; 16:253-270.

188. Jhaveri A, Shvets V, **Torchilin VP**, Stimuli-sensitive nanopreparations: Overview, In: Torchilin VP, ed. *Smart Pharmaceutical Nanopreparations*, Imperial College Press, London, 2016, Chapter 1, 1-48.
189. Sarisozen C, **Torchilin VP**, Intracellular delivery of proteins and peptides, In: Wang B, Hu L, Siahaan TJ, eds. *Drug Delivery. Principles and Application*, Wiley, Hoboken, NJ, 2016, Chapter 23, 576-622.
190. Aryasomayajula B, Sriraman SK, **Torchilin VP**, Crossing the endothelial barrier, In: Muro S, ed. *Drug Delivery Across Biological Barriers*, PanStanford Publishers, Singapore, 2016, Chapter 8, 209-238.
191. Deshpande M, Sriraman SK, **Torchilin VP**, Nanotheranostics in gene therapy, In: Mura S, Couvreur P, eds. *Nanotheranostics for Personalized Medicine*, World Scientific, Singapore, 2016, Chapter 8, 191-221.
192. Agardan NBM, **Torchilin VP**, Engineering of stimuli-sensitive nanopreparations to overcome physiological barriers and cancer multidrug resistance, In: Grumezescu A, ed. *Engineering of Nanobiomaterials*, vol. 2, Elsevier, 2016, Chapter 1, 1-28.
193. Aryasomayajula B, **Torchilin VP**, Nanoformulations: A lucrative tool for protein delivery in cancer therapy, In: Grumezescu A, ed. *Nanobiomaterials in Cancer Therapy*, Elsevier, 2016, vol. 7, Chapter 10, 307-330.
194. Campos PM, VILopes M, Bentley B, **Torchilin VP**, Nanopreparations in skin cancer therapy, In: Gruminescu A, ed. *Nanobiomaterials in Cancer Therapy*, Elsevier, 2016, vol. 7, Chapter 1, 1-28.
195. Sarisozen C, Salzano G, **Torchilin VP**, Lipid-based siRNA delivery systems: challenges, promises and solutions along the long journey, *Curr Pharm Biotechnol*, 2016.
196. Aryasomayajula B, Salzano G, **Torchilin VP**, Multifunctional liposomes, In: Zeineldin R, ed. *Cancer Nanotechnology. Methods and Protocols*, Humana Press, 2017, vol. 7, Chapter 3, 41-61.
197. Sriraman SK, Salzano G, **Torchilin VP**, Drug delivery to the central nervous system, In: Caplan LR, Bitter J, Leary MC, Lo EH, Thomas AJ, Yenari M, Zhang JH, eds. *Primer on Cerebrovascular Diseases*, Academic Press, 2017, Chapter 41, 198-201.
198. Oliveira MS, Mendes LP, **Torchilin VP**, Targeted delivery of anticancer drugs: New trends in lipid nanocarriers, In: Grumezescu A, ed. *Nanostructures for Cancer Therapy*, Elsevier, 2017, Chapter 18, 455-484.
199. Mussi SV, **Torchilin VP**, Solid lipid nanoparticles and nanostructured lipid carriers as anti-cancer delivery systems for therapy and diagnostics, In: Rege K, Goklany S, eds. *Cancer Therapeutics and Imaging*, World Scientific, Singapore, 2018, Chapter 9, 317-344.
200. Costa DF, **Torchilin VP**, Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy. *Biomed Microdevices*, 2018;20:59.
201. **Torchilin VP**, Fundamentals of stimuli-responsive drug and gene delivery systems, In: Singh A, Amiji M, eds. *Stimuli-responsive Drug Delivery Systems*, Royal Soc. Chem., Cambridge, UK, 2018, Chapter 1, 1-32.
202. Sarisozen C, Pan J, **Torchilin VP**, Chemo-resistance reversal using nanomedicines, In: Chitkara D, Mittal A, Mahato R, eds. *Molecular Medicine for Cancer: Concepts and Applications of Nanotechnology*, CRC Press, 2018, Chapter 4, 91-136.

203. Mendes L, Lima EM, **Torchilin VP**, Targeted nanotheranostics for selective drug delivery in cancer, In: Conde J, ed. *Handbook of Nanomaterials for Cancer Theranostics*, Elsevier, Amsterdam, Netherlands, 2018, Chapter 9, 243-277.
204. Sarisozen C, Joshi U, Palmerston Mendes L, **Torchilin VP**, Stimuli-sensitive polymeric micelles for extracellular and intracellular drug delivery, In: *Stimuli-responsive Polymeric Nanocarriers for Drug Delivery Applications*, Elsevier, Amsterdam, Netherlands, 2018, Chapter 12.
205. Prabhu P, Vyas S, Patravale V, Date A, **Torchilin V**, Disouza J, Nanotheranostics, In: Nalwa HS, ed. *Encyclopedia of Nanoscience and Nanotechnology*, 2018, vol. 29, 165-196.
206. El-Sawy HS, Al-Abd AM, Ahmed TA, El-Say KM, **Torchilin VP**, Stimuli-responsive nano-architecture drug-delivery systems to solid tumor micromilieu: Past, present, and future perspectives. *ACS Nano*, 2018;12:10636-10664.
207. Costa DF, Mendes LP, **Torchilin VP**, The effect of low- and high-penetration light on localized cancer therapy. *Adv Drug Deliv Rev*, 2019;138:105-116.
208. Narayanaswamy R, **Torchilin VP**, Hydrogels and their application in targeted drug delivery. *Molecules*, 2019;24.
209. Pan J, Rostamizadeh K, Filipeczak N, **Torchilin VP**, Polymeric co-delivery systems in cancer treatment: An overview on component drugs' dosage ratio effect. *Molecules*, 2019;24. 424.
210. Subhan MA, **Torchilin VP**. Efficient nanocarriers of siRNA therapeutics for cancer treatment. *Transl Res*. 2019 Dec;214:62-91.
211. Rostamizadeh K, **Torchilin VP**, Polymeric nanomicelles as versatile tool for multidrug delivery in chemotherapy, In: Shegokar R, ed. *Nanopharmaceuticals*, Elsevier, 2020, Ch.3, 45-72.
212. Narayanaswamy R, **Torchilin VP**, Hydrogels and their applications in targeted drug delivery, In: Mousa SA, Bawa R, Audette GF, eds. *The Road from Nanomedicine to Precision Medicine*, Parts A and B, Jenny Stanford Publishing, Singapore, 2020, Part B, Chapter 35, 1117-1150.
213. Filipeczak N, Pan J, Yalamarty SSK, **Torchilin VP**, Recent advancements in liposome technology. *Adv. Drug Deliv. Rev.* 2020; 156:4-22.
214. Subhan MA, **Torchilin VP**, siRNA based drug design, quality, delivery and clinical translation, *Nanomedicine*, 2020; 29.
215. Shahriari M, **Torchilin VP**, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M, "Smart" self-assembled structures: toward intelligent dual responsive drug delivery systems. *Biomater Sci.* 2020; 8(21):5787-5803.
216. Subhan MA, **Torchilin VP**, Biocompatible polymeric nanoparticles as promising candidates for drug delivery in cancer treatment, In: Hussain CM, Thomas S, eds. *Handbook of Polymers and Ceramic Nanotechnology*, Springer Nature Switzerland AG, 2021, 1-18.
217. Mendes LP, Sarisozen C, **Torchilin VP**, Physiological barriers in cancer: A challenge to overcome, In: Lucio M, Lopes C, Oliviera ER, eds. *Functional Lipid Nanosystems in Cancer*, Jenny Stanford Publishing, Singapore, 2021, Chapter 1, 1-41.
218. Subhan MA, Attia SA, **Torchilin VP**, Advances in siRNA delivery strategies for the treatment of MDR cancer. *Life Sci.* 2021; 274:119337.
219. Khan MM, N.Filipeczak, **V.P.Torchilin**, Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer. *J Control Release.* 2021; 330:1220-1228.

220. Pan J, Attia SA, Filipczak N, **Torchilin VP**, Dendrimers for drug delivery purposes, In: Mozafari, M, ed. *Nanoengineered Biomaterials for Advanced Drug Delivery*, Elsevier, 2020, Ch.10, 201-242.
221. Filipczak N, Yalamarty SSK, Li X, Parveen F, **Torchilin VP**, Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases. *Molecules* 2021; 26:3304. Subhan MA, SAttia SA, **Torchilin VP**, Advances in siRNA delivery strategies for the treatment of MDR cancer. *Life Sci.* 2021; 274:119337.
222. Raval N, RMaheshwari R, Shukla H, Kalia K, **Torchilin VP**, Tekade RK, Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2021; 126:112186.
223. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, **Torchilin VP**, Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. *J Pers Med.* 2021; 11:571.
224. Filipczak N, Yalamarty SSK, Li X, Khan MM, Parveen F, **Torchilin VP**, Lipid-Based Drug Delivery Systems in Regenerative Medicine. *Materials (Basel)* 2021; 14:5371.
225. Subhan MA, **Torchilin VP**, Neutrophils as an emerging therapeutic target and tool for cancer therapy. *Life Sci.* 2021; 285:119952.
226. Subhan MA, **Torchilin VP**, Advances with antibody-drug conjugates in breast cancer treatment. *Eur J Pharm Biopharm.* 2021; 169:241-255.
227. Yalamarty SSK, Li X Filipczak N, **Torchilin VP**, Directing Therapies to Lysosomes, In: *Organelle and Molecular Targeting*, 2021, Ch.13, 381-402.
228. Subhan MA, **Torchilin VP**, Biocompatible polymeric nanoparticles as promising candidates fro drug delivery in cancer treatment, In: Hussain CM, Thomas S, eds., *Handbook of Polymer and Ceramic Nanotechnology*, Springer, 2021, 1-18.
229. Mendes LP, Sarisozen C, **Torchilin VP**, Physiological barriers in Cancer: A Challenge to Overcome, In; Lucio M, Lopes CM, and Real Oliveira MECD, eds., *Functional Lipid Nanosystems in Cancer*, Jemmy Stanford Publishing, 2022, Ch. 1, 3-43.
230. Taghipour YD, Zarebkohan A, Salehi R, Rahimi F, **Torchilin VP**, Hamblin MR, Seifalian A, An update on dual targeting strategy for cancer treatment. *J Control Release.* 2022;349:67-96.
231. Khan MM, **Torchilin VP**, Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors. *Cancers (Basel).* 2022;14(17):4123.
232. Subhan A, Attia SA, **Torchilin V**, Targeted siRNA nanotherapeutics against breast and ovarian metastatic cancer: a comprehensive review of the literature. *Nanomedicine (Lond)*, 2022;17(1):41-64.
233. Nayak AK, Hasnain MS, Aminabhavi TM, **Torchilin VP**, Nanovesicular systems in drug delivery, In: Nayak AK, Hasnain MS, Aminabhavi TM, **Torchilin VP**, eds. *Systems of Nanovesicular Drug Delivery*, Academic Press, 2022, Ch.1, 1-16.
234. Subhan MA, Filipczak N, **Torchilin VP**. Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers. *Pharmaceuticals (Basel).* 2023;16(7):970.

235. Subhan MA, Parveen F, Shah H, Yalamarty SSK, Ataide JA, **Torchilin VP**. Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. *Cancers* (Basel). 2023;15(8):2204.
236. Subhan MA, **Torchilin VP**. Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate. *Pharmaceutics*. 2023;15(4):1242.
237. Yalamarty SSK, Filipczak N, Li X, Subhan MA, Parveen F, Ataide JA, Rajmalani BA, **Torchilin VP**. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM). *Cancers* (Basel). 2023;15(7):2116.
238. Subhan MA, Parveen F, Filipczak N, Yalamarty SSK, **Torchilin VP**. Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis.. *J Pers Med*. 2023;13(3):389.
239. Yalamarty SSK, Filipczak N, Khan MM, **Torchilin VP**. Role of circular RNA and its delivery strategies to cancer - An overview. *J Control Release*. 2023;356:306-315
240. Ataide JA, Coco JC, Dos Santos ÉM, Beraldo-Araujo V, Silva JRA, de Castro KC, Lopes AM, Filipczak N, Yalamarty SSK, **Torchilin VP**, Mazzola PG. Co-Encapsulation of Drugs for Topical Application-A Review. *Molecules*. 2023;28(3):1449.
241. Subhan MA, **Torchilin VP**. Biopolymer-Based Nanosystems for siRNA Drug Delivery to Solid Tumors including Breast Cancer. *Pharmaceutics*. 2023;15(1):153.

Books and Special Journal Issues:

1. **Torchilin VP**. *Immobilizovannye Fermenty v Medicine*. Moscow: Znaniye, 1986.
2. **Torchilin VP**, ed. *Chemical Modification and Design of the New Formulations of Biologically Active Substances*. Moscow: VINITI Publishers, 1988.
3. **Torchilin VP**. *Immobilized Enzymes in Medicine*. Berlin-Heidelberg: Springer Verlag, 1991.
4. **Torchilin VP**, Trubetskoy VS, eds. *Liposomes in Diagnostic Imaging*, Special Issue, *J Liposome Res*. 1994:4.
5. **Torchilin VP**, ed. *Handbook of Targeted Delivery of Imaging Agents*. Boca Raton: CRC Press, 1995.
6. **Torchilin VP**, ed. *Long-Circulating Drugs and Drug Carriers*, Special Issue, *Advanced Drug Delivery Reviews*, 1995:16 (2/3).
7. **Torchilin VP**, N.Okun, eds. *Carriers for Delivery of Imaging Agents*, Special Issue *Advanced Drug Delivery Reviews*, 1999:37 (1-3).
8. Weissig V, **Torchilin VP**, eds. *Drug Delivery to Mitochondria*, Special Issue, *Advanced Drug Delivery Reviews*, 2001:49 (1/2).
9. Muzykantov VR, **Torchilin VP**, eds. *Biomedical Aspects of Drug Targeting*. Kluwer Academic Publishers, Boston/Dordrecht/London, 2002.

10. **Torchilin VP**, Weissig F, eds. *Liposomes: A Practical Approach*. UK: Oxford University Press, 2003.
11. **Torchilin VP**, ed. *Protein- and peptide-mediated transduction: Mechanisms and implications for drug delivery*, Special Issue, *Advanced Drug Delivery Reviews*, 2005:57 (4).
12. **Torchilin VP**, ed. *Delivery of protein and peptide drugs in cancer*, Imperial College Press, London, 2006.
13. **Torchilin VP**, ed. *Nanoparticulates as Pharmaceutical Carriers*, Imperial College Press, London, 2006.
14. **Torchilin VP**, ed. *Nanomedicine for Cancer*, Special Issue, *Anti-Cancer Agents in Medicinal Chemistry*, 2006:6(6).
15. **Torchilin VP**, ed. *Multifunctional Pharmaceutical Nanocarriers*, Springer, New York, 2008.
16. **Torchilin VP**, Amiji M, eds. *Handbook of Materials for Nanomedicine*, Pan Stanford, Singapore, 2011.
17. Grodzinski P, **Torchilin VP**, eds. *Cancer Nanotechnology*, Special Issue, *Adv Drug Deliv Rev*, 2014:66.
18. Vandamme TF, Anton N, **Torchilin VP**, eds. *Targeted Imaging*, Special Issue, *Adv Drug Deliv Rev*, 2014.
19. **Torchilin VP**, ed. *Handbook of Nanobiomedical Research*, vol 1-4, World Scientific, Singapore, 2014.
20. **Torchilin VP**, ed. *Smart Pharmaceutical Nanocarriers*, Imperial College Press, London, 2016.
21. **Torchilin VP**, ed. *Handbook of Materials for Nanomedicine*, vol 1-3, Stanford Publishing, Singapore, 2020.
22. Nayak AK, Hasnain MS, Aminabhavi TM, **Torchilin VP**, eds. *Systems of Nanovesicular Drug Delivery*, Academic Press, 2022.
23. Nayak AK, Hasnain MS, Aminabhavi TM, **Torchilin VP**, eds. *Applications of Nanovesicular Drug Delivery*, Academic Press, 2022.

Visiting Professor to:

1. Institute of Medical Biochemistry, Copernik Academy, Krakov, Poland, 1977.
2. Assoreni Co., Rome, Italy, 1979, 1981.
3. Institute of Physiological Chemistry, Martin Luter University, Halle, Germany, 1980, 1982.
4. Department of Organic Chemistry, University of Mainz, Germany, 1986.
5. Cardiac Unit and Department of Nuclear Medicine, Massachusetts General Hospital, Boston, Massachusetts, 1978, 1982, 1985, 1987, 1989, 1990.

6. Department of Biochemistry, University of Tennessee, Knoxville, Tennessee, 1991.
7. University of South Paris, 2016.
8. Moscow State University, 2017.

Invited Lectures at Conferences:

1. II Soviet-American Symposium "Myocardial Metabolism", Sochi, May 1975.
2. VII European Cardiology Congress, Amsterdam, June, 1976.
3. Soviet-American Symposium on Protein Chemistry and Physics, Riga, August, 1976.
4. III Soviet-American Symposium "Myocardial Metabolism" USA, May 1977.
5. IV All-Union Symposium on Protein Physics and Chemistry, Minsk, September 1977.
6. II All-Union Symposium on Preparation and Application of Immobilized Enzymes, Erevan, October 1977.
7. Soviet-American Conference "Methods for Production and Application of Enzymes in Industry and Analytical Studies", Tallin, November, 1977.
8. International Symposium on Biomedical Engineering, Delhi, India, February, 1978.
9. XII FEBS Congress, Dresden, July, 1978.
10. 18 Symposium on macromolecules, Prague, July 1978.
11. International Symposium "Advances in Enzyme Engineering", Tbilisi, June 1978.
12. IV Soviet-American Symposium "Myocardial Metabolism", Tashkent, September 1979.
13. IV All-Union Biochemical Congress, Leningrad, September 1979.
14. V Soviet-American Conference on Enzyme Engineering, Yurmaia, September 1979.
15. Conference of CMEA countries, Warsaw, Poland, May 1980.
16. IV All-Union Symposium on Immobilized Enzymes, Leningrad, October 1980.
17. I All-Union Symposium "Liposomes in Biology and Medicine", Moscow, November 1980.
18. All-Union Symposium "Magnetic Resonance in Biology and Medicine", Chernogolovka, March 1981.
19. II Soviet-French Symposium "Mechanisms of Pathogenesis of Artherosclerosis and Thrombosis", Nalchik, September 1981.
20. III Soviet-Swedish Symposium on Physico-Chemical Biology, Tbilisi, September 1981.
21. VI International Conference on Enzyme Engineering, Japan, September 1981.
22. I All-Union Biophysical Congress, Moscow, August 1982.
23. IV All-Union Symposium on Immobilized Enzymes, Kiev, May 1983.
24. IV All-Union Symposium on Biochemistry of Lipids, Kiev, July 1983.
25. IV All-Union Symposium on Medical Enzymology, Alma-Ata, October 1983.
26. VI All-Union Symposium on Sythetical Polymers of Medical Application, Alma-Ata, October 1983.
27. International Symposium on Polymers in Biology and Medicine, Prague, June 1984.
28. VI Soviet-American Symposium "Myocardial Metabolism", Baku, September 1984.
29. II International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, February 1985.
30. V All-Union Conference on Enzyme Engineering, Kobuleti, May 1985.
31. Course on Drug Targeting at Volgograd Medical Institute, 1985.
32. V All-Union Biochemical Congress, Kiev, 1986.
33. V All-Union Symposium on Medical Enzymology, Makhachkala, 1986.
34. Course on Liposomes at the Institute of Biochemistry, Tashkent, 1986.
35. FEBS Congress, Ljubljana, Yugoslavia, 1987.
36. Liposome Symposium, Halle, Germany 1987.
37. Symposium on Biomedical Engineering, Alma-Ata 1987.
38. Natterman Symposium on Lipids, Cologne, West Germany, May 1988.
39. Interbiotech'88, Bratislava, Czechoslovakia, June 1988.

40. IUB Congress, Prague, Czechoslovakia 1988.
41. VIII All-Union Symposium "Synthetic Polymers of Medical Application", Kiev 1989.
42. All-Union Symposium "Reconstruction, Stabilization and Reparation of Biomembrane, Blagoveschensk 1989.
43. Vth International Pharmaceutical Technology Symposium, Ankara, September 1990.
44. International Symposium on Innovations in Pharmaceutical Sciences Technology, India, October 1990.
45. International Symposium "Liposomes in Biology and Medicine", Tashkent, November 1990.
46. International Conference on Thrombosis, The Netherlands, October 1991.
47. European Conference on Controlled Drug Release, The Netherlands, April 1992.
48. Gordon Research Conference on Polymers in Biosystems, Oxnard, February 1992.
49. 2nd Liposome Research Days, Leiden, The Netherlands, June 1992.
50. IUPAC Conference on Macromolecules, Prague, Czechoslovakia, July 1992.
51. American Chemical Society Meeting, San Francisco, March 1992.
52. AAAS Meeting, Boston, February 1993.
53. 6th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, February 1993.
54. International Liposome Conference, St. Petersburg, Russia, June 1993.
55. Second International Symposium on Polymers for Advanced Technologies, Oxford, United Kingdom, September 1993.
56. International Conference, "Liposomes in Drug Delivery," London, United Kingdom, December 1993.
57. 3rd Liposome Research Days Conference, Vancouver, Canada, June 1994.
58. Sapporo Symposium on Intelligent Polymer Gels, Sapporo, Japan, October, 1994.
59. 11th International Symposium on Affinity Chromatography and Biological Recognition, San Antonio, May 1995.
60. 22st International Symposium on Controlled Release of Bioactive Materials, Seattle, Washington, July-August 1995.
61. Fourth Liposome Research Days Conference, Freiburg, Germany, August-September 1995.
62. Current Concepts in Cardiovascular Diseases, New Dehli, India, December 1995.
63. 1st International Conference on Polymer Therapeutics, London, UK, January 1996.
64. New Drug Delivery Systems, Ahmedabad, India, March 1996.
65. 5th Liposome Research Days Conference, Shizuoka, Japan, July 1996.
66. 23rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan, July 1996.
67. 8th International Pharmaceutical Technology Symposium, Ankara, Turkey, September 1996.
68. Conference on Liposome Advances: Progress in Drug and Vaccine Delivery, London, UK, December 1996.
69. Blood Substitute Conference, San Diego, March 1997.
70. Chemistry and Biology of Polyethylene Glycol, ACS Meeting, San Francisco, April 1997.
71. 10th International Symposium on Radiopharmacology, Rapallo, Italy, May 1997.
72. 6th International Symposium on the Synthesis and Application of Isotopes and Isotopically Labeled Compounds, Philadelphia, September 1997.
73. International Symposium on Targeting the Cardiovascular System, Boston, September 1997.
74. 2nd Central European Symposium on Pharmaceutical Technology, Portoroz, Slovenia, September 1997.
75. 3rd International Symposium on Polymer Therapeutics, London, UK, January 1998.
76. Gordon Research Conference on Drug Carriers in Biology and Medicine, Ventura, February 1998.
77. Conference on Medical Imaging, Barcelona, Spain, May 1998.

78. 1998 Meeting of Brazilian Society of Biochemistry and Molecular Biology, Caxambu, Brazil, May 1998.
79. 216th American Chemical Society National Meeting, Boston, August 1998.
80. European Meeting on Frontiers in Pharmaceutical Sciences, Zermatt, Switzerland, October 1998.
81. American Chemical Society Meeting, Polymer Therapeutics, Anaheim, March 1999.
82. 3rd International Symposium on Frontiers in Biomedical Polymers, Shiga, Japan, May 1999.
83. 3rd International Conference on Advanced Polymers via Macromolecular Engineering, Williamsburg, August 1999.
84. 2nd International Symposium on Pharmaceutical Chemistry, Ankara, Turkey, September 1999.
85. International Symposium on Lipid and Dispersed Systems, Moscow, Russia, September 1999.
86. Meeting of American College of Clinical Pharmacy, Kansas City, October 1999.
87. International Symposium on Biomedical Polymers in 21st Century, Sapporo, Japan, November 1999.
88. Fourth International Conference on Liposome Advances, London, UK, December 1999.
89. 34th Gattefosse Conference on Frontiers in Biopharmacy, Saint-Remy, France, June 2000.
90. Gene Delivery Conference, Brooklyn Politechnic University, Brooklyn NY, June 2000.
91. 27th International Symposium on Controlled Release of Bioactive Materials, Paris, France, July 2000.
92. International Symposium on Biomaterials and Drug Delivery Systems, Cheju, Korea, August 2000.
93. Annual AAPS Meeting, Indianapolis, November 2000.
94. 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, June 2001.
95. European Symposium on Peptides, Krakow, Poland, September 2001.
96. 5th International Conference on Liposome Advances, London, UK, December 2001.
97. 1st NIH Meeting on TAT-mediated cancer treatment, Rockville, MD, February 2002.
98. American Chemical Society Meeting, Orlando, FL, April 2002.
99. International Symposium Particles 2002, Orlando, FL, April 2002.
100. International Conference Liposomes. From Models to Applications, Wroclaw, Poland, May 2002.
101. American Chemical Society Meeting, Boston, MA, August 2002.
102. 11th International Pharmaceutical Technology Symposium, Istanbul, Turkey, September 2002.
103. 2nd IBC's International Conference on Protein and Peptide Drug Delivery, Boston, MA, September 2002.
104. Transitioning Biomaterials in the 21st Century, Maui, December 2002.
105. Challenge in Drug Delivery for the New Millenium, Saint-Remy de Provence, France, June 2003.
106. 7th International Symposium on Pharmaceutical Sciences, Ankara, Turkey, June 2003.
107. Liposomes Revisited, Groningen, The Netherlands, June 2003.
108. 5th International Symposium on Frontiers in Biomedical Polymers, Ischia, Italy, September 2003.
109. Annual AAPS Meeting, Salt Lake City, November 2003.
110. International Conference on Advanced Materials, Singapore, December 2003.
111. 6th International Conference on Liposome Advances, London, UK, December 2003.
112. International Conference in Nanomaterials, Dallas, January 2004.
113. International Symposium on Nano-Biotechnology, Okayama, Japan, February 2004.
114. AAPS – Northeast Regional Meeting, Rocky Hill, Conn, April 2004.
115. 9th Liposome Research Days Conference, Hsinchu, Taiwan, May 2004.
116. International Conference on Pharmaceutics, Huanzhou, China, May 2004.
117. Israeli Chapter of Controlled Release Society Meeting, Haifa, Israel, September 2004.
118. AAPS Annual Meeting, Baltimore, November 2004.
119. Nanotechnology Conference. Nanotechnology for Cancer, Anaheim, May 2005.
120. Amphiphiles and Their Aggregates in Basic and Applied Science, Wroclaw, Poland, May 2005.
121. Cell-Penetrating Peptides and Applications, Stockholm, Sweden, May 2005.

122. Advances in Drug Discovery and Delivery, Moscow, Russia, July 2005.
123. 2005 AAPS Meeting, Nashville, November 2005.
124. Indo-Japanese Conference on Drug Delivery, Mumbai, India, November 2005.
125. Course on Nanomedicine, Helsinki, Finland, February 2006.
126. International Conference on Biotechnology and Nanomedicine, Moscow, Russia, March 2006.
127. Material Research Society Meeting, San Francisco, April 2006.
128. G.O.T.Summit, Boston, April 2006.
129. Particles 2006 Conference, Orlando, May 2006.
130. Nanomedicine for Cancer Conference, Boston, May 2006.
131. Annual Controlled Release Society Meeting, Vienna, Austria, July 2006.
132. Gordon Research Conference in Drug Carriers in Medicine and Biology, Big Sky, Montana, August 2006.
133. 13th International Pharmaceutical Technology Symposium, Antalya, Turkey, September 2006.
134. 4th International Symposium on Nanomedicine and Drug Delivery, Omaha, Nebraska, October 2006.
135. New Jersey Symposium on Biomaterials, Rutgers University, November 2006.
136. Symposium on Nanomedicine, Brooklyn Polytechnic, December 2006.
137. International Conference on Liposome Advances, London, UK, December 2006.
138. Conference on Nanomedicine, University of Kansas, Kansas City, February 2007.
139. Controlled Release Society Meeting, Mumbai, India, February 2007.
140. International Conference on Recent Advances in Drug Delivery Systems, Sal Lake City – February 2007.
141. International Symposium on Cell-Penetrating Peptides, Telford, UK – May 2007.
142. Symposium on Cancer Nanomedicine, Santa Clara – May 2007.
143. International Symposium on Drugs and Targets, Berlin, Germany – June 2007.
144. IUPAC Meeting on Biomedical Polymers, New York – June 2007.
145. International Symposium on Frontiers in Biomedical Polymers, Ghent, Belgium – June 2007.
146. Symposium on Cancer Nanomedicine, Paris, France – June 2007.
147. 34th Annual Controlled Release Society Meeting, Long Beach – July 2007.
148. 2007 American Chemical Society Meeting, Boston – August 2007.
149. 16th International Meeting on Microencapsulation, Lexington, KY – September 2007.
150. 2nd International Symposium on Intracellular Delivery of Therapeutic Molecules, Grenoble, France – September 2007.
151. International Peptide Symposium, Cairns, Australia – October 2007.
152. Liposome Advances, London, UK – December 2007.
153. BIROW-5, NIH – January 2008.
154. Symposium on Nanotechnology in Medicine, Boston University – April 2008.
155. American Chemical Society Annual Meeting, New Orleans – April 2008.
156. Symposium on Nanomedicine in Cancer, Boston – June 2008.
157. International Conference on Smart Materials, Aceriale, Italy – June 2008.
158. International Conference NanoBio'08, St. Petersburg, Russia – June 2008.
159. Gordon Research Conference on Barriers in CNS, Tilton, NH – June 2008.
160. Annual ACS meeting, Philadelphia – August 2008.
161. International Pharmaceutical Technology Symposium, Antalya, Turkey – September 2008.
162. 2008 Nanomedicine and Drug Delivery Symposium, Toronto, Canada – October 2008.
163. Nanotechnology Congress, Moscow, Russia – December 2008.
164. Indo-US Summit on Cancer Nanotechnology, New Delhi, India – February, 2009.
165. Annual ACS meeting, Salt Lake City – March 2009.
166. Liposome research Conference, Itaparica, Brazil – April 2009.
167. Phospholipid Conference, Heidelberg, Germany – May 2009.

168. Nanomedicine Symposium, Moscow, Russia – June 2009.
169. FEBS Meeting, Prague, Czech Republic – July 2009.
170. Annual CRS Meeting, Copenhagen, Denmark – July 2009.
171. Key Symposium, Stockholm, Sweden – September 2009.
172. International Symposium on Microencapsulation, Nagoya, Japan – September 2009.
173. International Conference on Nanotechnology, Rusnanotech, Moscow, Russia – October 2009.
174. International Nanotechnology in Oncology Conference, Moscow, Russia – October 2009.
175. NanoUtah Conference, Salt Lake City – October 2009.
176. American Society for Nanomedicine Conference, Potomac – October 2009.
177. Material Research Society Meeting, Boston – December 2009.
178. International Conference on Liposome Advances, London – December 2009.
179. International Conference on Biological Barriers, Saarbrücken, Germany – March 2010.
180. International Symposium on Biomedical Polymers for Drug Delivery, Salt Lake City – March 2010.
181. Russian-Greek Conference on Nanobiomedicine, Heraklion, Greece, May 2010.
182. 3rd European Conference on Clinical Nanomedicine, Basel, Switzerland, May 2010.
183. Symposium on Cancer Nanomedicine, Anaheim, CA, June 2010.
184. International Meeting on Liposomes, Vancouver, Canada, August 2010.
185. Round Table on Clinical Nanomedicine, Nuremberg, Germany, September 2010.
186. Conference on Cell Penetrating Peptides, Copenhagen, Denmark, September 2010.
187. 2nd US-China Meeting on Cancer Nanomedicine, Washington DC, September 2010.
188. Conference on Nanomedicine, Los Angeles, March 2011.
189. UKICRS Meeting, Belfast, UK, April 2011.
190. AVRO Annual Meeting, Fort Lauderdale, FL, May 2011.
191. Liposome Meeting, Jerusalem, Israel, May 2011.
192. Cell-penetrating Peptides in Therapeutic Delivery, Tallinn, Estonia, May 2011.
193. Pharmaceutical Technology Conference, Antalya, Turkey, September 2011.
194. International Liposome Society meeting, London, UK, December 2011.
195. Arden House Conference on Nanomedicine, West Point, March 2012.
196. European Conference and School on Nanomedicine and Nanotoxicology, Crete, Greece, May 2012.
197. Material Research Society Meeting, Montecatini Terme, Italy, June 2012.
198. Controlled Release Society Annual meeting, Quebec City, Canada, July 2012.
199. Israeli Controlled Release Society Meeting, Israel, September 2012.
200. International Pharmaceutical Technology Conference, Antalya, Turkey, September 2012.
201. Liposome Research Days, Hangzhou, China, October 2012.
202. AAPS Annual Meeting, Chicago, October 2012.
203. International Pharmaceutical Technology Conference, Kuala Lumpur, Malaysia, November 2012.
204. International Conference on Biopolymers, Maui, December 2012.
205. Nanomedicine Conference, Los Angeles, March 2013.
206. International Biotechnology Congress, Moscow, Russia, March 2013.
207. 19th International Meeting on Microencapsulation, Pamplona, Spain, September 2013.
208. AAPS Annual Meeting, San Antonio, October 2013.
209. International Conference on Pharmaceuticals, Ribeirao Preto, Brazil, November 2013.
210. International Conference on Nanotechnology for Health, Belo Horizonte, Brazil, November 2013.
211. International Meeting on Liposome Advances, London, UK, December 2013.
212. Nanotechnology for Health Care Conference, Little Rock, April 2014.
213. International Congress on Biomaterials, Heraklion, Greece, May 2014.
214. Drug Discovery and Therapy World Congress, Boston, June 2014.
215. Liposome Research Days, Copenhagen, Denmark, July 2014.

216. Nanotechnology Meeting, Buenos Aires, Argentina, September 2014.
217. Nanomedicine Conference, Los Angeles, March 2015.
218. Annual AACR Meeting, Philadelphia, April 2015.
219. International Congress on Biomaterials, Greece, May 2015.
220. International Conference on Pharmaceutical Technology, Istanbul, Turkey, May 2015.
221. France Nanotech, Paris, June 2015.
222. EVONIK Meets Science Conference, New Jersey, September 2015.
223. OMICS Conference on Cancer Therapy, Valencia, November 2015.
224. Liposome Advances Conference, London, December 2015.
225. BIONANOTOX, Greece, May 2016.
226. Canadian Society of Pharmaceutical Scientists Conference, Vancouver, Canada, May 2016.
227. CIMIT Meeting, Perugia, Italy, June 2016.
228. Central European Biomedical Congress, Krakow, Poland, June 2016.
229. Nanomedicien Meeting, Viterbo, Italy, September 2016.
230. Meeting on Nanocontainers, Tarragona, Spain, October 2016.
231. Pharmaceutica 2017, London, UK, March 2017.
232. BIONANOTOX, Heraklion, Greece, May 2017.
233. Nanodelivery 2017, Osaka, Japan, May 2017.
234. Drug Discovery and Therapy World Congress, Boston, July 2017.
235. Drug Delivery and Formulation Summit, Boston, August 2017.
236. YUCOMAT 2017, Montenegro, September 2017.
237. Liposome Advances, Athens, September, 2017.
238. 21st International Symposium on Microencapsulation, Faro, Portugal, September 2017.
239. World Congress on Pharmacology and Chemistry of Natural Compounds, Tbilisi, Georgia, October 2017.
240. 4th European Biopharma Congress, Vienna, Austria, November 2017.
241. 9th Global Drug Delivery and Formulation Summit, Berlin, Germany, March 2018.
242. 16th International Conference on Pharmaceutics and Novel Drug Delivery Systems, Berlin, Germany, March 2018.
243. AAPS-NERDG Meeting, Farmington, CT, April 2018.
244. BIONANOTOX, Greece, May 2018.
245. Global Conference on Pharmaceutics and Drug Delivery Systems, Rome, Italy, June 2018.
246. 8th Forum on New Materials, Perugia, Italy, June 2018.
247. World Preclinical Congress, Boston, June 2018.
248. 12th International Conference on Nanopharmaceutics and Advanced Drug Delivery, Dublin, Ireland, August 2018.
249. Frontiers in Delivery of Therapeutics, Tartu, Estonia, August 2018.
250. YUCOMAT 2018, Montenegro, September 2018.
251. Material Science-2018, Amsterdam, The Netherlands, October 2018.
252. 21st European Biotechnology Congress, Moscow, Russia, October 2018.
253. Pharmaceutics and Novel Drug Delivery Systems, Moscow, Russia, October 2018.
254. Applied Pharmaceutical Nanotechnology, Boston, October 2018.
255. 2nd International Conference on Pharmaceutical Nanotechnology and Nanomedicine, New York, March 2019
256. 6th World Summit on Cancer Research and Therapy, Dubai, UAE, April 2019
257. BIONANOTOX, Greece, May 2019
258. 3rd Global Conference on Pharmaceutics and Drug Delivery Systems, Paris, France, June 2019
259. International Cancer Conference, London, UK, June 2019.
260. INVITE Conference, March 2022, Germany
261. Global Summit on Pharmaceutics and Drug Delivery Systems, Munich, Germany, May 2022.

262. Global Summit and Expo on Materials Science and Engineering, Munich, Germany, May 2022
263. Liposome Research Days, Vancouver, Canada, June 2022.
264. CIMTEC, Perugia, Italy, June 2022.
265. 2022 YUCOMAT, Montenegro, August 2022.
266. ENDOCYTE conference, Berlin, Germany, September 2022.
267. Applied Science, Paris, France, October 2022.
268. 2023 YUCOMATE, Montenegro, September 2023.

Invited Lectures and Seminars at:

1. University of California, San Francisco - 1977
2. University of Florida, Gainesville - 1978
3. Medical Institute, Vladimir (Russia) - 1979
4. Assoreni, Rome (Italy) - 1979
5. Martin Luther University, Halle (Germany) - 1980
6. University of Rome (Italy) - 1981
7. Assoreni, Rome (Italy) - 1981
8. Institute of Biochemistry, Tashkent (Uzbekistan) - 1981
9. Institute of Biochemistry, Kiev (Ukraine) - 1981
10. Institute of Biochemistry, Minsk (Belorussia) - 1981
11. Martin Luther University, Halle (Germany) - 1982
12. Iozef Stefan Institute, Ljubljana (Slovenia) - 1983
13. Belgrade University (Yugoslavia) - 1983
14. University of Bombay (India) - 1984
15. Volgograd Medical Institute (Russia) - 1985
16. Institute of Biochemistry, Kiev (Ukraine) - 1986
17. Institute of Organic Chemistry, Mainz (Germany) - 1986
18. Institute of Chemistry, Alma-Ata (Kazakhstan) - 1987
19. ORIS, Paris (France) - 1988
20. Far East Center of USSR Academy of Sciences, Vladivostok - 1988
21. University of Frunze (Kirgizia) - 1988
22. Institute of Macromolecular Chemistry, Prague (Czech Republic) - 1988
23. University of Groningen (Netherlands) - 1988
24. Institute of Physics, Havana (Cuba) - 1989
25. Academy of Medical Sciences, Havana (Cuba) - 1989
26. Royal Free Hospital, London (UK) - 1990
27. University of Voronez (Russia) - 1990
28. University of Illinois, Chicago - 1991
29. University of Texas M.D. Anderson Cancer Center - 1991
30. University of Utah - 1991
31. CEADEN, Havana (Cuba) - 1991
32. University of Washington, Seattle - 1992
33. University of California, San Francisco - 1992
34. Amgen - 1992
35. University of Alberta, Edmonton (Canada) - 1993
36. Northeastern University, Boston - 1993
37. University of Pittsburgh - 1994
38. University of Shizuoka (Japan) - 1994
39. Daiichi Corporation, Tokyo (Japan) - 1994
40. Suffolk University, Boston - 1994

41. Nextar - 1995
42. Technical University of Munich (Germany) - 1995
43. Mallinkrodt - 1995
44. Amgen - 1995
45. Center of Pharmaceutical Education, Akhmedabad (India) - 1996
46. Northeastern University, Boston - 1996
47. Centocor - 1997
48. MIT, Department of Chemical Engineering - 1997
49. Procyon (Canada) - 1997
50. MGH, Department of Radiation Oncology - 1997
51. University of Rio de Janeiro (Brazil) - 1997
52. Institute of Macromolecules, Rio de Janeiro (Brazil) - 1997
53. University of Padova (Italy) - 1997
54. Northeastern University, Boston - 1997
55. Aronex - 1998
56. University of Texas M.D.Anderson Cancer Center - 1998
57. University of Campinas, Department of Chemistry (Brazil) - 1998
58. University of Campinas, Department of Pharmacology (Brazil) - 1998
59. University of San Paulo in San Carlos, Institute of Chemistry (Brazil) - 1998
60. University of Utah - 1998
61. IDEXX - 1998
62. MIT, Department of Chemical Engineering - 1998
63. Martin Luther University, Halle (Germany) - 1998
64. University of Marburg (Germany) - 1998
65. Baxter – 1999
66. University of Nebraska Medical Center – 1999
67. University of Pennsylvania Medical Center – 1999
68. BASF – 2000
69. M.D.Anderson Cancer Center – 2001
70. Roxbury Community College – 2001
71. Department of Biology, Northeastern University – 2002
72. University of Minnesota Medical Center – 2002
73. Department of Pharmaceutics, Rutgers, University of New Jersey – 2002
74. Tufts University – 2003
75. Department of Physics, Northeastern University – 2004
76. Washington University – 2004
77. Institute of Biophysics, Academia Sinica – 2004
78. University of Utah – 2004.
79. University of Massachusetts, Lowell – 2004.
80. M.D.Anderson Cancer Center, Houston – 2005.
81. Auburn University, Auburn – 2005.
82. University of Wisconsin, Madison – 2006.
83. University of North Carolina, Chapel Hill – 2006.
84. University of Nebraska, Omaha – 2006.
85. University of Pennsylvania, Philadelphia – 2006.
86. University of Iowa, Iowa City – 2006.
87. Abbott – 2007
88. Biogen Idec – 2007.
89. Stevens Institute of Technology, New Jersey – 2007.
90. Institute of Molecular Pharmacology, Berlin, Germany – 2007.

91. University of Montreal – 2008.
92. Albany College of Pharmacy – Albany, 2008.
93. University of Barcelona, Spain – 2008.
94. University of Washington, Seattle – 2008.
95. Enzon Corp. – 2008.
96. Emory University, Atlanta – 2008.
97. Purdue University, West Lafayette – 2008.
98. Tempo Pharmaceuticals, Boston – 2008.
99. University of North Dakota, Fargo – 2008.
100. Wolfe Laboratories, Boston – 2008.
101. CIMIT (Beth Israel Deaconess Hospital), Boston – 2009.
102. University of Maryland – 2009.
102. University of North Carolina – 2009.
103. Eisai Co. – 2009.
104. University of Pennsylvania – 2010.
105. University of Tennessee, Memphis – 2010.
106. Pfizer – 2010.
107. Roche – 2010.
108. MIT – 2010.
109. Ben Gurion University, Beer Sheba, Israel – 2011.
110. RTI, North Carolina – 2013.
111. University of Kentucky – 2013.
112. University of Missouri, Kansas City – 2014.
113. King Abdulla University of Science and Technology, Saudi Arabia – 2014.
114. Technion, Israel – 2015.
115. King Abdulaziz University, Saudi Arabia – 2015.
116. York University, Toronto, Canada - 2015.
117. Catalan University, Barcelona, Spain – 2015.
118. University of South Paris, France – 2016.
119. Center for Atomic Energy, France – 2016.
120. Shubnikov Crystallography Institute, Russian Academy of Sciences, Russia – 2017.
121. Russian Cardiology Center, Russia – 2018.
122. University of Pennsylvania – 2019.
123. University of Massachusetts Lowell – 2022.
124. University of Texas Health Rio Grande Valley – 2022.
125. Georgia State University – 2022.

Patents:

1. USSR Patent #568662 (1977)
Method for the preparation of encapsulated ionites.
Inventors: **V.P. Torchilin**, A.V. Smirnov, O.N. Mertyzhina, G.V. Gryaznov, A.M. Klivanov, K. Martinek, I.V. Berezin
2. USSR Patent #586182 (1977)
Method for the preparation of immobilized amilase.
Inventors: **V.P. Torchilin**, S.B. Makarova
3. USSR Patent #677415 (1977)
Method for the preparation of polysaccharide derivatives of heparin.
Inventors: **V.P. Torchilin**, E.G. Tischenko, R.A. Markosyan, V.N. Smirnov

4. UK Patent #2003603 (1978)
Method and apparatus for producing by ultrasonics a visible image of an object.
Inventors: I.V. Berezin, V.S. Goldmacher, K. Martinek, A.A. Mishin, G.P. Samokhin,
V.N. Smirnov, **V.P. Torchilin**, E.I. Chazov, A.M. Klibanov
5. France Patent #7821419 (1979)
Procede d'obteniton de l'image visible d'un objet et dispositif pour sa mise en oeuvre.
Inventors: I.V. Berezin, V.S. Goldmakher, A.M. Klibanov, K. Martinek, A. A. Mishin,
G.P. Samokhin, V.N. Smirnov, **V.P. Torchilin**, E.I. Chazov
6. USSR Patent #671285 (1979)
Method for the preparation of water soluble compounds of proteolytic enzymes.
Inventors: **V.P. Torchilin**, E.V. Il'ina, V.N. Smirnov, E.I. Chazov
7. USSR Patent #722124 (1979)
Method for the preparation of polymeric derivatives of insulin.
Inventors: **V.P. Torchilin**, E.G. Tischenko, E.V. Il'ina, V.N. Smirnov
8. USSR Patent #824053 (1980)
Method for determining the rate of fibrin clot lysis.
Inventors: E.V. Il'ina, E.G. Tischenko, **V.P. Torchilin**
9. USSR Patent #759947 (1980)
Method and device for obtaining the visible imaging of an object.
Inventors: I.V. Berezin, V.S. Goldmakher, K. Martinek, A.M. Klibanov, A.A. Mishin,
G.P. Samokhin, **V.P. Torchilin**, V.N. Smirnov, E.I.Chazov
10. USSR Patent #798660 (1980)
Radiation detector.
Inventors: I.V. Berezin, V.S. Goldmakher, K. Martinek, A.M. Klibanov, A.A. Mishin,
G.P. Samokhin, **V.P. Torchilin**, V.N. Smirnov, E.I.Chazov
11. USSR Patent #770495 (1980)
Method for the treatment of thromboses.
Inventors: A.V. Mazaev, **V.P. Torchilin**, B.S. Lebedev, V.N. Smirnov E.I. Chazov
12. USSR Patent #946038 (1980)
Thrombin derivatives possessing coagulative activity, and method for their preparation.
Inventors: **V.P. Torchilin**, E.V. Il'ina, A.V. Mazaev, V.N. Smirnov
13. USSR Patent #790785 (1980)
Method for the preparation of immobilized streptokinase.
Inventors: E.I. Chazov, V.N. Smirnov, **V.P. Torchilin**, B.V. Moskvichev, G.M. Grinberg,
A.Sh. Skuya, G.I. Kleiner
14. USSR Patent #892971 (1981)
Stabilized cholesteroxidase - thermostable biocatalyst of cholesterol transmutation.
Inventors: A.V. Maksimenko, E.G. Tischenko, **V.P. Torchilin**, V.N. Smirnov
15. USSR Patent #822551 (1981)
Immobilized streptokinase possessing thrombolytic activity.
Inventors: E.I. Chazov, V.N. Smirnov, **V.P. Torchilin**, B.V. Moskvichev, I.M. Tereshin,
B.V. Moskvichev
16. US Patent #4257269 (1981)
Method and apparatus for producing by ultrasonics a visible image of an object.
Inventors: I.V. Berezin, V.S. Goldmacher, K. Martinek, A.A. Mishin, G.P. Samokhin,
V.N. Smirnov, **V.P. Torchilin**, E.I. Chazov, A.M. Klibanov
17. FRG Patent #3032606 (1981)
Polysaccharidderivat der streptokinase, verfahren zu dessen hersiellung und anwendung.
Inventors: E.I. Chazov, V.N. Smirnov, **V.P. Torchilin**, I.M. Tereshin, B.V. Moskvichev

18. FRG Patent #3033030 (1981)
Termostabiles derivat der urokinase und verfahren zu dessen herstellung.
Inventors: A.V. Maksimenko, **V.P. Torchilin**, E.I. Chazov
19. Sverige Patent #78079688 (1982)
Forfarande och anordning for astadkommande av en synlig bild av ett foremal.
Inventors: I.V. Berezin, V.S. Goldmakher, A.M. Klibanov, K. Martinek, A.A. Mishin,
G.P. Samokhin, V.N. Smirnov, **V.P. Torchilin**, E.I. Chazov
20. FRG Patent #2831782 (1982)
Verfahren zur erzeugung eines sichtbaren bildes von einem objekt und anlage zu desse
realisierung.
Inventors: I.V. Berezin, V.S. Goldmacher, K. Martinek, A.A. Mishin, G.P. Samokhin,
V.N. Smirnov, **V.P. Torchilin**, E.I. Chazov, A.M. Klibanov
21. FRG Patent #3150318 (1982)
Verfahren zur herstellung eines polysaccharaiddervivats des fibrinolysins.
Inventors: E.I. Chazov, V.N. Smirnov, **V.P. Torchilin**, I.M. Tereshin, B.V. Moskvichev,
G.M. Grinberg, A.Z. Skuya, G.I. Kleiner
22. US Patent #4349630 (1982)
Heat-resistant water soluble urokinase derivative.
Inventors: A.V. Maximenko, **V.P. Torchilin**, V.N. Smirnov, E.I. Chazov
23. USSR Patent #938617 (1982)
Stabilized urokinase possessing thrombolytic activity.
Inventors: A.V. Maksimenko, **V.P. Torchilin**, V.N. Smirnov, E.I. Chazov
24. USSR Patent 1002356 (1982)
Method for the preparation of immobilized fibrinolysin possessing prolonged thrombolytic
activity.
Inventors: E.I. Chazov, V. N. Smirnov, **V.P. Torchilin**, I.M. Tereshin, B.V. Moskvichev,
G.M. Grinberg, A.Sh. Skuya, G.I. Kleiner
25. USSR Patent #1022988 (1983)
Urokinase stabilized derivatives possessing thrombolytic activity and method for their
preparation.
Inventors: A.V. Maksimenko, **V.P. Torchilin**, V.N. Smirnov, E.I. Chazov
26. USSR Patent # 1018634 (1983)
Method for the treatment of eye haemorrhage.
Inventors: R.A. Gundorova, A.D. Romaschenko, V.P. Makarova, **V.P. Torchilin**,
A.V. Mazaev, V.N. Smirnov, E.I. Chazov
27. USSR Patent #1037633 (1983)
Method for the preparation of modified urokinase.
Inventors: A.V. Maksimenko, **V.P. Torchilin**, V.V. Kukhartchuk, O.S. Medvedev,
P.M. Leschinsky, G.G. Arabidze, V.N. Smirnov
28. USSR Patent #1137760 (1983)
Urokinase immobilized on heparin.
Inventors: A.V. Maksimenko, **V.P. Torchilin**, E.G. Tischenko, V.N. Smirnov
29. USSR Patent #1141336 (1984)
Method for the determination of antibodies to glicolipids.
Inventors: G.P. Vlasov, **V.P. Torchilin**, T.A. Gremyakhkova, V.G. Likhoded,
M.D. Korosteleva, N.N. Ivanov
30. USSR Patent #1128601 (1984)
Urokinase immobilized on fibrinogen.
Inventors: A.V. Maksimenko, E.G. Tischenko, **V.P. Torchilin**, V.N. Smirnov, E.I. Chazov

31. US Patent #4446316 (1984)
Dextran derivative of fibrinolysin.
Inventors: E.I. Chazov, V.N. Smirnov, **V.P. Torchilin**, I.M. Tereshin, B.V. Moskvichev,
G.M. Grinberg, A.Z. Skyua, G.I. Kleiner
32. USSR Patent #1309980 (1985)
Method for the treatment of eye haemorrhage.
Inventors: R.A. Gundorova, A.D. Romaschenko, N.S. Khodzhaev, A.V. Mazaev,
V.P. Torchilin, V.P. Bykov
33. USSR Patent #1301406 (1986)
Liposomal vesicle for drug targeting of biologically active compounds.
Inventors: S.A. Burkhanov, **V.P. Torchilin**, G.A. Ermolin, V.E. Kotelyansky,
E.E. Efremov, I.N. Trakht, A.L. Klibanov, A.N. Lukyanov
34. US Patent #4564596 (1986)
Urokinase derivatives covalently bound to fibrogen.
Inventors: **V.P. Torchilin**, A.V. Maksimenko, E.G. Tischenko, V.N. Smirnov, E.I. Chazov
35. Sverige Patent #85000933 (1986)
Urokinas derivat bestaende av urokonas bundet till fibrinogen.
Inventors: A.V. Maximenko, E.G. Tischenko, **V.P. Torchilin**, V.N. Smirnov, E.I. Chazov
36. USSR Patent #1371004 (1987)
Method for the preparation of immobilized urokinase.
Inventors: B.V. Moskvichev, T.M. Taratina, G.P. Ivanova, E.D. Kostin, **V.P. Torchilin**
37. US Patent #5223242 (1993)
Negatively charged specific affinity reagents.
Inventors: B.A. Khaw, **V.P. Torchilin**, A.L. Klibanov
38. US Patent #5534241 (1996)
Amphipathic polychelating compounds and method of use.
Inventors: **V.P. Torchilin**, V.S. Trubetskoy, G.L. Wolf
39. US Patent #5567410 (1996)
Compositions and methods for radiographic imaging.
Inventors: **V.P. Torchilin**, V.S. Trubetskoy, S. Gazell, G.L. Wolf
40. US Patent #5780033 (1998)
Use of autoantibodies for tumor therapy and prophylaxis.
Inventors: **V.P. Torchilin**, L.Z. Iakoubov
41. US Patent #5746998 (1998)
Targeted co-polymers for radiographic imaging.
Inventors: **V.P. Torchilin**, V.S. Trubetskoy, S. Gazell, G.L. Wolf
42. US Patent #5756069 (1998)
Amphipathic polychelating compounds and method of use.
Inventors: **V.P. Torchilin**, V.S. Trubetskoy, G.L. Wolf
43. US Patent #5780052 (1998)
Compositions and methods useful for inhibiting cell death and for delivering an agent into cell.
Inventors: B.A. Khaw, **V.P. Torchilin**, J. Narula, I. Vural
44. US Patent #5993818 (1999)
Use of antibodies for tumor therapy and prophylaxis
Inventors: **V.P. Torchilin**, L.Z. Iakoubov
45. US Patent #6875423 (2005)
Methods for increasing peripheral blood circulation
Inventors: M. Intaglietta, **V.P. Torchilin**, V.S. Trubetskoy, A.G. Tsai
45. US Patent #7,279,326 (2007)

- Copmposition for delivery of a mitochondrial genome to a cell
 Inventors: V.Weissig, **V.P.Torchilin**
47. Application 60/368,913 (2002)
 Micelles from polymer-lipid conjugates with incorporated anti-cancer drugs
 Inventors: **V.P.Torchilin**, A.N.Lukyanov, Z.Gao
48. Application 60/368,546 (2002)
 Targeted micelles for delivery of pharmaceuticals
 Inventors: **V.P.Torchilin**, A.N.Lukyanov, Z.Gao
49. Application 60/356,526 (2002)
 Intracellular delivery of drugs and DNA
 Inventors: **V.P.Torchilin**, R.Rammohan, T.Levchenko, N.Volodina
50. Application 60/403,797 (2002)
 Cell organelle transplantation
 Inventors: **V.P.Torchilin**, V.Weissig
51. Application 11/885,491 (2004)
 Mitochondriotropic Phospholipid Vesicles
 Inventors: V.Weissig, S.Boddapati, R.Hanson, **V.P.Torchilin**
52. Application 10/503,776 (2005)
 Intracellular delivery of therapeutic agents
 Inventors: **V.P.Torchilin** et al.
53. Application 10/553612 (2005)
 Micelle delivery system loaded with a pharmaceutical agent
 Inventors: **V.P.Torchilin** et al.
54. Application PCT US/08/08326 (2006)
 Mixed micelles and uses thereof
 Inventors: **V.P.Torchilin**
55. Application 60/832,085 (2007)
 Immunotherapy with microparticles
 Inventors: **V.P.Torchilin**, D.Mongayt, L.Iakoubov
56. Application 11/879,017 (2007)
 Condition-dependent, multiple target delivery system
 Inventors: **V.P.Torchilin**
57. Application (2007)
 Delivery of siRNA
 Inventors: **V.P.Torchilin** et al.
58. Application 60/959,728 (2007)
 Stable nanocolloids of poorly soluble drugs
 Inventors: **V.P.Torchilin**, Yu.Lvov, et al.
59. Application 61/163.145 (2008)
 Stable aqueous nanocolloids of paclitaxel and atavoquone
 Inventors: Yu.Lvov, **V.P.Torchilin**, et al.
60. Application PC/US08/012660
 Self-assembling micelle-like nanoparticles for DNA delivery
 Inventors: Y.Ko, A.Kale, **V.P.Torchilin**
61. Application 61/225,298 (2009)
 siRNA-phospholipid conjugate
 Inventors: **V.P.Torchilin**, T.Musacchio
62. Application 61/225,298 (2009)
 Ascorbate-decorated nanosystems for targeted brain delivery

- Inventors: S.Salmaso, **V.P.Torchilin**, et al.
63. Application 61/239,145 (2009)
Multi-biomarker biosensor
Inventors : A.Busnania, **V.P.Torchilin**, et al.
64. US Patent 8,685,538 as of 4/1/2014
Stable polyelectrolyte coated nanoparticles
Inventors : **V.P.Torchilin** et al.

Updated 09/22/23